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1.1  BACKgrouNd
Over the last decades, total health expenditures have increased significantly (Melt-
zer, 2001; Folland et al., 2004). Governments in low- and middle-income countries 
(LMICs) as well as in high-income countries face the difficult challenge of ensuring 
that necessary interventions are accessible for those who need them, while keeping 
care affordable. Since good quality health care and new medical interventions can 
be expensive, the process of balancing the goals of ensuring access to good quality 
health care for all citizens and ensuring affordability of health care is a difficult one 
(Weale, 1998). The need for both efficient financing and budget allocation in health 
care hence is ever increasing. Economic resources being limited, the issue of how 
health care can be organized in an affordable manner is at the heart of many policy 
discussions. It is ultimately also scarcity that forces politicians and policymakers alike 
to decide on how to organize health care, what interventions to implement and 
how to finance them. This is a daunting task since setting priorities or rationing care 
which encompasses “explicit and regular attempts to define how much of which 
services should be provided and moving resources between services” (Hunter, 1997), 
clearly are unpopular topics among constituents.
Although both LMICs and high-income countries are confronted with issues of scarcity 
and affordability, the degree of scarcity obviously differs between these countries. 
For many people in LMICs the right to health, as laid down in several treaties (United 
Nations General Assembly, 1948; United Nations Office of the High Commissioner for 
Human Rights, 1966), is still not secured (Backman et al., 2008). As the majority of 
LMICs do not have a properly functioning system of health care financing through 
health insurance, out-of-pocket payments (OOP) still account for a large proportion of 
all health care expenditures (McIntyre et al., 2006; Van Doorslaer et al., 2006; Lagarde 
& Palmer, 2011). Hence, besides questions about which care interventions to invest in, 
ensuring that their populations can financially and physically access the services they 
need in either the public or private sector is an important challenge LMICs face. Espe-
cially when OOP payments are the main source of health care financing, at the patient 
or micro level, access to health care may be strongly influenced by affordability or 
ability to pay (Bruce & Grana, 1998).1 Therefore, for LMICs, improving the level and 
distribution of public health and establishing appropriately functioning health care 
1. Other parameters influencing access are: the availability of services, the distance 
between health care facilities and patients, the appropriate organization of these 
facilities (decent opening hours, appointment systems etc.) and the acceptability of 
providers’ attitudes towards patients (Penchansky & Thomas, 1981).
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systems, is vital. Next to being an important goal in its own right, perhaps as the single 
most important capital good, a healthy population is also an essential prerequisite for 
development. This is highlighted by the eight Millennium Development Goals, three 
of which are directly related to health (United Nations Development Program, 2012b).2 
While the disease burden in LMICs was mostly caused by communicable diseases in the 
past decades, more recently the burden of non-communicable (or lifestyle) illnesses in 
these countries is rapidly increasing (Lopez et al., 2006). This epidemiological transi-
tion, next to the fact that populations in most LMICs are growing, raises additional 
questions about an optimal provision of health care in the context of clear budget 
restrictions at the macro and micro level. Consequently, governments in LMICs need to 
set priorities and ration health care services. With funds being (much) scarcer than in 
developed countries and health care systems mostly being underdeveloped (Leather-
man et al., 2010), presumably, for these countries deciding in which care to invest is 
more urgent and may have larger health consequences.
High-income countries also face problems regarding the affordability of health care. 
However, in most high-income countries (social) health insurance systems are function-
ing and accessibility is not as strongly linked to ability to pay as in many LMICs. Indeed, in 
those health insurance systems, solidarity between high and low risk groups and high- 
and low-income groups is ensured through the pooling of risks and pre-paid contribu-
tions. This leads to accessible health care for the (vast) majority of citizens and patients in 
high-income countries (Thomson et al., 2009). The problem that many of these countries 
face is that of rising health care expenditures, raising questions regarding the sustain-
ability and affordability of (social) health insurance systems. Aging populations, being 
ahead in the epidemiological transition to non-communicable diseases compared to 
LMICs and expensive new technological innovations are an important cause for this 
(Newhouse, 1992; Costa Font & Sato, 2012). Thus, high-income countries are confronted 
with difficult decisions regarding how to maintain an affordable health care system at 
a macro-level. More private payments and limiting the entitlements of the insured are 
two ways of doing so, but both may lead to issues of affordability of care at a micro-level.
The above briefly introduces the topic of this thesis; the issue of affordability in the 
health care sector. The main aim of this thesis is to contribute to the understanding 
of the role and importance of affordability in relation to choices in health care and 
to its measurement. This thesis does so through several studies in both LMICs and 
high-income countries.
2. Reduce child mortality, Improve Maternal Health and Combat HIV/AIDS, Malaria and 
other diseases.
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1.2 reseArCH QuestioNs
The main research questions of this thesis are the following:
1. How can the affordability of health care services be measured in LMiCs?
 This thesis addresses this question in part I, in which chapters 2 – 4 focus on 
affordability at the micro level in LMICs.
2. How can the concept of affordability inform choices regarding the benefit pack-
age of a mandatory health insurance system?
 With a focus on a high-income country, this question is addressed in part II, chapter 5.
3. How can choices regarding the allocation of scarce resources be informed?
 In part III of this thesis, chapters 6 – 8 indicate how policymakers can be provided 
with information to inform choices in the areas of breast cancer and HIV/AIDS.
1.3 HeALtH eCoNoMiCs ANd AffordABiLity
Health economists try to inform policymakers on how to best use their (limited) re-
sources. To see what the impact of health care expenditures is on family incomes and 
poverty, and hence study the issue of affordability, health economists have developed 
and worked with the impoverishment and catastrophic payment methods (Wagstaff 
& Van Doorslaer, 2001; Wagstaff & Van Doorslaer, 2003). The catastrophic payment 
method calculates the proportion of the population that would spend more than a 
certain percentage of their income to pay for some health care commodity. Hence, it 
expresses affordability in terms of a maximum percentage of income to be spent on 
a certain good. Beyond that percentage the payment for the commodity is deemed 
“catastrophic” (unaffordable). The impoverishment method estimates the propor-
tion of the population that would be pushed below some relevant poverty line by 
procuring a given medicine. Hence, this method focuses on the residual income after 
a purchase and works from the premise that people should not fall below some ab-
solute minimum level of income due to a purchase. If people do or would, the good 
can be considered unaffordable. Applying these methods requires information on 
the price of a commodity, incomes and some level of unacceptable burden, i.e., the 
maximum percentage of income to be spent on some good or the minimum income 
level left after a purchase. However, in many LMICs the micro data that are commonly 
used to operationalize these methods are not readily available, limiting their use 
and hence the monitoring of affordability. Furthermore, the impact of the thresholds 
used -i.e., the maximum percentage of income spent or the poverty line used- when 
working with these methods is very influential on final outcomes. This thesis broadens 
the possible application of the impoverishment and catastrophic payment concepts 
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by applying them with (more readily available) macro data and investigating what 
impact using different methods and thresholds has on levels of affordability.
Over the last three decades the field of health economics has developed the tools 
and models to calculate the incremental costs and effects of health care interventions 
in cost-effectiveness analyses. The development of the Quality Adjusted Life Year, or 
QALY, has made it possible to compare the relative efficiency of interventions across 
different disease areas (Drummond et al., 2005). Although interventions delivering 
QALYs at lower cost may be considered more efficient than those delivered at a 
higher cost, the cost per QALY metric does not give insight in ‘the affordability’ of 
an intervention. The ratio only indicates at what price health can be bought through 
an intervention, but not whether this is deemed ‘value for money’. To answer the 
latter question, one needs to know how much a society is prepared to pay for health: 
the value attached to a QALY. This amount will probably depend on the income 
level of a country (as suggested by the World Health Organization3) and, hence, can 
be considered related to affordability. If the price per QALY exceeds what a society 
is willing and able to pay, the related intervention may be deemed unaffordable. 
Then, the opportunity costs in the form of other goals worthy of collective financing 
are simply too high. The actual value people place on one QALY or our willingness to 
pay for one year in full health is an increasingly researched topic (Culyer et al., 2007; 
McCabe et al., 2008; Pinto-Prades et al., 2009; Bobinac et al., 2010).
Most social insurance systems have developed criteria for determining the en-
titlements (basic benefit package) of the insured population (le Polain et al., 2010; 
Franken et al., 2012). Although efficiency arguments play a role in all these sys-
tems, not many countries (openly) ration on the basis of efficiency considerations. 
In the Netherlands the Dutch Health Care Insurance Board (CVZ) has developed a 
framework to delineate the basic benefit package. In this framework CVZ assesses 
the necessity for medical intervention and the studied technology’s effectiveness, 
efficiency and the feasibility (of it being implemented or included). The necessity 
criterion addresses the question whether the disease or required health care war-
rants a claim on solidarity. One of the reasons why this does not need to be the case 
is that people can afford to pay for the technology out-of-pocket. This thesis further 
refines the operationalization of the necessity criterion, as used in the context of 
delineating the Dutch basic benefits package.
Health economists also have advanced techniques to study equity in health care 
(Van Doorslaer et al., 1992; O’Donnell et al., 2008). This concerns not only the fair 
distribution of health (which can be defined as “the absence of systematic dispari-
ties in health between groups with different levels of underlying social advantage/
3. http://www.who.int/choice/costs/CER_thresholds/en/print.html
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disadvantage—that is, wealth, power, or prestige” (Braveman & Gruskin, 2003)), but 
also a fair distribution of health care and (financial) health care contributions. These 
issues may obviously be interrelated. In countries where OOP-payments account for 
a substantial portion of health care financing, wealth differences may cause differ-
ences in health care utilization and access, which may, in turn, lead to (unfair) differ-
ences in health. Research into equity in breast cancer care is relatively rare, especially 
in LMICs. This can partly be explained by the relatively high data requirements of 
such studies, which are not easily met in most LMICs (Parkin et al., 1999; Parkin et al., 
2005; O’Donnell et al., 2008). In this thesis, the results of a study inquiring whether 
breast cancer treatment outcomes differ across socio-economic quintiles -i.e., people 
for whom treatment is more or less affordable- in an academic hospital in Ghana will 
be presented.
1.4 outLiNe of tHe tHesis
PArt i – Affordability at the micro level in low- and middle-income 
countries: the example of medicine affordability.
The first part of this thesis focusses on the affordability of medicines in LMICs, which 
account for a large proportion of total health care costs in LMICs and are often 
paid for OOP. The work presented in this part results from a joint project with the 
World Health Organization (WHO) and Health Action International (HAI). WHO/HAI 
gathered information on medicine prices and availability in LMICs (Cameron et al., 
2009b). Cameron et al. (2009b) did not use the aforementioned impoverishment or 
catastrophic payment methods to calculate the affordability of medicines. Instead, 
medicine affordability was expressed in terms of the days’ wages that a country’s 
Lowest Paid unskilled Government Worker (LPGW) needs to spend on a standard 
course of treatment (Cameron et al., 2009b). This metric, although perhaps easy to 
understand, does not clearly indicate (especially in country comparisons) for how 
many people a medicine is deemed unaffordable. This is especially due to the fact 
that the metric does not consider the income distribution in a country nor the fact 
that many people might earn less than the LPGW.
The application of the impoverishment and catastrophic payment methods requires 
micro data from household surveys. Because in LMICs these are not available on a 
yearly basis and are not conducted in a standardized way, the comparability of results 
across countries and over time is limited (Van Doorslaer et al., 2006; O’Donnell et al., 
2008). In an attempt to address these limitations, in chapter 2 the impoverishment 
and catastrophic payment methods are operationalized with macro data, which are 
more readily available. In chapter 3 the impoverishment method as operationalized 
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with macro data is applied to calculate the affordability of four essential medicines 
in sixteen LMICs using poverty lines of US$1.25 and US$2.00 per day. Chapter 4 then 
focusses on the importance and challenges that relate to the choice of when to 
consider something to be unaffordable when applying either the impoverishment 
or catastrophic payment method.
PArt ii – Affordability at the macro level in a developed country: 
delineating entitlements in social health insurance systems.
Because increasingly expensive medical technology is an important reason for ris-
ing health care costs (Newhouse, 1992; Fuchs, 1996; Organization for Economic 
Co-operation and Development, 2006; Organization for Economic Co-operation and 
Development, 2010; Chandra & Skinner, 2012; Sorenson et al., 2013) delineating the 
basic benefit package in a stricter manner is a prime candidate to control the growth 
of health care expenditures in the Netherlands (Ham, 1997; Rijksoverheid, 2013). The 
discussion on how to do so, however, has been debated ever since the Dunning com-
mittee in 1991 published a report which proposed a methodology for this. Depicting 
the concepts of necessity, effectiveness, efficiency and own account & responsibility 
as sieves in a funnel, the committee argued that only those interventions passing 
through all four sieves of this funnel should enter the basic benefit package (Dun-
ning A.J., 1991). Although there has been much support for these general principles, 
their definition and operationalization has been much debated and researched (e.g., 
Commissie Criteria Geneesmiddelenkeuze (chair: van Winzum), 1994; Wetenschap-
pelijke Raad voor het Regeringsbeleid, 1997). In the Netherlands, CVZ is responsible 
for advising the Minister of Health on reimbursement decisions. It is good to note 
that its current decision framework is importantly based on Dunning’s first three cri-
teria (College voor Zorgverzekeringen, 2009a). The necessity criterion is now formed 
by two distinct sub-criteria: disease burden and necessity of insurance. To determine 
the disease burden, which is a measure of disease severity, CVZ applies the concepts 
of fair innings (Williams, 1997) and proportional shortfall (Stolk et al., 2004; Van de 
Wetering et al., 2013). Under the former, people are considered to be entitled to 
some ‘normal’ health achievement whereby those who do not meet this could re-
ceive more weight in health care decision making. According to the latter approach 
those people who stand to lose a larger proportion of their remaining health expec-
tancy should be given priority in the decision making process. The sub-criterion of 
necessity of insurance concerns the question whether, from an individual viewpoint, 
insuring some intervention is necessary and appropriate. The operationalization of 
this criterion to date has not received much attention outside the field of medical 
aids (College voor Zorgverzekeringen, 2008a). Chapter 5 introduces a framework 
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which aims to provide guidance, structure and transparency for the application of 
the necessity of insurance criterion, also in other health care domains.
PArt iii – Health economics at the macro level in low- and middle-income 
countries: choices in breast cancer and Hiv/Aids.
While studying the affordability of health care services and systems at the micro and 
macro level provides useful insights for policy makers in both LMICs and high-income 
countries, in the end scarcity of resources requires choices. Part III of this thesis hence 
reports on the application of (health-economic) techniques that can be used to in-
form those choices. The last three studies again focus on LMICs where the burden of 
disease is typically higher than in high-income countries (Lopez et al., 2006) and the 
available per capita budget for health care is much lower (The World Bank Group, 
2013c). Hence, an inefficient or unfair use of resources in these countries may have 
even larger effects on (the distribution of) population health than in high-income 
countries. Providing an optimal mix of health care interventions and ensuring that 
those needing them can access them, is an important goal in these countries which 
can be supported by scientific evidence. In chapter 6 we use a general longitudinal 
population model (Lauer et al., 2003; Zelle et al., 2012) to calculate the costs and ef-
fects of various breast cancer interventions in Costa Rica and Mexico. After adjusting 
the model parameters to best resemble the breast cancer treatment and outcome 
situations in these countries, these cost-effectiveness analyses provide informa-
tion for decision makers on how to further improve the breast cancer programs in 
their countries. Next, chapter 7 reports on an equity study in Ghana, investigating 
whether patients from different socio-economic backgrounds experience different 
treatment outcomes from breast cancer care. Finally, chapter 8 of this thesis sheds 
light on which policy areas need to be strengthened to tackle the HIV/AIDS epidemic 
in sub-Saharan Africa. While many studies focus on how various specific variables/
policy areas impact HIV-prevalence, these variables/policy areas do not stand alone, 
i.e., they all influence HIV-prevalence simultaneously, perhaps offsetting each other. 
Therefore, we decided to take several variables from the United Nations’ Human 
Development Reports and study if, and if so how, they simultaneously impacted 
changes in HIV-prevalence over a five-year span.
In Chapter 9 the results from the individual chapters will be discussed and linked to 
the main research questions. Furthermore, their limitations will be debated and it 
will be shown how decision makers can use the outcomes presented in this thesis for 
policy making. Finally, future research questions will be identified.

PArt i
Affordability at the Micro Level in Low- 
and Middle-income Countries: The 
Example of Medicine Affordability

Chapter 2
Practical Measurement of Affordability: 
An Application to Medicines
Published as:
Niëns LM, Van de Poel E, Cameron A, Ewen M, Laing R, Brouwer WBF. 
“Practical measurement of affordability: an application to medicines.”
Bulletin of the World Health organization 2012 90(2): 219-227.
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ABstrACt
We use two practical methods for measuring the affordability of medicines in 
developing countries. The proposed methods –impoverishment and catastrophic 
payment methods– rely on easily accessible aggregated expenditure data and take 
into account a country’s income distribution and absolute level of income. The 
catastrophic payment method quantifies the proportion of the population whose 
resources would be catastrophically reduced by spending on a given medicine; the 
impoverishment method estimates the proportion of the population that would be 
pushed below the poverty line by procuring a given medicine. These methods are 
illustrated by calculating the affordability of glibenclamide, an antidiabetic drug, in 
India and Indonesia. The results were validated by comparing them with the results 
obtained by using household micro data for India and Indonesia.
We find that when accurate aggregate data are available, the proposed methods 
offer a practical way to obtain informative and accurate estimates of affordability. 
Their results are very similar to those obtained with household micro data analysis 
and are easily compared across countries.
The impoverishment and catastrophic payment methods, based on macro data, 
can provide a suitable estimate of medicine affordability when the household level 
micro data needed to carry out more sophisticated studies are not available. Their 
usefulness depends on the availability of accurate aggregated data.
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2.1  iNtroduCtioN
Affordability is not an unequivocal concept; Bradley (2008) calls it vague, and White-
head (1991), Milne (2006) and Komives et al. (2005) deny it having a clear basis in 
economic theory. The theory assumes that a household chooses the bundle of goods 
and services that maximizes utility -i.e. the benefit derived per money spent- subject 
to its preferences and budget. Clearly, different preferences lead to different choices 
on how much to spend on a particular commodity. The definition of what consti-
tutes an “affordable” price is thus a normative one that, according to some, lacks 
an economic foundation (Stone, 2006). A commodity is obviously unaffordable if it 
costs more than what is in the full (potential) budget, but such a definition is overly 
restrictive.
According to MacLennan & Williams, describe affordability as securing a standard 
of living (e.g. housing, education or transport) at a price that “does not impose, in 
the eyes of a third party (usually government), an unreasonable burden on house-
hold incomes” (in: Hancock, 1993). To operationalize the concept of affordability, 
one therefore needs (i) information on household incomes; (ii) knowledge of the 
price of the commodity in question, and (iii) a definition of “unreasonable burden”. 
This highlights two problems related to measuring unaffordability. First, there is 
arbitrariness in defining “an unreasonable burden”. Previous work has identified 
two ways to define this unreasonable burden: (i) the so-called catastrophic payment 
method, which is based upon the ratio of the payment for a particular commodity 
to a household’s total resources, and (ii) the impoverishment method, which looks at 
a household’s residual income after paying for a good (Whitehead, 1991; Hancock, 
1993; Carruthers et al., 2005; Kutty, 2005; Stone, 2006). The second problem is that 
measuring affordability in practice requires a large amount of household level data 
that is often difficult to access, only available for certain years, not comparable across 
different time periods or countries, or simply lacking.
To address the second problem while simultaneously acknowledging the first, 
in this paper we apply the impoverishment and catastrophic payment methods in 
a manner that can be applied to a broad range of commodities when micro data 
are scarce. We do this by applying these methods using widely available aggregate 
data, which makes for easy implementation and comparison across countries. We 
explore their use in elucidating the affordability of medicines, a commodity critically 
related to affordability. Indeed, in the developing world, medicines account for a 
substantial part of health-care costs (World Health Organization, 2000; World Health 
Organization, 2004b; Van Doorslaer et al., 2006; Cameron et al., 2009b). Since most 
of the population in many low-income countries lacks health insurance (Dror et al., 
2002), medicines have to be paid for out of pocket when people fall ill. If their 
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prices are too high, people are unable to procure them and often forego treatment 
altogether or get into debt (Flores et al., 2008). It is therefore important to examine 
and compare the affordability of medicines across countries in the developing world 
and to monitor the impact of interventions seeking to improve it.
Measuring affordability
As explained before, two approaches are generally used to estimate affordability. One 
relies on the ratio of expenditures to total household resources, whereas the second 
focuses on the residual income after an expenditure. Under the first approach, the 
payment for a commodity is deemed “catastrophic” (unaffordable) when it exceeds a 
certain proportion of a household’s resources. The idea is that if a household spends 
a large fraction of its available budget on a specific item, it will have to reduce its 
consumption of other goods and services. The affordability threshold is subjective 
(Hancock, 1993; Xu et al., 2003; Stone, 2006). Studies of this approach, which have 
focused primarily on the affordability of transportation (Carruthers et al., 2005), 
education (Murakami & Blom, 2008), health care (Wagstaff & Van Doorslaer, 2003; 
Xu et al., 2003) and utilities such as energy and water (Organization for Economic 
Co-operation and Development, 2003; Frankhauser & Tepic, 2005) define the afford-
ability of a commodity in terms of the share of available resources that it consumes. 
Since spending even a small share of the budget can have catastrophic consequences 
for very poor individuals, it makes sense to define affordability in terms of the share 
of the budget that is left after spending on basic necessities (usually food). The lat-
ter has been referred to as “nondiscretionary expenditure” or “capacity to pay” 
(Wagstaff & Van Doorslaer, 2003; Xu et al., 2003).
The second or “impoverishment” method considers the absolute quantity of avail-
able resources before and after payment for a commodity. If the household is initially 
above the poverty line but drops below it after paying for the commodity, it can be 
said to have been “impoverished” by the payment (Dolbeare, 1966; Wagstaff & Van 
Doorslaer, 2003; Xu et al., 2003; Kutty, 2005). This approach has been commonly used 
to study housing affordability (Kutty, 2005; Stone, 2006) and has also been applied 
to health care (Wagstaff & Van Doorslaer, 2003; Xu et al., 2003). Niëns et al. (2010) 
have recently calculated the affordability of medicines in 16 low- and middle-income 
countries using this impoverishment method. The method is clearly more specifically 
focused on the poor within society, as the closer an individual is to the poverty line, 
the more likely it is that certain expenditures will push the individual below it.
The methods as operationalized by Xu et al. (2003) and Van Doorslaer et al. 
(2006), while theoretically optimal, may be difficult to apply in practice, especially in 
low- and middle-income countries, because they are relatively data intensive. This is 
particularly so if the goal is to monitor outcomes over time and make cross-country 
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comparisons. Comparisons across countries and over time are further complicated by 
the fact that individual household surveys suffer from methodological heterogene-
ity.
Aware of the problems inherent to measuring affordability, the World Health 
Organization (WHO) and Health Action International (HAI) have used the wage of 
the lowest paid unskilled government worker (LPGW) to calculate the affordability 
of medicines (World Health Organization & Health Action International, 2008; Cam-
eron et al., 2009b). Such affordability has been expressed in terms of the number 
of days the LPGW has to work to be able to pay for a course of treatment with a 
particular drug. This LPGW-based metric is easy to apply and to understand; people 
in any country can easily position themselves relative to the LPGW. However, this 
metric may overestimate the affordability of medicines because a substantial propor-
tion of the population in some countries earns less than the LPGW (Cameron et al., 
2009b; Niëns & Brouwer, 2009; Niëns et al., 2010). Furthermore, the number of days 
of LPGW wages that makes something unaffordable is not clearly determined; this 
income metric is used only by WHO/HAI and no reference standards are available in 
the literature. As a result, the quest for a feasible way of applying the catastrophic 
payment and impoverishment methods in data-poor countries is amply justified.
In the remainder of this paper, we explain the methodological details of a less 
data-demanding and easily applicable operationalization of the catastrophic pay-
ment and impoverishment methods, and we illustrate them by calculating the af-
fordability of glibenclamide, a drug for diabetes. For this purpose we have used data 
from a price survey undertaken with the WHO/HAI price measurement tool in India 
and Indonesia (World Health Organization & Health Action International, 2008). We 
then compare the results of applying this method with the results of theoretically 
similar calculations using household data.
2.2  MetHods
Throughout this paper we refer to household level data as micro data and to ag-
gregated data as macro data. The methods proposed in this paper only require 
aggregated data and are therefore referred to as macro methods, whereas methods 
typically calling for micro data are referred to as micro methods. To check the sensi-
tivity of our proposed method to using different data, we produce results for several 
combinations of data and methods.
26 Chapter 2
Micro and macro methods
O’Donnell et al. (2008) elaborately explain how to calculate impoverishment and 
catastrophic payments at the household level using micro data. Other applications 
can be found in Van Doorslaer et al. (2006), Xu et al. (2003), Wagstaff and Van Door-
slaer (2003) and Russell (2004).
The method for calculating medicine affordability that we propose in this paper 
requires a knowledge of four components: (i) the price of (treatment with) a given 
medicine (P) (ii) a country’s total population (Pop); (iii) the aggregate income level 
of a country (Y); and (iv) the proportion of the total income earned across income 
groups (D) within a country. The last three components are first combined to draw 
an income distribution that plots the average daily income for each income group. 
Figure 1 shows an example of such a distribution. The x-axis ranks the total popula-
tion (Pop) by increasing income (income groups D1 to D7), whereas the y-axis plots 
the average daily incomes (groups Y1 to Y7). Because aggregated data are usually 
available for up to seven income groups, the explanation of our methods is based on 
this number, but the methods can be applied to more groups.
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figure 1: Distribution of average daily per capita income across income groups in Indonesia (2005)
PL: Poverty Line
Note: The x axis ranks the total population by increasing income (income groups D1 to D7), 
whereas the y axis plots the average daily incomes (groups Y1 to Y7).
Since we have no information on how income is distributed within each income 
group, we assume linearity and plot the average income of each group at the mid-
point, i.e., we assume that the mean and median incomes in each income group 
coincide. For example, for the income group between the 40th and 60th percentiles 
we plot the average income on the 50th percentile. This is clearly a simplification. 
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In reality, the income distribution within each income group is likely to be skewed 
because most people in the group probably earn less than the average. This means 
that we are likely to overestimate the average income for each income group and 
therefore to underestimate the affordability of the medicine later on in the analysis.
the impoverishment approach
This method aims to compare the proportion of the population below the poverty 
line (PL) before (Ipre) and after (Ipost) the hypothetical procurement of a medicine. 
Assume that line PL in Figure 1 represents the poverty line in a specific country. To 
calculate the proportion of the population living below this line, we focus on the 
income distribution between two income points, one just below and the other just 
above the poverty line, in this case A and B. With the coordinates of these points 
known [i.e., for A, (D1, Y1); for B, (D2, Y2)], we can calculate the linear function of the 
(thick black) line going through A and B (Equation 1: Y= Y
2−Y1  D+C
D2−D1
) which allows 
us to estimate the proportion of the population living below the poverty line (Ipre).
To estimate the proportion of the population below the poverty line after purchas-
ing a medicine, Ipost, we assume a parallel shift downwards of the linear function 
equal to the medicine price P. Equation 1 then changes into Equation 2:
Y’=
Y2−Y1
D+C−P
D2−D1
Again, substituting Y’ by PL in this Equation 2 gives us Ipost, the proportion of the 
population in poverty after procurement of the medicine. The difference in the 
proportion of the population below the PL before and after paying P, Ipost – Ipre, gives 
the proportion of the population that would be impoverished if everyone had to 
buy a medicine costing P. For the percentage of the population represented by Ipost, 
the medicine is deemed unaffordable.
the catastrophic payment approach
In the existing literature, total health care expenditures are usually considered cata-
strophic if they exceed 10% of a household’s total spending or 40% of non-food 
spending (Prescott, 1999; Ranson, 2002; Wagstaff & Van Doorslaer, 2003; Xu et al., 
2003; McIntyre et al., 2006; O’Donnell et al., 2008).
In developing countries, such as India and Indonesia, medicines make up a rela-
tively large portion (20–70%) of total health expenditure and are paid largely out of 
pocket (World Health Organization, 2000; World Health Organization, 2004b; Van 
Doorslaer et al., 2006). According to data from WHO’s 2003 World Health Survey 
for India, drug spending in the country accounts for about 44% of all out-of-pocket 
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spending on health. Low health insurance coverage in Indonesia (26.1% in 2007) and 
India (approximately 20%) indicate that most spending on medicines is paid for out 
of pocket (World Health Organization, 2003; Rokx et al., 2009).
Hence, to calculate the affordability of medicines we propose using a threshold 
that is roughly half the threshold generally used when calculating total health care 
expenditure, i.e., 5% instead of 10%. However, the method can obviously accom-
modate different percentages.
The proportion of the population for which purchasing a medicine costing P is 
catastrophic is again calculated from Figure 1. At a 5% catastrophic threshold, the 
medicine with price P is unaffordable for people earning less than 20 times P. This 
proportion is again calculated by drawing a line between the points for average 
income that include 20P. By substituting Y by 20P in Equation 1, we get the propor-
tion of the population exposed to catastrophic payments, Xcat.
data sources
We obtained medicine prices from the WHO/HAI database, which lists median treat-
ment prices for a large range of medicines. WHO/HAI collects medicine prices from 
five medicine outlets per sector in at least four geographic or administrative regions 
in a given survey area. For each medicine, prices are collected for both the originator 
brand (OB) and the lowest-priced generic (LPG) equivalents in the private and public 
sectors. We use private sector prices because drug availability in the public sector is 
low and the data are often insufficient to make reliable price estimates (Cameron et 
al., 2009b; Niëns et al., 2010).
In our examples we use the price of 5-mg capsules/tablets of the LPG glibenclamide 
in India (April 2003 – January 2005) and Indonesia (August 2004) and assume the stan-
dard treatment regimen of 2 tablets a day. We chose these two countries because of 
the availability of micro, macro and medicine price data. We selected glibenclamide 
because in India and Indonesia diabetes affects 50.7 million and 6.9 million people 
(4.6% and 7.1% prevalence, respectively) (International Diabetes Federation, 2010).
When the lowest-priced generic equivalent of glibenclamide is procured in the 
Indonesian private sector, the median price of treatment with the drug is 417 Indo-
nesian rupiah (IDR) a day. For India, seven WHO/HAI surveys are available, and each 
covers a state or part of a state. As the price of LPG glibenclamide in the private 
sector varies little (between 1.28 and 1.60 Indian rupees (INR) a day) and given the 
aim of this paper, we work with the average price of LPG glibenclamide over the 
seven surveys, i.e., INR 1.40.
The aggregate income level (Y) and income distribution of India and Indonesia are 
retrieved from the World Bank’s World Development Indicators (WDIs). Gross do-
mestic product (GDP) per capita is often used as a proxy for people’s actual incomes. 
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However, a country’s GDP consists of consumption, gross investment, government 
spending and net trade. For this study the main interest lies in consumption, since 
it reflects the amount of money people can actually spend. Therefore, household 
final consumption expenditure as provided in the WDIs, is used. This is in line with 
micro-level analysis, in which expenditure data are usually preferred to income data 
because the former are believed to better reflect household resources in developing 
countries (O’Donnell et al., 2008). As for income distribution D, the WDIs provide the 
percentage of total income earned in seven income groups: five quintiles, with the 
upper and lower quintiles split into two deciles each.
We use the 2005 PL thresholds of 1.25 and 2.00 United States dollars (US$) a day, as 
suggested by the World Bank (The World Bank Group, 2010; The World Bank Group, 
2013c). We convert the PL thresholds to 2005 Indonesian rupiahs (IDR 4917 and IDR 
7869) and 2000 Indian rupees (INR 18.20 and INR 29.12) with conversion factors from 
the World Bank International Comparison Program (The World Bank Group, 2011a). 
We perform all calculations of Ipre, Ipost – Ipre and Xcat in local currency units, but we 
express all prices and amounts in this paper in 2005 purchasing power parity US$.
To check the robustness of our results, we also calculate the affordability of LPG 
glibenclamide using micro data from the 2005 wave of the Indonesian National 
Socioeconomic Survey (Susenas) (n = 7302 households) and the Indian National 
Sample Survey (NSS) data set from 2000 (round 55) (n = 93 854 households). These 
surveys collect information on total household expenditures through an extensive 
expenditure module in the household survey (Ministry of Statistics and Program 
Implementation, 2011; RAND Corporation, 2011).
2.3  resuLts
Micro data
Table 1 shows the results of the calculations based on micro data. In Indonesia the 
proportions of the population living below the US$ 1.25 and US$ 2.00 PLs (Ipre) are 
28.8% and 61.7%, respectively. The proportions of the population at risk of being 
impoverished by procuring LPG glibenclamide (Ipost – Ipre) are 5.8% and 3.7%, respec-
tively. The catastrophic payment approach shows the proportion at risk of being 
confronted with catastrophic payments (Xcat) to be 65.9%.
In India, the proportion of people living below the US$ 1.25 and US$ 2.00 PLs (Ipre) 
is 53.0% and 80.4%, respectively. The impoverishment rates (Ipost – Ipre) in the country 
are 5.1% and 1.9%, and the proportion of the population at risk of catastrophic 
payments (Xcat) is 78.6%.
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table 1: Proportion (%) of population impoverished or at risk of incurring catastrophic 
payments by purchasing treatment with lowest-priced generic equivalent of glibenclamide, 
by micro method using micro data for India and Indonesia
Country (source) Below PL before medicine 
purchase (ipre)
impoverished by medicine 
purchase (ipost – ipre)
a
Catastrophic 
payment (xcat)
b
indonesia (wdi 2005)
PL threshold < US$ 1.25c < US$ 2.00d < US$ 1.25c < US$ 2.00d
% of population 28.8 61.7 5.8 3.7 65.9
india (wdi 2000)
PL threshold < US$ 1.25c < US$ 2.00d <  US$ 1.25c < US$ 2.00d
% of population 53.0 80.4 5.1 1.9 78.6
Ipost, percentage of the population below the poverty line after expenditure; Ipre, percentage 
of the population below the PL before expenditure; WDI, World Bank world development 
indicators;  Xcat, percentage of the population at risk of incurring catastrophic payments at a 
threshold of 5% of per capita household expenditures.
a Impoverishment method.
b Catastrophic payment method.
c Purchasing power parity United States dollars (2005).
d Purchasing power parity United States dollars (2005).
Macro data
Table 2 shows the results of using the aggregate income, as measured by the house-
hold final consumption expenditure (Y), the proportion of total income earned 
across income groups (D) and the total population (Pop) to calculate the daily aver-
age income per capita for each income group in India and Indonesia.
Dividing Y by Pop to derive per capita income estimates relies on the assump-
tion that the average household size is constant across income groups. Since poorer 
households are typically larger (Lipton & Ravaillon, 1994), the average income per 
capita is likely to be overestimated in the lower income distribution ranges, which 
should make our affordability estimates conservative.
In Indonesia, the daily cost of the standard treatment with LPG glibenclamide is 
US$ 0.11, so individuals earning between US$ 1.25 and US$ 1.35 and between IDR 
US$ 2.00 and US$ 2.10 are at risk of being pushed below the US$ 1.25 and US$ 2.00 
PLs, respectively, should they have to buy glibenclamide. In India, where the cost of 
LPG glibenclamide is US$ 0.10, the individuals at risk of being pushed below the US$ 
1.25 and US$ 2.00 PLs are those whose income ranges between US$ 1.25 and US$ 
1.34 and between US$ 2.00 and US$ 2.09, respectively.
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table 2: Use of aggregated income and population data to calculate average daily income 
per capita (IPC) in specific income groups in India and Indonesia
Cumulative % 
of populationa,b
income group india (wdi 2000) indonesia (wdi 2005)
income 
distribution
(%)
Average 
daily iPC 
(iNrc)
income 
distribution 
(%)
Average 
daily iPC 
(idrd)
D1  0–10 Poorest 10% 3.64 13.21 3.00 6,649
D2  10–20 Second poorest 10% 4.44 16.11 4.15 9,209
D3  20–40 Second 20% 11.27 20.45 10.74 11,914
D4  40–60 Third 20% 14.94 27.11 14.38 15,949
D5  60–80 Fourth 20% 20.37 36.96 20.45 22,683
D6  80–90 Second richest 10% 14.21 51.56 14.96 33,172
D7  90–100 Richest 10% 31.13 112.96 32.32 71,679
WDI, world development indicators (World Bank).
a In 2005 purchasing power parity United States dollars, aggregate income level (Y) for 
Indonesia is $425,869,484,516;Y for India is $1,046,538,703,424.
b Population of Indonesia: 220 558 000; population of India: 1 015 923 000.
c 1US$ = 14.56 INR.
d 1US$ = 3934 IDR.
Table 3 shows the results of calculations based on macro methods and macro data. 
The differences are graphically presented in Figure 2. For India, the figure displays 
the two poverty lines and the average daily incomes per capita based on the macro 
and micro data and methods. The proportions of the population below the US$ 2.00 
PL are indicated with vertical lines from both the square and the triangle.
table 3: Proportion (%) of population impoverished by or at risk of incurring catastrophic 
payments by purchasing treatment with lowest-priced generic equivalent of glibenclamide, 
by macro method using macro data for India and Indonesia
Country/year Below PL before medicine 
purchase (Ipre)
impoverished by medicine 
purchase (Ipost – Ipre)
a
Catastrophic 
payment (Xcat)
b
PL thresholds US$ 1.25c US$ 2.00d US$ 1.25 US$ 2.00
Indonesia (2005) 0.0 9.8 0.0 1.6 11.6
PL thresholds US$ 1.25c US$ 2.00d US$ 1.25 US$ 2.00
India (2000) 22.2 54.1 4.8 2.8 51.8
Ipost, percentage of the population below the poverty line after expenditure; Ipre, percentage 
of the population below the PL before expenditure;  Xcat, percentage of the population 
at risk of incurring catastrophic payments at a threshold of 5% of per capita household 
expenditures.
a Impoverishment method.
b Catastrophic payment method.
c Purchasing power parity United States dollars (2005).
d Purchasing power parity United States dollars (2005).
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figure 2: Poverty lines and incomes for India based on macro and micro data and methods
Note: The x-axis lists the middle of the income group percentiles used with the macro 
approach to plot our graph. As such, the graph based on macro data begins and ends at the 
5th and 95th percentiles, respectively. The proportions of the population below the US$ 2.00 
PL are indicated with vertical lines from both the square and the triangle.
There are large differences between Ipre poverty estimates and World Bank WDIs. 
For Indonesia, the World Bank’s poverty estimates for 2006 are 28.04% (US$ 1.25 
PL) and 62.76% (US$ 2.00 PL), whereas for India (2005) they are 41.6% (US$ 1.25 
PL) and 75.6% (US$ 2.00 PL) (The World Bank Group, 2013c). These estimates closely 
resemble the figures obtained using the micro method and micro data (Table 1), but 
not the ones (Ipre) obtained using the macro method and macro data (Table 3).
For each PL in Indonesia, the proportion of the population impoverished by the 
purchase of glibenclamide (Ipost – Ipre) is lower when calculated with the macro method 
and data (US$ 1.25 PL: 0.0%; US$ 2.00 PL: 1.6%; Table 3) than when calculated with 
the micro method and data (US$ 1.25 PL: 5.8%; US$ 2.00 PL: 3.7%; Table 1). In India, 
the proportion impoverished (Ipost – Ipre) is lower only for the US$ 1.25 PL (4.8% versus 
5.1%; Table 1), not for the US$ 2.00 PL (2.8% versus 1.9%; Table 1). This is because 
in India the US$ 2.00 PL, here measured with the macro methods, is now located in 
a lower income region (the region marked with a square in Figure 2) where D is less 
skewed -i.e., compared with the region marked with a triangle in Figure 2. In other 
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words, the linear line in the region marked with a square is slightly flatter than the 
convex income distribution (D) in the region marked with a triangle, which causes 
the shift over D to be larger for the same parallel drop of the linear function.
In both countries, the proportion of the population at risk of being confronted 
with catastrophic spending by purchasing glibenclamide (Xcat) differs substantially 
when calculated with the micro and macro approaches. While with the former, the 
proportion is 65.9% for Indonesia and 78.6% for India (Table 1), the latter approach 
gives proportions of 11.6% and 51.8% respectively (Table 3).
The results so far illustrate that the affordability of treatment with glibenclamide in 
India and Indonesia varies markedly depending on the method used to calculate it, 
but both the micro and macro approaches show that its affordability poses problems 
in both countries. The differences in the results obtained with the two methods may 
reflect a methodological effect or a data effect. We investigated this in more detail 
and found that while the methodological effect is negligible, the data effect is real, 
i.e., differences in micro and macro data account for the differences in the results 
found (Appendix).
2.4  disCussioN
The issue of affordability is not straightforward. Although it is a rather normative 
concept (Stone, 2006), this paper has explored two methods for estimating the af-
fordability of medicines in low- and middle-income countries: the catastrophic pay-
ment and the impoverishment method. To ensure their practical applicability, both 
were designed for use with aggregated data on medicine prices, per capita income 
level, and income distribution that are easily available for a broad set of developing 
countries from the WDIs and the WHO/HAI medicine price database. This facilitates 
the measurement, comparison and monitoring of affordability in a range of coun-
tries over time, as illustrated by Niëns et al. (2010). Clearly, the use of aggregated 
data does require some simplifying assumptions. For instance, in our study we have 
conservatively assumed per capita income to be linearly distributed across income 
groups, which is likely to generate bias and lead to lower affordability results. Other 
assumptions can be made in a relatively straightforward manner (e.g. by fitting a dis-
tribution line to the observed points). Worthy of note is that the methods presented 
here assess the catastrophic and impoverishing effects of hypothetical expenditures 
on medicines. In this setting, a medicine is considered 100% affordable if everyone 
can procure it without experiencing financial hardship.
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This study has some limitations. First, the usefulness of the proposed aggregated 
method depends largely on the validity of the aggregated income data. We found 
the WDI’s household final consumption expenditure estimates to be substantially 
higher than the income data collected in household surveys, a finding in line with 
Ravaillon’s observation that income data from household surveys for 88 countries 
with national accounts were lower 77% of the time (Ravallion, 2003). Thus, the 
use of macro methods leads to impoverishment rates that are lower than expected 
most of the time. Although household survey data generally yield the most precise 
estimates of affordability, total expenditure estimates from household surveys also 
differ because of differences in survey structure and in the questions asked (Lu et al., 
2009; Xu et al., 2009).
A more general limitation of our study is that it focuses on the affordability of a 
single medicine, which obviously ignores the need for more than one medicine and 
for other therapeutic methods in some cases, as well as related costs, such as fees for 
physician visits. However, our objective was not to provide a measure of treatment 
affordability as a whole, but only of medicine affordability. Since medicines account 
for a large portion of total treatment costs in low- and middle-income countries 
(World Health Organization, 2000; World Health Organization, 2004b; Van Doorslaer 
et al., 2006; Cameron et al., 2009b), their cost is largely indicative of people’s ability 
to afford the treatment for specific diseases.
Another limitation is the choice of the thresholds used to define impoverishment 
and catastrophic payments. Such a choice obviously influences the affordability 
outcomes and cannot be unambiguously defined. The impoverishment method calls 
for defining a threshold below which people are considered to be impoverished. 
Although the thresholds used in our study are well accepted and commonly applied, 
even in the context of global development initiatives, including the Millennium 
Development Goals (United Nations, 2010), they are ultimately based on norma-
tive choices regarding minimum human requirements in areas such as housing and 
nutrition. Many countries have defined their own poverty lines and these could also 
be used in this context, since the absolute threshold required for use of the impov-
erishment method should reflect the living standards in a given country. The thresh-
olds employed for the catastrophic payment method are even more arbitrary. We 
therefore recommend using a range of thresholds when applying the catastrophic 
payment method. The level of analysis should also be considered when setting a 
threshold. For instance, the relevant threshold may be set lower when assessing the 
affordability of individual medicines rather than total health-care expenditures. It is 
important that such choices be explicitly justified within studies.
The methods proposed in this paper allow for a more accurate estimate of afford-
ability than the LPGW method when reliable aggregated expenditure data are avail-
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able to mitigate the data effect. The methodological effect is negligibly small when 
macro methods are used, but the data effect can be sizable. Thus, using the WDI’s 
household final consumption expenditures as a proxy for expenditures at the ag-
gregate level can be useful in identifying trends in the affordability of medicines or 
other commodities, but the absolute numbers have to be interpreted with caution. If 
better aggregated data -i.e., data that is closer to estimates from household surveys- 
are available, the proposed macro methods allow for quite reliable affordability 
estimates. We have for example used aggregated spending indicators from India’s 
Planning Commission web site (Government of India, 2010) for Maharashtra state 
and confirmed affordability estimates to be very close to those based on household 
NSS data. (The results are available from the corresponding author upon request.)
A critique to the LPGW approach is that it may tend to overestimate affordability, 
as in many countries a substantial proportion of the population earns less than the 
LPGW. This was confirmed by our data. Using the micro method with micro data we 
find 95.5% of the population earns less than the LPGW in Indonesia, in India this 
percentage is 99.8%. In Indonesia, the average LPGW wage was IDR 20 700 a day in 
2004 (WHO/HAI survey). In India, the average LPGW wage over the seven WHO/HAI 
surveys was INR 133.81 (range: 120.00–143.93).
The two methods described herein, which are conceptually different, present 
ample opportunities for future research. Which method should be applied depends 
to a great extent on a particular country’s economic situation. When a large per-
centage of the population has a pre-payment income below the poverty line, the 
impoverishment method is useful only if this percentage is known. On the other 
hand, the catastrophic payment method does not capture to what extent, if at all, 
the “catastrophic” payments on medicines actually cause poverty and hardship. Very 
rich households can spend a “catastrophic” percentage of their income on medi-
cines without experiencing any financial difficulties. Again, affordability is a vague 
concept and its measurement requires some normative assumptions. This paper’s 
purpose was not to impose particular assumptions, but rather to propose measure-
ment tools that can be easily applied in settings were detailed household-level data 
are limited or unavailable to operationalize the concept of affordability, whether 
they are applied to medicines or to other health commodities. Such methods are 
particularly helpful in comparing affordability across countries or over time and their 
use can provide policy-makers with useful insights into people’s purchasing power in 
relation to the cost of medicines.
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APPeNdix
Macro versus micro data
Table 4 displays the average incomes for seven income groups (D1 to D7) calculated 
from the micro Susenas (Indonesia) and NSS (India) data sets (columns A and D). We 
calculated the incomes in columns B and E by aggregating total household incomes 
from the micro data and applying the WDI income distributions for 2005, i.e., as in 
Table 2. Finally, for comparison, columns C and F in Table 4 present the same incomes 
that are listed in Table 2.
The results presented in Table 4 clearly show that the average incomes obtained 
from the macro data are much higher (by a factor 1.5 to 2.5) than the ones obtained 
from the micro data. This can explain the low poverty estimates obtained when 
calculations are based on macro data.
table 4: Average incomes (Indonesia and India) per income group for micro & macro level 
data with both micro and macro income distributions
income group indonesia (idr) india (iNr)
income source (y) Microa Microa Macro Microb Microb Macro
distribution (d) Microa Macro Macro Microb Macro Macro
A B C d e f
D1 - Poorest decile 2,876 2,556 6,649 7.96 8.13 13.21
D2 - Second poorest 10% 3,908 3,540 9,209 10.63 9.91 16.11
D3 - Second 20% 5,008 4,580 11,914 13.46 12.58 20.45
D4 - Third 20% 6,666 6,131 15,949 17.58 16.68 27.11
D5 - Fourth 20% 9,073 8,720 22,683 23.95 22.74 36.96
D6 - Second richest 10% 12,755 12,752 33,172 33.33 31.73 51.56
D7 - Richest 10% 24,407 27,554 71,679 60.78 69.51 112.96
IDR, Indonesian rupiah; INR, Indian rupee; Macro, based on the World Bank’s World 
Development
Indicators.
a Susenas.
b NSS.
Macro methods applied to micro data
To further investigate whether the different results could be reflecting methodologi-
cal differences, we applied macro methods to the aggregate incomes as computed 
from micro data (columns A, B, D, E in Table 4) to calculate the proportion of the 
population below the PL (Ipre), the rates of impoverishment (Ipost − Ipre) and the pro-
portion at risk of facing catastrophic payments (Xcat) (Table 5). To see if the income 
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distribution (D) used caused the results to differ, we calculated D with both micro 
and macro data sets.
When we applied macro methods to micro data (both Y and D), the proportion of 
the population living below the PLs (Ipre) in both India and Indonesia was found to 
be lower than when we applied micro methods to micro data (Table 1). In Indonesia, 
Ipre was 28.8% and 60.0% respectively. In India Ipre was 51.9% and 78.3%, respectively 
(Table 5, Panel A).
table 5: macro methods on micro data
Panel A: Proportion below PL
Below PL before medicine purchase (ipre)
distribution (d) from micro macro
year country / PLs us$ 1.25c us$ 2.00d us$ 1.25 us$ 2.00
2005 Indonesiaa 28.8% 60.0% 34.4% 63.4%
2000 Indiab US$ 1.25c US$ 2.00d US$ 1.25 US$ 2.00
51.9% 78.3% 55.0% 80.6%
Ipre, percentage of the population below the PL before expenditure
a Susenas.
b NSS.
c Purchasing power parity United States Dollars (2005).
d Purchasing power parity United States Dollars (2005).
Panel B: impoverishment rates (Ipost - Ipre) & catastrophic payments (Xcat) at 5% of an 
individual’s total resources
impoverished by medicine purchase (ipost – ipre)
c
distribution (d) from Micro Macro
year Country /PLs us$ 1.25 us$ 2.00 us$ 1.25 us$ 2.00
2005 Indonesiaa 5.7% 3.5% 5.4% 3.2%
US$ 1.25 US$ 2.00 US$ 1.25 US$ 2.00
2000 Indiab 4.4% 2.2% 4.6% 2.3%
Catastrophic payment (Xcat)
d
2005 Indonesiaa 63.9% 68.1%
2000 Indiab 76.4% 78.8%
Ipost, percentage of the population below the poverty line after expenditure; Ipre, percentage 
of the population below the PL before expenditure; WDI, World Bank world development 
indicators;  Xcat, percentage of the population at risk of incurring a catastrophic payment at a 
threshold of 5% of per capita household expenditures.
a Susenas.
b NSS.
c Impoverishment method.
d Catastrophic payment method
c Purchasing power parity United States Dollars (2005).
d Purchasing power parity United States Dollars (2005).
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Impoverishment rates (Ipost − Ipre; see Table 5 Panel B) in Indonesia (5.7% and 3.5%, 
respectively, for the US$ 1.25 and US$ 2.00 PLs) were lower than when we applied 
micro methods to micro data (Table 1). In India, Impoverishment rates (Ipost − Ipre) are 
only lower at the US$ 1.25 USD PL, i.e., 4.4% compared to 5.1% in Table 1. However, 
at the US$ 2.00 PL we find Ipost − Ipre to be higher -i.e., 2.2% compared to 1.9% in 
Table 1- when applying the macro methods. The explanation for this is that a parallel 
shift downwards of the linear function in Fig. 1 (macro methods) causes a larger 
shift over the income distribution (D) than when using the real D with a convex 
curve (micro methods), because the latter is steeper between higher income groups. 
Thus, whereas the macro methods cause the proportion below the poverty line (Ipre) 
to be lower, this is not necessarily the case for the impoverishment rate (Ipost − Ipre), 
especially in higher income regions where the convex curve likely will be steeper. The 
proportion of the populations in Indonesia and India at risk of catastrophic payments 
drops to 63.9% and 76.4%, respectively (compared to 65.9% and 78.6% in Table 1).
Using the income distribution (D) from the macro data shows the results to be slightly 
different. In Indonesia the proportion below the poverty line (Ipre) increases slightly 
to 34.4% and 63.4% and the impoverishment rates (Ipost − Ipre) drop further to 5.4% 
and 3.2%. In India Ipre also increases to 55.0% and 80.6% below the PLs of US$ 1.25 
and US$ 2.00, respectively. However, Ipost − Ipre for the two poverty lines increases to 
4.6% and 2.3%. For both Indonesia and India, up to income group D6, (apart from D1 
in India) all the average incomes in columns B and E are lower than those in columns 
A and D. For income group D7 it is the other way around. Thus, compared to the mi-
cro income distribution (D), in this case D from the WDIs is more skewed in favour of 
the rich. As a result the proportion below the PLs (Ipre) and the proportion confronted 
with catastrophic payments (Xcat) are higher. For the impoverishment rates (Ipost − Ipre) 
on the other hand, this does not matter much as this figure does not depend on the 
absolute level of the income (but a shift over the same income distribution). The 
reasons for Ipost − Ipre to be higher for the 2.00 USD PL in India is the same as explained 
in the previous paragraph, i.e., the parallel shift equal to the price of a medicine (P) 
over a linear line takes up a larger portion of the income distribution D than the 
same shift over a convex curve.
The proportion of the populations in Indonesia and India at risk of catastrophic 
payments increases to 68.1% and 78.8% respectively (compared to 65.9% and 78.6% 
in Table 1).
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Letter to tHe editor: Better MeAsures of AffordABiLity reQuired
A. Cameron and colleagues (Cameron et al., 2009b) address the important topic of 
affordability of medicines in low-income and middle-income countries. The magni-
tude of the affordability problem depends on medicine prices and on the income 
level and distribution in a country. Regarding income level, a convenient yet uncom-
mon metric is used by Cameron and colleagues -i.e., the salary of the lowest-paid 
unskilled government worker (LPGW). Use of this unusual measure hampers the 
interpretation of results and might overestimate the affordability of medicines. As 
they acknowledge, often “a substantial proportion of the population” earns less 
than the LPGW. In collaboration with WHO and Health Action International, we 
investigated this situation in 17 of the countries in the Cameron study (Niëns et al., 
2009). It turned out that, in 13 of these countries, half or more of the population was 
actually able to spend (much) less than the LPGW. The LPGW therefore is relatively 
well-off in most countries and at least half of the population in the 13 countries needs 
to work more days than the LPGW to pay for necessary medicines. Using household 
expenditure data and income distributions, we applied more common measures of 
affordability of medicines, based on impoverishment -i.e., earning less than US$1 or 
$2 per day- and catastrophic spending on medicines, i.e., more than a certain propor-
tion of total spending (Hancock, 1993; Wagstaff & Van Doorslaer, 2003). Our results 
highlight that the already compelling results shown by Cameron and colleagues are, 
in fact, substantial overestimates of the affordability of medicines. Unfortunately, 
therefore, even more people lack financial access to necessary medicine, stressing 
the need for intervention.
Published as:
Niëns LM, Brouwer WBF, “Better measures of affordability required” Lancet 2009, March 28; 
373 (9669):1081 – Letter to the Editor

Chapter 3
Quantifying the Impoverishing Effects of 
Purchasing Medicines: A Cross-Country 
Comparison of the Affordability of 
Medicines in the Developing World
Published as:
Niëns LM, Cameron A, Van de Poel E, Ewen M, Brouwer WBF, Laing R 
“Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-
Country Comparison of the Affordability of Medicines in the Developing 
World.”
PLoS Medicine 2010 7(8): e1000333.doi:10.1371/journal.pmed. 1000333
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ABstrACt
Increasing attention is being paid to the affordability of medicines in low- and 
middle-income countries (LICs and MICs), where medicines are often highly priced 
in relation to income levels. The impoverishing effect of medicine purchases can be 
estimated by determining pre- and post-payment incomes, which are then compared 
to a poverty line. Here we estimate the impoverishing effects of four medicines in 
sixteen LICs and MICs using the impoverishment method as a metric of affordability.
Affordability was assessed in terms of the proportion of the population being 
pushed below US$1.25 or US$2 per day poverty levels because of the purchase of 
medicines. The prices of salbutamol 100mcg/dose inhaler, glibenclamide 5mg cap/
tab, atenolol 50mg cap/tab and amoxicillin 250mg cap/tab, were obtained from 
facility-based surveys undertaken using a standard measurement methodology. The 
World Bank’s World Development Indicators provided household expenditure data 
and information on income distributions. In the countries studied, purchasing these 
medicines would impoverish large portions of the population (up to 86%). Origina-
tor brand products were less affordable than lowest-priced generic equivalents. In 
the Philippines, for example, originator brand atenolol would push an additional 
22% of the population below USD1.25 per day, whereas for the lowest priced ge-
neric equivalent this is 7%. Given related prevalence figures, substantial numbers of 
people are affected by the unaffordability of medicines in practice.
Comparing medicine prices to available income in LICs and MICs shows that medi-
cine purchases by individuals in those countries could lead to the impoverishment of 
large numbers of people. Action is needed to improve medicine affordability, such 
as promoting the use of quality assured, low-priced generics, and establishing health 
insurance systems.
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3.1  iNtroduCtioN
In developing countries the cost of medicines accounts for a relatively large portion 
of total healthcare costs (World Health Organization, 2000; World Health Organiza-
tion, 2004b; Van Doorslaer et al., 2006; Cameron et al., 2009b). As the majority of 
people in developing countries do not have health insurance (Dror et al., 2002) and 
medicines provided free through the public sector are often unavailable (Cameron 
et al., 2009b), medicines are often paid for out-of-pocket at the time of illness. Con-
sequently, where medicine prices are high, people may be unable to procure them 
and forego treatment or they may go into debt. For this reason, the World Health 
Organization (WHO) has designated affordable prices as a determinant of access 
to medicines (together with rational selection and use, sustainable financing, and 
reliable health and supply systems) (World Health Organization, 2008a). In several 
international treaties, access to healthcare is laid down as a right (United Nations 
General Assembly, 1948; United Nations Office of the High Commissioner for Human 
Rights, 1966). States have a legal obligation to make essential medicines available to 
those who need them at an affordable cost. Determining the degree of affordability 
of medicines, especially in low- and middle-income countries (LICs and MICs), is an 
important, yet complex undertaking as affordability is a vague concept.
Medicine affordability has been investigated in terms of the days’ wages that a 
country’s lowest paid unskilled government worker (LPGW) needs to spend on a 
standard course of treatment (World Health Organization & Health Action Interna-
tional, 2008; Cameron et al., 2009b). However, this metric is limited in that it does 
not provide insight into the affordability of medicines for the often large sections 
of the population that earn less than the LPGW (Cameron et al., 2009b; Niëns & 
Brouwer, 2009). Recently, Niëns et al. (2009) have proposed two alternative methods 
to gain insight into the affordability of medicines in the developing world. A first 
method focuses on the catastrophic impact of expenditures on medicines, while the 
second approach consists of studying the impoverishing effect of these expenditures. 
This paper discusses the application of the latter approach and presents the results 
of a cross-country analysis of the affordability of four medicines in 16 developing 
countries.
3.2  MetHods
Our measurement of the affordability of medicines is based on the approach taken 
by Van Doorslaer et al. (2006), who reassessed poverty estimates in 11 Asian countries 
after taking into account household expenditures on health care. The impoverish-
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ment approach has also been used in other fields of study such as housing afford-
ability (Hancock, 1993; Kutty, 2005) and health insurance (Bundorf & Pauly, 2006).
The impoverishing effect of a medicine is defined in terms of the percentage of the 
population that would be pushed below an income level of US$1.25 or US$2 per day 
when having to purchase the medicine. Although different income levels have been 
used/proposed (Van Doorslaer et al., 2006; Chen & Ravallion, 2008), the US$1.25 and 
US$2 poverty lines were chosen because they are the most recent widely recognized 
poverty indicators as used by the World Bank (The World Bank Group, 2013b). Thus, 
the approach essentially compares households’ daily per capita income before and 
after (the hypothetical) procurement of a medicine. If the pre-payment income is 
above the USD1.25 (or USD2) poverty line and the post-payment income falls below 
these lines, purchasing the medicine impoverishes people. We used this method to 
generate ‘impoverishment rates’, which denote the percentage of the population 
that would become impoverished. The unaffordability of a medicine then refers to 
the percentage of the population that either already is or would fall below the pov-
erty line when having to procure the medicine. First, we consider the affordability 
of medicines in the total population at risk of becoming ill. We also indicate, using 
prevalence rates for the three chronic diseases, the expected number of patients 
actually affected.
data
To conduct the first analysis, three types of data were required per country: medi-
cine prices, aggregate income data, and information on the income distribution. In 
calculating expected numbers of patients affected, prevalence data is also required. 
Medicine prices were taken from standardized surveys using the WHO/Health Action 
International (HAI) price measurement methodology, which report median patient 
prices for a selection of commonly-used medicines in the private sector, for both 
originator brand (OB) and lowest priced generic (LPG) products (Health Action 
International, 2012). We focused on the private sector because the availability of 
essential medicines in the public sector is much lower (Cameron et al., 2009b). In the 
countries studied here, therefore, many people will depend on the private sector for 
their medicines.
The World Bank’s world development indicators (WDIs) provided household final 
consumption expenditure (HHFCE) data and information on income distribution 
(The World Bank Group, 2013c). Although WDIs have shortcomings (highlighted in 
the Discussion section), they have the advantage of being available for a wide range 
of countries. Moreover, in this context commonly used household surveys are often 
not available on a yearly basis and are not conducted in a standardized way, limiting 
the comparability of results across countries and over time (Van Doorslaer et al., 
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2006; O’Donnell et al., 2008). This paper uses an affordability measure that can be 
quite easily applied in LICs and MICs where the use of more detailed household 
survey data may be limited.
HHFCE was selected as an aggregate income measure rather than GDP per capita 
as it better reflects households’ resources (O’Donnell et al., 2008), while GDP also 
includes consumption, gross investment and net trade. Because the WDI did not pro-
vide any information on HHFCE for Nigeria and Yemen, the Economist Intelligence 
Unit (EIU) nominal private consumption figure was used for these countries (The 
Economist, 2013). For simplicity, we will refer to “income” as measured by HHFCE 
or nominal private consumption. Apart from average income, the WDIs also provide 
some information on a country’s income distribution by listing the proportion of 
total income earned in seven income groups; five income quintiles, with the poorest 
and richest quintiles split into deciles.
At the time of analysis, medicine price surveys were available for 53 countries. In 
large countries such as India and China, price surveys were carried out on a state or 
provincial level (Cameron et al., 2009b). Because the WDIs do not provide state-level 
income distributions, HHFCE and population figures, these countries were excluded 
table 1: Overview of countries studied and years of data sources used.
Countries
Medicine price survey and 
wdi income data
wdi data on income 
distribution
Low-income
Kyrgyzstan 2005 2003
Mali 2004 2001
Nigeria 2004* 2003
Pakistan 2004 2002
Tajikistan 2005 2004
Tanzania 2003 2000
Uganda 2004 2002
Uzbekistan 2004 2003
Yemen 2006* 2005
Middle- income
El Salvador 2006 2002
Indonesia 2004 2002
Jordan 2004 2002
Mongolia 2004 2002
Peru 2005 2003
Philippines 2005 2003
Tunisia 2004 2000
* Nominal private consumption from Economist Intelligence Unit was used.
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from the current study. To ensure cross-country comparability, the analysis was lim-
ited to countries where income distributions (WDI data) were available from the 
year 2000 onwards. We used WDI income data from the same year as the WHO/HAI 
price data. Data on income distributions for the same year were used when possible, 
if not, the most recent income distribution data prior to the year of the price and 
income data were used.
Table 1 provides an overview of all countries and data used in this study. When 
discussing results, countries were grouped into LICs and MICs according to the 2008 
World Bank’s classification (The World Bank Group, 2013a). Sixteen countries were 
selected based on the availability of WHO/HAI data. They are not representative 
of the developing world as a whole. However, as these countries vary substantially 
in terms of economic development, health care infrastructure and medicine prices, 
they provide an interesting sample to study affordability of medicines.
We selected four medicines for which price data was available for the majority of 
countries and for which treatment regimens are relatively standard across countries. 
While these may not lead to results that are in a strict sense generalizable, they pro-
vide valuable insight in the affordability of common medicines in the selected coun-
tries. Table 2 lists the medicine, the ill health conditions for which these medicines are 
used, the total number of units per treatment course, and the treatment duration in 
days (Health Action International, 2012). Three of the four study medicines are used 
to treat chronic conditions (asthma, diabetes, and hypertension). For each of these, 
we also calculated the expected numbers of patients becoming impoverished, using 
the prevalence data shown in Table S1. We could not do this for Acute Respiratory 
Infection because of unavailability of comparable prevalence data.
table 2: Description of studied medicines
Medicine name
ill health 
condition
Medicine 
strength 
per dose
total number 
of doses per 
treatment
dosage form
treatment 
duration in 
days
Salbutamol inhaler Asthma 100 mcg 200 inhaler 30 (1 inhaler)
Glibenclamide Diabetes 5 mg 60 capsule/tablet 30
Atenolol Hypertension 50 mg 30 capsule/tablet 30
Amoxicillin Acute Respiratory 
Infection
250 mg 21 capsule/tablet 7
The emphasis on medicines for chronic disease is justified by the fact that these 
conditions require ongoing, usually lifelong expenditures, making it more difficult 
for households to use financing strategies like borrowing and selling assets (Flores 
et al., 2008). Table 2 shows that the treatment duration for these medicines was 
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set at 30 days to represent the monthly treatment costs. The affordability of one 
acute condition (acute respiratory infection) treated with a 7-day treatment course 
of amoxicillin was also studied. Recently, the WHO increased the guidelines for treat-
ment of acute respiratory infection with amoxicillin to a daily regimen of three times 
500mg amoxicillin. This implies that the affordability of this medicine is likely to be 
lower than reported here (World Health Organization, 2008c).
Calculation Methods
Our method to estimate the impoverishing effect of procuring medicines was based 
on the method as developed by Wagstaff and Van Doorslaer ( 2001; 2003) and ex-
plained by O’Donnell et al. (2008). However, using aggregate data requires some 
simplifying assumptions about the income distribution across population groups. 
For a detailed discussion of the method used to calculate the impoverishing effect 
of medicines, we refer to Niëns et al. (2009). The basic idea is to compare poverty 
estimates before and after a (potential) purchase of the medicines listed in Table 
1. Average per capita income within each income group is estimated by combining 
information on the proportion of total income earned across income groups with 
data on the HHFCE (as provided by the WDIs). As only data on average income in 
the different quintiles and deciles was available, we assumed linearity of the income 
distribution within these relevant groups in which the USD1.25 and USD2 poverty 
lines were located in calculating poverty and impoverishment. The proportion of 
the population that would earn less than US$1.25 or US$2 per day after buying 
a medicine but not before would therefore be impoverished due to purchasing 
medicines. The medicine is deemed affordable for the proportion of the popula-
tion that would remain above the poverty line after having purchased it. We also 
estimated the actual number of patients with one of the three chronic illnesses for 
which the medicine is unaffordable. To do so, we use prevalence rates from various 
data sources and again assume that the respective disease is evenly spread over the 
income distribution.
Because HHFCE is measured in current US$, we recalculated the US$1.25 and US$2 
poverty lines to US$ values for the HAI/WHO survey year. HAI/WHO medicine prices 
were expressed in US$ for the same year.
3.3  resuLts
Table 3 presents the percentages of the population below the poverty line owing 
to the purchasing of each of the four study medicines, both LPG and OB products.
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For each country, Table 3 first highlights the proportion of the population already 
below the US$1.25 and US$2 poverty lines without purchasing these medicines. 
These poverty estimates correlate highly with the commonly used (household survey 
based) estimates from the United Nations Development Program (UNDP) with Pear-
son correlation coefficients equal to 0.90 for the proportion of the population below 
the U$D1.25 poverty line, and 0.86 for the proportion below the US$2 poverty line 
(United Nations Development Program, 2008). Table 3 also shows the proportion of 
the population earning less than the LPGW, which varies widely across countries: from 
only 1% in Tajikistan to 96% in Tanzania. This cross country variability represents one 
of the limitations of the LPGW-metric as used by the WHO/HAI methodology (World 
Health Organization & Health Action International, 2008).
Comparing the proportion of the population below the US$1.25 and US$2 poverty 
lines before and after procurement of medicines gives insight into the impoverishing 
effect of medicine procurement. By adding the proportion of the population already 
living below the US$1.25 and US$2 poverty lines to the group that would fall below 
these poverty lines when procuring the medicines, we get the proportion of the 
population for which the four medicines are unaffordable.
The results in Table 3 illustrate that the impoverishing effect of medicines varies 
substantially between OB and LPG products. For example in Yemen, a LIC where 
7% of the population lives on a pre-payment income of less than US$1.25 a day, OB 
glibenclamide purchased in the private sector would impoverish an additional 22% 
of the population versus 3% for the LPG equivalent. In Nigeria, a LIC where 56% of 
the population lives below US$1.25 per day, purchasing amoxicillin from the private 
sector would impoverish an additional 23% if the OB is bought and 12% if buying 
the LPG.
Rather than showing proportions of the population, Table 4 presents both the 
absolute number of individuals that would be pushed into poverty due to the cost 
of buying medicines from the private sector (“Impoverished” column) and the 
number of people for which medicines are unaffordable (“Unaffordable” column). 
Besides absolute figures, in Table 5 we present the relative change of the poverty 
estimates for the total population studied as well as for the patient population. So, 
if 40% of the population is initially above the poverty line, while only 30% would 
remain above after purchasing medicines, this proportion is 25% (10% out of 40% 
are impoverished). These numbers are listed for all four medicines, both OB and 
LPG. The total population of the sixteen countries analyzed amounts to over 775 
million people, of which approximately 126 million live on less than US$1.25 and 209 
million on less than US$2 per day, respectively. Table 4 illustrates that across this set 
of 16 developing countries, for respectively almost one-fourth and two-fifth of the 
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total population essential medicines are unaffordable using the US$1.25 and US$2 
poverty line.
The upper half of Table 4 shows the proportions of the total population for which 
medicines would be unaffordable when having to procure them. The actual number 
of people affected by this unaffordability (in terms of experiencing the disease) de-
pends on the prevalence of diseases as well. Therefore, the lower half of Table 4 also 
shows the expected absolute number of patients affected by the unaffordability of 
medicines using the prevalence rates listed in Table S1 (Supplementary information). 
As the prevalence rates of hypertension are substantially higher than those of asthma 
and diabetes, the impoverishing effect, and therefore also the unaffordability, of 
atenolol is substantially higher than that for the other medicines. In this approach, 
given the height and distribution of income, impoverishment is determined by both 
medicine prices and prevalence rates for the relevant diseases.
3.4  disCussioN
The results illustrate that substantial proportions of the population would be pushed 
into poverty as a result of medicine procurement, implying that in many countries 
affordability of these treatments is low. In the private sector, LPGs were generally 
substantially more affordable than OB products. Thus, increasing the use of quality-
assured generics could reduce the impoverishing effect of medicines. This use of 
table 5: The relative change of the poverty estimates, i.e., the impoverished population 
expressed as a proportion of the population initially above the poverty line.
Total Population
Medicine additional percentage under usd1.25 additional percentage under usd2
 
Originator Brand
Lowest Priced 
Generic Originator Brand
Lowest Priced 
Generic
Salbutamol inhaler 10 2 13 4
Glibenclamide 11 6 20 6
Atenolol 12 3 23 9
Amoxicillin 17 7 25 13
Chronic Patient Population
Medicine additional percentage under usd1.25 additional percentage under usd2
 
Originator Brand
Lowest Priced 
Generic Originator Brand
Lowest Priced 
Generic
Salbutamol inhaler 10 2 10 3
Glibenclamide 10 5 18 5
Atenolol 12 4 21 7
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generics, in turn, could bring about improvements in the health status of these popu-
lations by avoiding low compliance to recommended dosages or duration of treat-
ment, resulting in problems such as sustained hypertension, elevated blood glucose 
levels, or the promotion of bacterial resistance due to too short courses of antibiotics.
Our calculation method has the advantage of allowing for comparisons of medi-
cine induced impoverishment across time and across countries using widely available 
aggregate data. The method, therefore, is useful and generalizable to study the 
affordability of a wide range of goods and health care services. The use of such 
data also brings some limitations, which are discussed in further detail in Niëns et 
al. (2009). First, dividing HHFCE by total population to get an estimate of income 
per capita assumes that each household is the same size. However, poor households 
are generally larger than their richer counterparts (Lipton & Ravaillon, 1994). This 
discrepancy causes the average income per capita to be overestimated in the lower 
income groups, making our affordability estimates rather conservative. Second, the 
assumption of linearity of the income distribution between income groups is also 
likely to lead to an overestimation of average incomes across the income distribu-
tion and therefore to a downward bias in our results. We also assumed a linear 
distribution of illness over the income distribution to calculate expected numbers 
of affected people. Although, in general, disease may be more prevalent in low-
income groups, which would imply conservative estimates of unaffordability, this 
also depends on the exact diseases studied. Moreover, it is clear that considering only 
medicine costs, for four medicines independently, merely demonstrates the larger 
problem of medicine and health care affordability. The treatment of chronic condi-
tions often requires a combination of medicines and is therefore likely to be even 
more unaffordable than what is reported here (Cameron et al., 2009b). For chronic 
asthma patients, for example, appropriate management of their disease requires 
use of both salbutamol and beclometasone inhalers for treatment and prevention 
(Health Action International, 2012). Due to the lack of available price information on 
beclometasone inhalers (because of poor availability), it was not possible to include 
this medicine in the analysis. As such, the true affordability of asthma treatment is 
likely to be lower than reported in Table 3 and 4. Having said this, the medicines 
studied in this paper are commonly used to treat ill health conditions from which 
considerable proportions of the population in the developing world suffer, as is also 
illustrated in Table S1 (World Health Organization, 2004a). As such, low affordability 
of these medicines is likely to signal a more general problem of low affordability of 
medicines in LIC and MIC. Further, it should be noted that comparability of impover-
ishment rates for acute and chronic conditions may be limited. If people suffer from 
an acute respiratory infection, on average, three times per year and are able to shift 
resources over time, the impoverishment rates for amoxicillin should be interpreted 
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with caution. Further research is needed on this issue, for example by calculating af-
fordability for standardized time periods taking into account the relevant incidence 
rates of respiratory infections.
Notwithstanding these limitations, this study provides useful insights into the afford-
ability of these four medicines in the developing world. When medicine prices are 
known, the methods used, as they rely on easily obtainable aggregated data, can be 
used to compare affordability of medicines across countries and over time. Clearly, 
medicines represent only a part of the costs associated with the management of an 
illness. Other costs, such as for diagnostics, physician consultations and transport 
costs to clinics, lost work time etc., place an additional burden on household finances 
in developing countries. However, given the relatively large share of health care 
costs for medicines in developing countries (World Health Organization, 2000; World 
Health Organization, 2004b; Van Doorslaer et al., 2006; Cameron et al., 2009b), medi-
cine affordability is likely to be an important determinant to access to treatment.
This study shows high medicine costs can push large groups of patients into pov-
erty. These results call for action, both by governments, civil society organizations 
and others, to make access to essential medicines a priority, and not only to ensure 
access to necessary medicines, but also in the context of reducing poverty. Possible 
lines of action include developing, implementing and enforcing sound national and 
international price policies. In the short term these policies could encompass, for ex-
ample, restrictions on supply chain mark-ups, tax exemptions and regulating prices 
for end-users. Promoting the use of quality assured, low-cost generics, for example 
through preferential registration procedures, is also an important strategy (Cameron 
et al., 2009b). In the public sector, ensuring availability of essential medicines at little 
or no charge to the poor is critical. In the longer-term, establishing health insur-
ance systems with outpatient medicine benefits, seems crucial to avoid poverty due 
to health shocks (and poor health due to poverty). Innovative approaches, such as 
using private distribution systems to supply subsidized medicines to chronic disease 
patients, should also be considered. For medicines which are still subject to patent 
restrictions, pharmaceutical companies should be encouraged to differentially price 
these products as occurs with antiretrovirals (Waning et al., 2009). Countries also 
have the option to use compulsory licensing to oblige patent holders to grant its use 
to the state or others (World Health Organization, 2006), as was recently done by 
Thailand (Ford et al., 2007; Seim, 2007).
When resources are limited, those in greatest need, such as people suffering from 
chronic disease who earn less than US$1.25 per day, should benefit from state and/
or donor actions. The price in terms of health losses due to unaffordable medicines 
is something we cannot afford.
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suPPLeMeNtAry iNforMAtioN
table s1: the prevalence of three chronic diseases
Proportion of the population suffering from
Condition asthma diabetes hypertension
Low-income    
Kyrgyzstan 4,3 4,3 28,0
Mali 2,6 3,3 27,5
Nigeria 5,7 3,9 34,8
Pakistan 4,1 7,6 24,0
Tajikistan 4,3 1,0 24,0
Tanzania 4,4 2,6 27,5
Uganda 4,4 1,7 27,5
Uzbekistan 4,3 7,0 7,6
Yemen 5,8 2,5 9,7
Middle- income    
El Salvador 3,8 7,8 42,0
Indonesia 3,3 4,6 23,3
Jordan 5,8 7,5 22,2
Mongolia 2,1 1,3 42,0
Peru 9,9 5,6 15,2
Philippines 7,9 6,7 20,2
Tunisia 3,7 8,5 33,0
Diabetes prevalence data was retrieved from the international diabetes federation’s data 
website (http://www.diabetesatlas.org/).
Asthma prevalence comes from the Global Initiative for Asthma’s Burden of Asthma Report 
(http://www.ginasthma.com/ReportItem.asp?l1=2&l2=2&intId=94).
Hypertension prevalence comes from WHO infobase online (https://apps.who.int/infobase/
report.aspx) and a Lancet article by Kearney et al. (2005).
Chapter 4
Measuring the Affordability of Medicines: 
Importance and Challenges
Published as:
Niëns LM, Brouwer WBF. “Measuring the affordability of medicines: 
Importance and challenges”
Health Policy 2013 112(1): 45-52.
56 Chapter 4
ABstrACt
The issue of affordability of health care services remains high on the (health) policy 
agenda. Determining whether health care services are affordable is complex how-
ever, as the concept ‘affordability’ is inherently normative. With a focus on measur-
ing affordability in low- and middle-income countries, we discuss different methods 
used to operationalize this concept. Using the example of medicine purchases in 
Indonesia, we show the choice of method and threshold to have a significant impact 
on outcomes. We argue it is important to further standardize methods and appropri-
ate threshold use in applied research to increase comparability of results and to 
facilitate sound assessments of affordability.
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4.1  iNtroduCtioN
Issues of affordability appear to be at the center of health care discussions and 
decisions. Politicians and health care policy makers alike, in high- and low- and 
middle-income countries (LMICs), see themselves confronted with the challenge of 
ensuring and, where possible, increasing access to health care services of sufficient 
quality for all those in need while at the same time containing (public) health care 
expenditures. This challenge raises numerous important questions and dilemmas. 
Some have even argued that these goals form an ‘inconsistent triad’, i.e., that they 
can never be completely fulfilled simultaneously (Weale, 1998). Still, policy makers 
may attempt to strike an optimal balance in reaching these goals.
An important issue in that context is that of affordability. In both high as well as 
low- and middle-income countries policy makers struggle with questions regarding 
the payments people should be able to make out-of-pocket (OOP) on health care or 
through copayments in some form (affordability at micro level) and the sustainability 
of public funding of the health care sector raised through premiums or taxes (afford-
ability at macro level) (Van Doorslaer et al., 2006; Cameron et al., 2009b). Because 
in LMICs the large majority of the population does not have health insurance (Dror 
et al., 2002), OOP payments are an important source of health care financing. Much 
of these OOP payments are on medicines, as in LMICs medicine expenditures often 
constitute a large portion of total health expenditures (World Health Organization, 
2000; World Health Organization, 2004b; Van Doorslaer et al., 2006; Cameron et al., 
2009b; Niëns et al., 2010). Indeed, as in LMICs the availability of ‘free’ quality assured 
medicines in the public sector often is low, people are forced to buy their medication 
in the private sector where prices are commonly high (Cameron et al., 2009b). This 
immediately stresses the issue of affordability. By definition, an average individual 
in a low- or middle-income country has only a limited amount of resources with 
which all basic needs (food, housing, etc.) need to be fulfilled. The amount of money 
people thus can spend on health care, or more specifically medicines, therefore is 
limited. If prices of these medicines exceed the budget, people may forego procure-
ment of essential drugs, go into debt or forego other essential purchases (Flores et 
al., 2008; Cameron et al., 2009b; Niëns et al., 2010). This stresses the gravity of the 
topic of affordability, which is also emphasized in several international treaties in 
which the access to health care is established as a right. This therefore must imply 
that OOP payments should be, somehow, ‘affordable’ (United Nations General As-
sembly, 1948).
In this paper, we will highlight the issue of defining and measuring affordability. 
We focus on affordability of health care, and medicines in particular, at the micro 
level in LMICs. We will emphasize how different methods to quantify affordability 
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can have their specific limitations and lead to different results. Within methods, a 
further source of variation in affordability is setting a specific threshold for afford-
ability. We will address these issues generally and will use the example of Indonesia 
to illustrate our point.
The paper is structured as follows. After a concise introduction of affordability, we 
first discuss several empirical studies of affordability in health care. We will highlight 
the differences in methods used and differences in operationalizations of similar 
methods. Next, we use an example of hypothetical medicine procurements in Indo-
nesia to show how these different methods and their operationalizations influence 
the outcome of affordability measurement. The paper concludes by arguing that 
further standardization of methods used in this area will allow better comparison of 
results across studies and may stimulate further debate on when specific health care 
interventions can be deemed affordable or should be deemed unaffordable.
4.2 oN AffordABiLity of HeALtH CAre ANd MediCiNes
Affordability is an important, yet hard to define let alone operationalize concept. 
This has much to do with the fact that, by definition, defining affordability is 
a normative issue (Bradley, 2008). Indeed, it requires defining when we consider 
something to be too expensive for someone. One (extreme) answer could be that a 
good is unaffordable when the price of that good/service exceeds the total budget a 
person can attract. That however disregards all other spending (even at subsistence 
level) that a person needs to do. Another viewpoint could be that a person should 
at least be able to fulfill other basic needs after having purchased the good/service. 
From such a viewpoint a good is unaffordable if the individual, after the purchase, 
does not have enough resources left to fulfill his basic needs, i.e., falls below a pov-
erty line. A difficult subsequent issue relates to the level at which the poverty line is 
set. A final alternative would be to link the price of a good/service to the income of 
the individual and require it not to exceed some percentage of total income. Again 
here, a difficult next question is what this percentage should be exactly. When is it 
too expensive, that is, unaffordable? Unsurprisingly therefore, scholars in various 
fields, working on defining and measuring affordability, have indeed acknowledged 
the normativity of the affordability concept (Whitehead, 1991; Komives et al., 2005; 
Milne, 2006; Stone, 2006; Bradley, 2008; Niëns & Brouwer, 2009; Niëns et al., 2012). 
Moreover, it need not surprise that in applied work different concepts are used to 
calculate affordability in different areas such as housing (Hulchanski, 1995; Kutty, 
2005; Stone, 2006), education (Usher & Cervenan, 2005; Murakami & Blom, 2008), 
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transportation (Carruthers et al., 2005; The World Bank Group, 2007) and utilities 
(Frankhauser & Tepic, 2005; Milne, 2006).
In many studies investigating (un)affordability of goods and services, the focus is 
on estimating a proportion of the population for which a particular good or service 
is unaffordable. In general, this requires three different sources of information: i) 
the price of a commodity or service; ii) income(s), and iii) some measure of unac-
ceptable burden (Hancock, 1993; Niëns et al., 2012). The latter shall be labeled as 
‘threshold’ henceforth. Whereas the first two parameters are to a large extent a 
matter of obtaining appropriate data (which can be challenging as well), setting 
the threshold essentially involves a normative choice, but one that influences the 
outcomes significantly. It thus lies at the heart of the ‘vagueness’ (Bradley, 2008) of 
the affordability concept and appears an issue that deserves more debate and, if 
possible, further standardization.
In calculating affordability, the two most applied methodologies relate to the concepts 
of impoverishment and catastrophic spending as developed and applied by renowned 
health economists (Wagstaff & Van Doorslaer, 2001; Wagstaff & Van Doorslaer, 2003). 
Methods based on the impoverishment concept calculate the proportion of the popula-
tion that, after spending on a good/service, drops below a relevant poverty line. Thus, 
the impoverishment method works from the premise that there is an absolute mini-
mum level of income people require for basic necessities. Implicitly, some poverty line is 
used as a threshold, therefore. The other method, catastrophic payment, calculates the 
proportion of the population that would spend more than X percent of their income to 
pay for a good/service. This method thus sets a threshold in terms of a forgone propor-
tion of income. The underlying idea is that if a household spends a larger fraction of 
its income than the specified percentage on a particular good or service, it will have to 
scale back its consumption in other areas to an inappropriate extent. A common way 
of using these methods is to retrospectively assess how many people actually experi-
enced impoverishment or catastrophic payments due to expenditures (on health care) 
(Wagstaff & Van Doorslaer, 2001; Wagstaff & Van Doorslaer, 2003). The methods can 
also be used to prospectively calculate the proportion of the population for which the 
good would be unaffordable if it needed to be purchased. This provides insight in the 
proportion of the population at risk of facing either impoverishment or catastrophic 
payments if the good or service would need to be bought (Niëns et al., 2010).
Because affordability in the impoverishment and catastrophic payment methods 
is calculated in relation to the actual incomes in the population, they automatically 
take into account the income distribution. An alternative methodology recently de-
veloped by the World Health Organization (WHO) and Health Action International 
(HAI) measuring affordability does not use this distribution. This straightforward 
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method expresses the affordability of medicines in the number of days’ wages the 
lowest paid unskilled government worker (LPGW) needs to spend to procure a course 
of treatment of a particular medicine (World Health Organization & Health Action 
International, 2008; Cameron et al., 2009b). WHO/HAI do not pose a threshold with 
the LPGW-method and leave the judgment regarding whether some medicine is 
deemed affordable to local policy makers who more easily can position the LPGW 
wage in relation to the average income (and its distribution) of the local population. 
Each of these three methods has own limitations, which will be briefly discussed in 
the next section.
different methods, different limitations
The retrospective or prospective application of the impoverishment method captures 
the people that were or would be pushed below some relevant poverty line due 
to the procurement of health care or medicines (the impoverishment rate) and, as 
such, immediately shows which proportion of the population was impoverished or 
is potentially at risk of becoming impoverished. The method’s main weakness is that 
it normally works from a rather extreme threshold. If used naively the method also 
ignores those already below the poverty line, which obviously can be easily corrected 
by including those living below that line anyhow (Niëns et al., 2010). Furthermore, 
for those people who are not pushed below a (commonly low) poverty line, but 
nonetheless experience a strong income drop, the relevant good is not deemed 
unaffordable, which may be considered debatable. Elevating the poverty line to a 
higher level could help, of course, but at the same time stretches the concept of 
poverty. A clear consensus on what the poverty line is or should be, does not exist. 
This is reflected in the range of values used in applied literature (Xu et al., 2003; Van 
Doorslaer et al., 2006; Limwattananon et al., 2007; Somkotra & Lagrada, 2008; Cam-
eron et al., 2009b; Sun et al., 2009; Niëns et al., 2010). Hence, the more fundamental 
question is what poverty actually entails.
The main weakness of the catastrophic payment approach is that the rich, who can 
easily spend more than X percent of their income on medicines without suffering 
any hardship, are included in the estimates of ‘unaffordability’, while the very poor, 
for whom spending less than X percent may already be difficult (due to strict budget 
constraints and perhaps being pushed under a poverty line) are not. Hence, the 
method may not fully capture those individuals in estimating affordability, for which 
affordability, loosely defined, is actually a problem. The main question remaining 
in the catastrophic payment approach hence concerns the level of spending to be 
deemed affordable, and whether such a level might differ for high and low incomes.
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The main advantage of the LPGW method is its simplicity and straightforwardness, 
both in terms of its application and how, on a local level, many people may be able 
to position themselves in relation to this LPGW. However, in its simplicity also lies its 
main weakness, i.e., knowing the number of daily wages the LPGW needs to pay for 
a course of medicines does not provide clear information on what this means for the 
population as a whole. Furthermore, its link to the concept off affordability also is 
less clear as is setting a threshold for the number of days the LPGW needs to work 
for medicines.
A shortcoming the three methods have in common is that comparing their re-
sults across countries and time is not possible when different thresholds (let alone 
methods) are used. The choice of methods and their operationalization thus requires 
attention. This is highlighted in the next section, where we focus on the most com-
monly used impoverishment and catastrophic payment methods.
Practical applications of the methods
As the impoverishment and catastrophic payment methods define affordability in 
different ways, they can yield different answers to the question whether some medi-
cine is affordable to specific populations. Moreover, within methods the variation in 
answers can also be rather large when different poverty lines are used within the 
impoverishment method or when different percentages are used in operationalizing 
the catastrophic payment method. The next paragraph will substantiate this point 
by summarizing the findings of different empirical studies (it needs noting that dif-
ferent data sources can also affect the outcomes).
Several studies have been conducted applying these methods in the health care 
sector. In investigating the effect of OOP payments in health care on poverty es-
timates in 11 LMIC, Van Doorslaer and colleagues used the World Bank’s absolute 
PLs of US$1.08 and US$2.15. Using household data and actual expenditures they 
retrospectively show 78 million people to have dropped below the US$1.08 poverty 
line when their payments for health care were subtracted from their incomes (Van 
Doorslaer et al., 2006). Niëns et al. (2010) worked with the World Bank’s 2005 pov-
erty line of US$1.25 and US$2.00 (The World Bank Group, 2008) to calculate medicine 
affordability for four essential medicines across 16 LMICs with a total population 
over 775 million. Applying the methods prospectively, their results for example indi-
cate that, at the US1.25 PL, the lowest cost medicine (salbutamol inhaler), would be 
unaffordable for 140 million people in these countries (Niëns et al., 2010). Finally, in 
Mexico, Knaul et al. (2006) applied a US$1.00 threshold, reporting 3.8% of families 
to suffer from impoverishing health care expenditures each trimester.
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Besides these PLs other thresholds have been used as well within the impoverishment 
method. In Vietnam, Wagstaff and Van Doorslaer applied both a food-based PL, 
based on the cost of reaching an intake of 2100 calories per day, as well as a poverty 
line that captured spending requirements on food and non-food items (Wagstaff 
& Van Doorslaer, 2003). Furthermore, in Thailand several studies used the official 
national poverty line adapted to the specific province (Limwattananon et al., 2007; 
Somkotra & Lagrada, 2008). These studies showed that households using private 
inpatient services had a higher incidence of impoverishment (Limwattananon et al., 
2007) and that impoverishment rates decreased after the implementation of a policy 
broadening insurance coverage (Somkotra & Lagrada, 2008).
For catastrophic payment methods in the realm of health care, Xu et al. (2003) retro-
spectively applied a threshold of “40% of income remaining after subsistence needs 
have been met”. They found that a 1% increase in the total proportion of total 
health expenditures provided by out-of-pocket payments resulted in a 2.2% increase 
in households facing catastrophic payments. Although Sun et al. (2009) also used the 
40% of non-food expenditure threshold when retrospectively calculating the afford-
ability of total health care in rural China, using sensitivity analyses with thresholds of 
20%, 30%, 50% and 60%, they found catastrophic payments to decrease by 34.77% 
comparing the 20% and 60% thresholds. Using similar thresholds (20%,30%,40% 
and 60%) in a study in Burkina Faso, Su et al. (2006) found catastrophic health care 
payments to decrease by 57.26% comparing the 20% and 60% thresholds. Niëns et 
al. (2012) prospectively applied a 5% threshold of daily income when calculating the 
affordability of an anti-diabetic drug, glibenclamide, and found 65.9% and 78.6% 
of the Indonesian and Indian populations respectively to be at risk of facing cata-
strophic payments. Wagstaff and Van Doorslaer (2003) retrospectively used a range 
of thresholds (2.5%, 5%, 10% and 15%) which were applied for both pre-payment 
income and non-food expenditures. One of their findings was that, in Vietnam, it was 
not inpatient care that increased poverty so much, but rather expenditures related 
to non-hospital care like medicine procurements. Knaul et al. (2006) also applied the 
catastrophic payment method but did so using a 30% threshold of income. Whereas 
they found almost all households with impoverishing effects to be from the poorest 
quintile, catastrophic health care payments were observed throughout the income 
distribution. In Thailand, whereas Limwattananon et al. (2007) applied a threshold 
of 10% of total consumption including expenditures on food Somkotra and Lagrada 
(2008) used ranges of thresholds of both total consumption (5%, 10% and 15%) and 
non-food consumption (20%, 25% and 30%). Both studies reported that moving 
towards implementation of universal health insurance coverage in 2001 decreased 
catastrophic payments (Limwattananon et al., 2007; Somkotra & Lagrada, 2008).
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The previous overview shows the affordability of health care and medicines in 
LMICs to vary and highlights the different thresholds used between, but also within 
methods. Whereas some of these differences are likely to be data driven others may 
reflect differences in approach to, or (even) opinion about, affordability.
Using the LPGW methodology, Cameron et al. (2009b) find medicine affordability to 
differ significantly between WHO-regions. They show that, whereas treating an ul-
cer with a month’s course of private sector OB ranitidine (150 mg capsules or tablets, 
two a day for 30 days) costs more than 35 days’ wages in Africa, in Southeast Asia 
this is just 2.7 days’ wages. Moreover, when defining affordability in relation to some 
normative threshold in terms of a maximum number of wage days a person could 
spend on a purchase of medicines before deeming it unaffordable, similar problems 
regarding comparability between studies could occur as for the two other methods 
described above. These results are summarized in Table 1.
We will show that the previously explained differences and choices are not only 
theoretical but in effect influence outcomes. To illustrate this, and to stimulate 
the debate regarding appropriate and comparable measurement of affordability, 
we prospectively calculate the affordability of Lowest Priced Generic (LPG) gliben-
clamide, amoxicillin and atenolol in Indonesia, using both the impoverishment and 
catastrophic payment methods.
4.3 PuttiNg tHe MetHods iNto PrACtiCe: tHe CAse of MediCiNe 
AffordABiLity iN iNdoNesiA
Niëns et al. (2012) used LPG prices to prospectively calculate the affordability of LPG 
glibenclamide (used for treating diabetes; 5mg per tablet at a daily cost of US$0.11) 
in Indonesia. They applied the impoverishment method as described by O’Donnell et 
al. (2008), using household level income data from the 2005 wave of the Indonesian 
National Socioeconomic Survey (Susenas – n=7302 households) (RAND Corporation, 
2011). Thus, they calculated the percentage of the population that would be pushed 
below a poverty line when having to procure LPG glibenclamide. Using PLs of US$1.25 
and US$2.00 they found 28.8% and 61.7% of the population, respectively, to already 
live below the poverty line before hypothetical medicine purchases. For them, the 
medicines may therefore be deemed unaffordable at any price above zero.
Applying the impoverishment method prospectively indicated that 5.8% and 
3.7% of the population would be impoverished due to medicine procurement, using 
the two respective poverty lines (Niëns et al., 2012). Working with the prospective 
catastrophic payment method and a threshold of 5% (using household level income 
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data), indicated that a proportion of 65.9% of the population would not be able to 
purchase glibenclamide without a catastrophic payment exceeding 5% of their daily 
income (Niëns et al., 2012). Using the LPGW approach WHO/HAI finds the LPGW 
needs 0.6 days’ wages to pay for one course of treatment.
Here we repeated the same calculations for glibenclamide, amoxicillin (used for 
treating an acute respiratory infection; 250mg per tablet at a daily cost of US$0.27) 
and atenolol (against hypertension; 50mg per tablet at a daily cost of US$0.43) (see 
Table 2: panel A).
table 2: Affordability estimates: impact of methods and thresholds
Panel A: Affordability estimates for 3 LPG medicines with micro data and methods
Methods outcome measure Medicine (condition)
 
 
Glibenclamide Amoxicillin Atenolol
(diabetes)
(acute 
respiratory 
infection)
(hypertension)
Impoverishment impoverishment 
rate <US$1.25 PL
5.8% 14.2% 21.6%
impoverishment 
rate <US$2.00 PL
3.7% 8.2% 11.6%
Catastrophic 
payment
Catastrophic 
payment at 5%
65.9% 95.8% 98.6%
Lowest paid 
government worker
# of daily wages 
needed
0.6 days 0.4 days 2.4 days
Panel B: Impoverishment rates at different thresholds
2011 National PL 
Indonesia (US$0.89)
4.7% 13.5% 22.5%
US$1.08 6.0% 15.2% 23.5%
US$2.15 2.8% 6.3% 9.3%
Panel C: Catastrophic payments at different thresholds
1.0% >99% >99% >99%
2.5% 92.3% >99% >99%
5.0% 65.9% 95.8% 98.6%
7.5% 37.1% 88.1% 96.4%
10.0% 17.2% 78.0% 92.5%
Besides the US$1.25 and US$2.00 PLs, we used the same household level income 
data to calculate the impoverishment and catastrophic payment rates for these three 
medicines at different thresholds. Impoverishment rates were calculated for the 
US$1.08 and US$2.15 PLs as used by Van Doorslaer et al. (2006) and the 2011 national 
poverty line of Indonesia which is US$0.89 (The Economist, 2012). All calculations 
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were done with PLs that were recalculated to local currency units using the Purchas-
ing Power Parity conversion factor from 2005 (The World Bank Group, 2011b). Panel 
B shows the impoverishment rates to vary strongly with the thresholds used. Whereas 
for glibenclamide we find 4.7% of the Indonesian population impoverished at the 
national poverty line, for the US$1.08 and US$2.15 this is 6.0% and 2.8% respectively. 
For amoxicillin and atenolol these proportions range from 15.2% and 23.5% at the 
US$1.08 poverty line to 6.3% and 9.3% at the US$2.15 PL, with the impoverishment 
rates at Indonesia’s national poverty line, i.e., 13.5% for amoxicillin and 22.5% for 
atenolol falling in between.
Varying the catastrophic payment thresholds we also find large differences (see 
Panel C). If people are allowed to spend no more than 1.0% of their daily income on 
glibenclamide this medicine is unaffordable for more than 99% of the population, 
whereas increasing the threshold to 10% results in glibenclamide being deemed 
unaffordable for 17.2% of the population. For amoxicillin and atenolol these pro-
portions range from over 99% for the 1% threshold to 78% and 92.5% at the 10% 
threshold, respectively.
4.4 CoNCLusioN ANd disCussioN
Affordability is an important issue in many health care systems, especially those in 
LMIC. Van Doorslaer et al. (2006) highlight that only in Asia, already 78 million people 
would be pushed below the poverty line of $1 per day after paying for health care. 
Medicines commonly constitute a large part of health care consumption. In many 
LMICs countries, therefore, essential medicines are unaffordable for many (Cameron 
et al., 2009b; Niëns et al., 2010). Niëns et al. (2010), for example, estimated that for 
over two-fifths of the in total approximately 775 million people in 16 LMICs, essen-
tial medicines are unaffordable. They show this problem to be especially pressing for 
people suffering from chronic non-communicable diseases which require life-long 
ongoing medicine purchases (Niëns et al., 2010).
These figures demonstrate that improving the affordability of health care, and 
especially medicines, should be an important policy goal. The current levels of unaf-
fordability can have important detrimental health effects in the most vulnerable 
groups in the world. Governments have several options at their disposal to increase 
the affordability of health care and medicines, also in LMICs. From ensuring that 
quality assured generic medicines are available in the public sector, to removing im-
port levies on medicines and exempting them from value added tax, to implement-
ing regulated (regressive) mark-up systems for medicines in the distribution chain 
(Cameron et al., 2009b). Furthermore, installing pre-payment schemes (insurance) to 
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finance healthcare offers the possibility for governments to better control (generic) 
medicine purchases and prices (Lee et al., 2006; Boonen et al., 2010; Dylst et al., 
2011). Such policies are ideally based on sound information on the current problem 
and evaluated to judge their impact. In that context it is pivotal to measure and 
quantify affordability.
Over the years, useful methodology has been developed by leading experts in the 
field that allows the quantification of the inherently ‘vague’ concept of affordability 
(e.g. Wagstaff & Van Doorslaer, 2001; Wagstaff & Van Doorslaer, 2003). Still, as the 
literature and our results show, the impact of the methods chosen to measure af-
fordability as well as the thresholds chosen within those methods is significant on 
final outcomes. It appears that the observed differences, which are also reflected in 
the empirical literature regarding affordability, reflect the difficulty of univocally 
grasping the concept of affordability and to find suitable and general thresholds 
for affordability. The two most prominent methods, the impoverishment and the 
catastrophic payment method, both use different operationalizations of the concept 
of affordability and within the methods different thresholds are used, reflecting the 
difficulty in setting one unique standard for affordability. While the difficulty is un-
derstandable, the implications are worrisome since arbitrary variations in thresholds 
may strongly affect affordability estimates and, hence, may –unduly if the thresholds 
or methods may be deemed inappropriate– influence policy makers and the sense of 
urgency regarding matters of financial access to health care and medicines.
In light of these findings, we argue that two things would be useful. First, it may be 
worthwhile to create a (preliminary) standard for calculating affordability. Rather 
than attempting to develop new methods (with own limitations) a fruitful way 
forward is to work with a fixed combination of methods and a fixed combination of 
affordability thresholds. As a first suggestion, we would recommend using both the 
impoverishment and catastrophic payment methods. This would ensure that large 
proportions of income being spent or required for the purchase of medicines would 
be detected (even when these do not push the individuals involved into poverty) 
and that those individuals who are pushed into poverty would also be detected; 
even when the proportion of income spent on medicines is fairly limited. Second, in 
terms of a threshold, it seems that a general discussion between policy makers and 
researchers leading to a (standard) range of thresholds would be a logical choice, 
given the current variation.
We emphasize that the threshold can and should be set in relation to the good 
or service under study. For instance, since medicines form only a portion of total 
health care expenditures, one may set catastrophic payments thresholds and im-
poverishment thresholds higher/lower when studying medicine expenditures than 
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when studying health care expenditures. Studying partial expenditures in some area 
should be judged against different thresholds than when considering the whole. 
Similarly, a distinction could be made between chronic and acute diseases, as the 
former require ongoing, sometimes lifelong expenditures. These may, ceteris pari-
bus, sooner be considered unaffordable than once only purchases. For instance, in 
case of chronic conditions, it is less possible for people to use coping mechanisms like 
spending savings, loaning or selling assets to pay for the health care expenditures 
(Flores et al., 2008).
To help politicians and governments improve the access to medicines, we therefore 
argue scholars and policy makers should discuss and agree on an international 
benchmark for how to best address the affordability question. An international 
benchmark, both in calculating and reporting, would foster transparency and inter-
temporal and international comparison. Since comparison in itself can increase the 
awareness and sense of urgency for governments to act swiftly on these issues, such 
a benchmark should be discussed.
To conclude, affordability is important and increasingly quantified. In order to 
increase comparability, also across countries, we urge for a further standardization 
of the measurement of affordability.

PArt ii
Affordability at the Macro Level in a 
Developed Country: Delineating Entitlements 
in (social) Health Insurance Systems

Chapter 5
Delineating the Benefit Package: The Necessity 
of Insurance Criterion in the Netherlands
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ABstrACt
In the Netherlands, the Dutch Health Care Insurance Board (CVZ) is responsible for 
managing the basic benefit package. In the last two decades, CVZ has developed a 
framework, combining four criteria (necessity, effectiveness, cost-effectiveness and 
feasibility), to inform reimbursement decisions. Although, in general, there is con-
sensus about these criteria, not all aspects of the criteria are sufficiently operational-
ized, which frustrates their application. One issue currently receiving much attention 
is that of affordability in the context of necessary to insure interventions. CVZ tries to 
cover this issue with a ‘necessity of insurance’ criterion which is part of the Necessity 
criterion. At present it is relatively unclear what this sub-criterion exactly entails and 
how it could be used in a systematic way in package management. Here we take 
forward this criterion’s operationalization by introducing a checklist that allows its 
application to be systematic, both in terms of content as well as process.
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5.1 iNtroduCtioN
Over the last decades health care costs have increased rapidly (Meltzer, 2001; Folland 
et al., 2004). This has raised a number of issues. First, governments may feel the 
need to justify the increasing expenditures on health care, also in light of the often 
mandatory nature of the contributions. This may involve demonstrating that the 
resources are spent on technologies that offer value for money. Second, the financial 
sustainability and affordability of the health care system may become a matter of 
debate. This calls for measures allowing the control of expenditures, also to ensure 
the accessibility of highly important facilities to future citizens. In order to control 
expenditures, many countries with (social) health care insurance schemes have taken 
various measures, like implementing deductibles and co-payment arrangements 
(Schoen et al., 2010; Barros et al., 2011; Organization for Economic Co-operation 
and Development, 2012). Another important development is that the content of 
basic benefit packages (the entitlements of the socially insured) is more frequently 
critically examined (Schreyogg et al., 2005; le Polain et al., 2010). This may be il-
lustrated by the use of Health Technology Assessment in an increasing number of 
countries (Franken et al., 2012; Kolasa & Wasiak, 2012). By clearly delineating the 
basic benefits package, through selectively taking out interventions or restricting 
entry of new interventions, health care expenditures can be controlled, but increases 
in expenditures can also be justified. However, this requires clear and broadly sup-
ported criteria for how to delineate the basic benefits package.
In the Netherlands, the Dutch Health Care Insurance Board (CVZ) advises the gov-
ernment on the delineation of the basic benefit package (College voor Zorgver-
zekeringen, 2009a).1 Its mission is to safeguard and develop the public conditions 
for the health care insurance system so that Dutch citizens can exercise their right 
to care (College voor Zorgverzekeringen, 2011b). An important task of CVZ is to 
advise the Dutch Minister of Health on which interventions should be included in 
the basic benefit package of the Dutch mandatory social health insurance scheme. 
In an attempt to standardize this procedure, and hence to come to a clear system 
of package delineation, CVZ has developed a ‘package management’ framework. 
The latter consists of four criteria that interventions have to meet if they are to 
be reimbursed. These criteria are: 1) necessity; 2) effectiveness; 3) efficiency and 4) 
1. Other examples of such institutes are: 1) The National Institute for Clinical Excellence 
(NICE) in the United Kingdom, 2) Gemeinsamen Bundesausschusses (G-BA) in Germany, 
3) Haute Autorithé de Santé (HAS) in France, 4) Tandvårds- och läkemedelsförmåns-
verket (TLF / LFN) in Sweden and 5) Scottish Medicines Consortium (SMC) in Scotland.
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feasibility (College voor Zorgverzekeringen, 2006). However, in practice, the clarity 
and degree of operationalization of these criteria differs, which poses challenges to 
CVZ’s aim to apply its criteria consistently.
Effectiveness and efficiency are operationalized through the measurable and well-
known concepts of evidence-based medicine and cost-effectiveness. Although these 
criteria are not without definitional, operational nor interpretational problems, 
this is even more so the case for the first and fourth criteria. The fourth criterion 
(feasibility) considers the attainability (from an implementation point of view) and 
sustainability (from an economic point of view) of including an intervention in the 
basic benefit package (College voor Zorgverzekeringen, 2006). Hence, the feasibility 
criterion identifies the conditions that need to be met in order for the intervention’s 
inclusion to be attainable and sustainable. The more fundamental desirability of its 
inclusion, however, is based on the first three criteria.
The operationalization of the first criterion, necessity, is also problematic. This 
criterion entails assessing whether “the disease or required health care warrants 
a claim on solidarity given the cultural context” (College voor Zorgverzekeringen, 
2006). The definition and operationalization of the necessity criterion has been the 
topic of much debate and research (e.g. Commissie Criteria Geneesmiddelenkeuze 
(chair: van Winzum), 1994; Luijn van et al., 1995; Wetenschappelijke Raad voor het 
Regeringsbeleid, 1997; College voor Zorgverzekeringen, 2001; College voor Zorgver-
zekeringen, 2006; College voor Zorgverzekeringen, 2009a). It is important to note 
that the criterion of necessity in the Dutch framework covers two distinct aspects 
(College voor Zorgverzekeringen, 2009a): (i) ‘disease burden’ and (ii) ‘necessity of 
insurance’ (NoI). Although its exact operationalization remains a matter of discus-
sion, much progress has been made in the quantification of disease burden.2 This 
facilitates its use in the process of delineating the basic benefits package. Similar 
progress has not been witnessed, however, for the NoI-aspect of necessity. Assessing 
NoI entails the question “whether it is socially necessary or appropriate to insure an 
intervention” (College voor Zorgverzekeringen, 2009a). At present it is relatively un-
clear what this sub-criterion exactly entails and how it could be used in a systematic 
way in package management. For instance, while the costs of an intervention at an 
individual level appears to be an element of NoI (College voor Zorgverzekeringen, 
2006) -i.e., it is not necessary to insure against very low cost interventions- much 
2. The operationalization discussion focuses mostly on the issue if disease burden should 
be measured in an absolute or relative manner. If measured absolutely, the concept 
of fair innings (Williams, 1997) can be applied. For relative health loss, the concept of 
proportional shortfall has been proposed (Stolk, Van Donselaar et al., 2004; Van de 
Wetering, Stolk et al., 2013). CVZ has not formally committed to either one of these 
concepts yet.
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remains unclear when attempting to use this criterion in practice (e.g., the exact 
level of acceptable costs).
This paper aims to contribute to improving the practical definition and operation-
alization of the NoI-element of the necessity criterion. We report the development 
of a checklist which can be used in the context of assessing and appraising health 
care technologies. It enables a structured way of considering the different aspects of 
the necessity of insurance element, enabling more consistent consideration of these 
aspects in decision making. The paper is structured as follows. First, we describe the 
history of the Dutch priority setting process and the NoI-element. Next, we concisely 
explain CVZ’s decision making framework in relation to NoI. Subsequently, we high-
light the importance of moving toward a systematic application of NoI drawing on 
insurance theory, literature and the element’s current use in the context of medical 
aids. From these analyses, we identify the main considerations that should underlie 
NoI and operationalize them with a checklist, which can be applied in the practice of 
delineating the basic benefits package.
5.2 Priority settiNg ANd Noi iN tHe NetHerLANds: A Brief History
The explicitness of the criteria used by CVZ in delineating the basic benefits package 
is a distinctive feature of the Dutch approach toward priority setting. The Dunning 
Committee’s report from 1991 on choices in health care laid the foundation for this 
approach and strongly influenced subsequent discussions (Dunning A.J., 1991). The 
Dunning Committee proposed a clear framework that could be used to decide on 
which interventions should enter the basic benefit package, based on four criteria. 
These criteria were 1) necessity, 2) effectiveness, 3) efficiency and 4) own account 
and responsibility. The committee used a powerful image for the use of these criteria 
in delineating the basic benefits package: the four criteria were depicted as four 
sieves of a funnel (the so-called ‘Funnel of Dunning’). Interventions (consecutively) 
had to pass all four criteria (sieves) in order to be included in the basic benefits 
package (Figure 1).
While much progress has been made in operationalizing the criteria put forward 
by the Dunning committee over the last two decades, it is good to note that the 
current decision framework is importantly based on Dunning’s first three criteria: ne-
cessity, effectiveness and cost-effectiveness. This emphasizes the influence the Dun-
ning report has had. The core of the current decision framework can be illustrated 
as done in Figure 2. In short, it indicates that rather than consecutively, the three 
main criteria are considered jointly. The idea behind the framework is that the cost-
effectiveness threshold -i.e., the amount society is willing to pay per unit of health, 
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(e.g. per QALY)- increases with disease burden, expressed in some meaningful way, 
as further highlighted below. Although the exact shape and level of the threshold is 
unclear, CVZ has indicated a range of 10.000 to 80.000 euros per QALY (6).
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 
20000 
60000 
80000 
100000 
120000 
140000 
40000 
Proportional shortfall 
C
os
t-e
ffe
ct
iv
en
es
s E
ur
o/
Q
A
LY
 
figure 2: Proportional Shortfall
While Figure 2 may illustrate the core of the CVZ framework, it is not complete. 
Dunning’s fourth criterion, own account and responsibility (OA&R), is not part of the 
core. Moreover, it is not a separate criterion anymore in the current CVZ framework. 
However, the content of the criterion was not dropped. Rather, its underlying con-
siderations became part of the necessity and feasibility criteria. The considerations 
Necessity 
Effectiveness 
Efficiency 
Basic Benefit  
Package 
Own account and 
Responsibility 
figure 1: The funnel of Dunning
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relating to the question whether, from an individual/patient perspective, it is necessary 
and appropriate to insure the intervention, were included in the necessity criterion as 
the NoI-element. This element is not captured in Figure 2 and less easily quantifiable. 
Those OA&R considerations which addressed the question whether, from a societal 
perspective, it is feasible to insure the intervention, were grouped under the feasi-
bility criterion, which focuses on macro-affordability and sustainability (College voor 
Zorgverzekeringen, 2001). Again, these are not part of Figure 2, but may still be impor-
tant in deciding on whether to include an intervention in the basic benefits package.
Necessity of insurance
The NoI-element of the necessity criterion relates to the question, whether, from an 
individual viewpoint insuring some intervention is necessary and appropriate. NoI 
captures two important considerations. First of all, the costs of an intervention, i.e., 
the financial accessibility of the intervention if not insured. The necessity of insuring 
low-cost, hence affordable care, is less obvious than that of high-cost interventions, 
ceteris paribus. Second, it concerns the appropriateness of health insurance as an in-
strument to ensure accessibility. For instance, interventions with a high risk of moral 
hazard3 may be less easily included in the basic benefits package, as are interven-
tions that are foreseeable. Health insurance is not necessarily the (most) appropriate 
financing mechanism for such interventions.
Arguably, financial accessibility is the most prominent aspect in determining NoI. 
Yet, while it may seem a straightforward criterion, using a concept like affordability in 
practice remains difficult as long as there is no agreement on a reasonable affordabil-
ity threshold. Furthermore, application of any threshold has been shown to be com-
plicated because what is affordable differs between people, adding to the complexity 
of operationalizing this concept (Hancock, 1993). Also, settling on a threshold might 
backfire as suppliers are induced to drive up their prices to just above this threshold 
as to ensure inclusion (College voor Zorgverzekeringen, 2008a). Nonetheless, in the 
decision making process in the medical aids sector (as opposed to other sectors like 
pharmaceuticals), anecdotally, a threshold of €100 is used for consumer products that 
last. That is, medical aids falling below that threshold were deemed to be affordable 
and, hence, insurance was deemed inappropriate. For low-cost disposables this thresh-
old is not used. However, it should be noted that low-cost disposables can become 
unaffordable for patients who need to procure these structurally and often (Niëns & 
Versteegh, 2011). In what follows we will shortly explain CVZ’s current decision making 
process and the way the NoI-element currently plays a role in it.
3. The situation whereby patients use more or more expensive care because they are 
insured.
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5.3 CvZ’s deCisioN MAKiNg frAMeworK ANd Noi
CVZ’s procedure of advising the government on the in- or exclusion of an interven-
tion currently consists of a two tier process. The intervention’s quantitative charac-
teristics are first assessed in an assessment phase. In this phase CVZ collects data and 
consults experts to judge the effectiveness and efficiency of the intervention, as well 
as the disease burden (as part of the necessity criterion). Together this forms the 
information required for an assessment as reflected in Figure 3.
For the NoI-element and the feasibility criterion, justice and solidarity consid-
erations are identified that could influence the reimbursement decision.4 This is 
currently not done in a structured way, so that the type of information gathered 
and the way it is presented can differ between interventions. Together with the 
information on effectiveness, cost-effectiveness and disease burden, these findings 
4. In the future CVZ plans to engage the stakeholders in the process of identifying these 
issues.
Consultation 
Experts 
Assessment 
• Necessity / Burden of Disease 
• Effectiveness 
• Efficiency 
• Feasibility 
List of societal considerations 
------------------------------------- 
 
Necessity of Insurance 
Formal 
Consultation 
Appraisal ACP   Is it necessary to 
  insure healthcare? 
 
• Weighing of possible critique on draft advise. 
• Make inventory of considerations 
• Determine direction and priorities 
Determine advice by Board of Directors 
Draft advice 
figure 3: CVZ’s package management process
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are interpreted and presented in a draft advice which is sent to all involved stake-
holders for a formal consultation (College voor Zorgverzekeringen, 2006; College 
voor Zorgverzekeringen, 2009a).
Subsequently, in the appraisal phase the draft advice, including stakeholder com-
ments and broader societal considerations, are publicly discussed. This is done in the 
so-called Package Appraisal Committee (ACP), consisting of a broad range of experts 
with different professional backgrounds. The ACP evaluates whether the conclusion 
in the draft advice is not at variance with important broader considerations not 
captured in the assessment.5 Besides evaluating this, the ACP also decides which 
broader considerations are most important, weights the comments of the various 
stakeholders, and formulates an advice to CVZ’s Board of Directors (College voor 
Zorgverzekeringen, 2009a). Finally, on the basis of the consultation, CVZ’s draft 
advice and the outcome of the ACP-discussion, the Board of Directors decides on the 
advice to the Minister of Health. This advice will always contain the outcome of the 
ACP appraisal, even if the final advice is not in line with the ACP appraisal (Figure 3) 
(College voor Zorgverzekeringen, 2009a).
For the necessity criterion, the subsequent steps are currently followed. In the 
assessment phase, the disease burden is assessed on the basis of fair innings (Wil-
liams, 1997) and proportional shortfall (Stolk et al., 2004; Van de Wetering et al., 
2013). Under the fair innings approach, people are considered to be entitled to 
some ‘normal’ health achievement. People falling short of this achievement could 
receive more weight in decision making than people exceeding this achievement. 
Using proportional shortfall as measure of disease burden, priority can be given to 
those who, without treatment, stand to lose a larger proportion of remaining health 
expectancy. Both measures can thus quantify disease burden, using Quality Adjusted 
Life Years as metric. CVZ currently demands information on both conceptualizations 
of disease burden, not wishing to adopt one particular measure exclusively. In the 
appraisal phase, the relevance of both sources of information can be weighed, 
alongside other potential considerations.
While disease burden therefore is calculated in the assessment phase, this is not 
the case for necessity of insurance. While this criterion arguably is more pluralistic 
and less easily quantifiable (College voor Zorgverzekeringen, 2009a), the lack of an 
instrument to operationalize the NoI-criterion in a structured fashion frustrates its 
5. For Pharmaceuticals the CVZ framework is slightly different. First, all pharmaceuticals 
are subject to assessment and appraisal by CVZ. Second, for pharmaceuticals a three 
tier process is applied whereby a commission Pharmaceuticals (CFH) deliberates on the 
technical assessment before it might be sent to the ACP, which is determined by CVZ. 
For more info see le Polain et al. (2010).
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systematic application and consideration. (The exception to some extent is medical 
aids, for which the NoI-element is more commonly addressed in the assessment phase 
(College voor Zorgverzekeringen, 2009a).) Without a structured way of considering 
necessity of insurance, both in the assessment and the appraisal phase, important 
aspects may be missed or considered unsystematically. This may negatively influence 
consistency of decision making. Hence, as a first step in taking the operationalization 
of the NoI-element forward, we set out to develop a checklist to systematically ad-
dress the NoI-elements in the assessment phase, thus facilitating a more structured 
and uniform consideration of these elements in the appraisal phase and decision 
making. The first step in developing this checklist was to consider the evidence in the 
literature and practice regarding the relevance, conceptualizations and operational-
ization of this criterion. This is highlighted in the next section.
5.4 tHe iMPortANCe of MoviNg towArd A systeMAtiC APPLiCAtioN 
of Noi
In this section we will highlight the rationale for using a NoI-criterion in the delinea-
tion of the basic benefits package by drawing on (i) insurance theory; (ii) the pub-
lished literature regarding (absence of) necessity to insure in the context of health 
insurance, and (iii) the current use of the criterion in the context of medical aids.
insurance
The NoI-criterion relates, first of all, to the rationale of insurance, which is primarily 
transferring risks over a larger pool (Pauly, 1992; van de Ven, 2009). The mandatory 
nature of the Dutch social health insurance system ensures solidarity across risk (the 
healthy subsidize the sick) and income (higher incomes are not compensated for 
their monthly premiums) (van de Ven & Schut, 2008; van de Ven, 2009). This system 
guarantees the Dutch population can access necessary treatments the majority could 
not afford otherwise. This can improve welfare since people derive utility from the 
financial protection against significant income drops (Nyman, 1999).
However, it is important to critically examine which risks should be insured. Indeed, 
insurance is not always the most efficient strategy. First, because insurers determine 
their premiums based on their expected payouts and add to that the loading fee 
(overhead costs and profit) (Nyman, 1999; van de Ven, 2009). Of course, the lower 
the cost of the intervention the less sensible it is to accept the loading fee costs as 
well (de Wit, 1987; College voor Zorgverzekeringen, 2001; van de Ven, 2009). Thus, 
a rational person will only take out insurance if its benefits outweigh its costs (van 
de Ven, 2009). Second, if an intervention is almost certainly required by all insured 
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individuals, insurance is an indirect and potentially inefficient way of paying the in-
tervention. Third, insuring an intervention can lead to moral hazard whereby people 
use more or more expensive care because it is insured (van de Ven, 2009). When 
people act as if health care is free of costs, they are bound to consume more than 
otherwise would have been the case. Although individual premiums do not increase 
significantly as these additional costs will be spread over all the insured, the impact 
on total health care costs can be large (de Kam, 2009). It is precisely because the 
Netherlands has a mandatory health insurance scheme that managing what is being 
insured is critically important. The insured entitlements should justify the mandatory 
financial contributions. For example, there are limits to people’s willingness to pay 
for the treatment of conditions with a low disease burden or cost. Thus, in critically 
assessing the entrance of new interventions in the basic benefits package, CVZ helps 
to protect Dutch citizens against unnecessary premium increases. As such, CVZ needs 
to balance equity and efficiency arguments in its advices.
Literature
Tinghög et al. (2010) present a framework that reverses the necessity of insurance 
discussion. Instead of looking whether it is necessary to insure an intervention, the 
authors identify six attributes of medical interventions that jointly preclude the 
necessity of insurance and therefore may make private financing morally justifiable. 
Not insuring an intervention in the basic benefit package could be based, accord-
ing to Tinghög et al. (2010) on the following criteria: 1) there should be sufficient 
knowledge amongst individuals to value the need and quality of the intervention 
before and after utilization; 2) there should be sufficient individual autonomy in or-
der to make informed choices regarding the health care they are procuring; 3) there 
should be low levels of positive externalities from the use of the care; 4) there should 
be sufficient demand to generate a private market; 5) the interventions should be 
affordable for most individuals and, finally; 6) the intervention should concern 
‘lifestyle enhancements’ and not ‘medical necessities’. In applying their framework, 
Tinghög et al. (2010) found affordability to be the most important aspect (Tinghög 
& Carlsson, 2012), which is in line with the experience in the medical aids sector, 
highlighted next.
Medical aids
As the NoI-element already plays an important and more systematic role in the 
review of medical aids, understanding this process might provide pointers for tak-
ing forward both its operationalization as well as CVZ’s goal of applying its criteria 
systematically across all interventions. In CVZ’s process for reviewing medical aids, 
the concepts of customary care and financial accessibility play an important role (Col-
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lege voor Zorgverzekeringen, 2008a). The concept of customary care is introduced 
to delineate the boundaries of health insurance, i.e., it emphasizes the fact that 
only those aids developed especially for people with a disability qualify for reim-
bursement. Because many medical aids are adapted versions of products that people 
without disabilities also have to procure, insurance may be considered inappropriate 
(College voor Zorgverzekeringen, 2009a). An intervention is not deemed customary 
care (and thus may be added to the benefit package) if it is developed specifically for 
people with a disability (e.g., medical stockings) and if it is delivered only by certified 
specialists (e.g., a trained professional is required for fitting hearing aids). If the 
intervention is deemed ‘customary care’ the necessity to insure this intervention is 
lower (College voor Zorgverzekeringen, 2008a). Whether medical aids are financially 
accessible is assessed by asking three questions. First it is examined whether they sub-
stitute for customary products. If so, the need for collective financing decreases (e.g., 
special cutlery or a bicycle with an add-on motor are substitutes for normal cutlery 
and a normal bicycle which everybody procures). Second, to ensure their accessibility 
is guaranteed the medical aid’s (additional) costs are assessed. If these are deemed 
too high for the individual to bear (partial) collective financing is warranted. An 
example of partial collective financing is expensive orthopedic shoes for which a 
co-payment of €137.50 (which may be considered reasonable costs for normal shoes) 
is in place (College voor Zorgverzekeringen, 2012). CVZ recommends higher levels 
of co-payments if the disability is foreseeable in a normal course of life (e.g., having 
trouble walking or losing normal visual acuity are ‘normal’ consequences of grow-
ing old). Finally, CVZ evaluates whether the medical aid is related to other already 
insured interventions which may lead to savings or quality issues (e.g., although a 
stocking aid for putting on medical stockings is cheap, it increases the compliance 
of wearing them which will offset other costs in the future). In reviewing the reim-
bursement of medical aids, CVZ assesses all aspects of customary care and financial 
accessibility jointly. Hence, no single aspect is a priori decisive.
All aspects highlighted above were taken into account in developing the checklist 
for NoI.
5.5 CHeCKList
In an effort to increase the transparency, consistency, and comprehensiveness of the 
appraisal discussion regarding the NoI-element, together with the assessors of inter-
ventions at CVZ, we developed a checklist that structures the main considerations 
identified in the previous paragraphs. We did so taking a patient perspective, which 
is in line with CVZ’s procedure of taking into account the costs of the intervention at 
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the individual level (College voor Zorgverzekeringen, 2006) under the NoI-element 
of the necessity criterion. This is in line with the guidelines for reviewing medical aids, 
in which the patient perspective is also leading (College voor Zorgverzekeringen, 
2009a). For matters of consistency we tried to stay close to the nomenclature used 
in assessing the reimbursement of medical aids where, as discussed, the ‘necessity 
of insurance’ considerations already play a more systematic role. The checklist was 
not intended to lead to clear-cut decision regarding in- or exclusion of the interven-
tion under study. Rather, its contribution should lie in providing transparency and 
structure in the application of the NoI-element in CVZ’s package management, e.g. 
facilitating structured debates in the ACP and leading to consistent consideration of 
these issues in decision making.
Drawing from insurance theory, literature and CVZ’s experience in the medical 
aids sector, as a first step in this process we developed a preliminary checklist that 
was sent to the assessors of interventions at CVZ for discussion. An iterative process 
ensued in which, based on their input regarding the scope and content of the con-
siderations underlying NoI, as well as their interpretation of the questions posed, we 
further developed the instrument. This process led to a checklist consisting of two 
themes with four questions each (Figure 4). The questions in the ‘health insurance as 
an instrument theme’ all address issues that are specifically related to the rationale 
for and consequences of health insurance. Hence, the issues of ‘moral hazard’, the 
fact that some ailments can be foreseen (thereby reducing the logic of insurance), 
and paternalistic motives in case positive or negative public health spill-over effects 
are to be expected (e.g. better public health due to tests for sexually transmitted 
diseases being provided free of cost) are addressed here. The theme of ‘financial 
accessibility’ looks at the costs of an intervention from an individual perspective and 
Health insurance as an instrument 
• Is the intervention customary care? 
• Is the intervention foreseeable? 
• Might there be under-usage of an intervention if it is not insured? 
• Might be over-usage of an intervention if it is insured (moral hazard)? 
 
Financial accessibility 
• Does the intervention substitute for something that the large majority of the 
population also uses? 
• Can the (additional) treatment costs be borne by the individual patient? 
• Can the patient expect relevant savings (offsetting the costs) due to the intervention? 
• Are treatment costs incurred only once or are structural in character?       
figure 4: CVZ/iMTA checklist
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asks if the patient can be expected to bear these costs. Historically, in the Nether-
lands, it has been difficult to agree on an absolute financial threshold below which 
interventions do not enter the benefit package (Luijn van et al., 1995). Moreover, 
setting one threshold fitting all circumstances seems unlikely to be realized. Hence, 
three questions address additional and contextual reasons why collective financing 
might not be required. These concern: (i) substitution, whereby an intervention 
substitutes for something the general population also uses/buys; (ii) whether the 
patient potentially saves money due to the intervention, which would (partially) 
offset the costs of the intervention and (iii) whether the costs are incurred only once 
or more often.
Putting it to the test
To see whether this checklist can be used in practice to structure the information 
regarding, and debate on the NoI-element (in the ACP), it was tested retrospectively 
on 10 different health care interventions. In Table 1, for each of the 10 interventions, 
the eight questions are answered. Finally, before we show the current reimburse-
ment policy, we also list the decision that would be based on the NoI-element of the 
necessity criterion only.
Table 1 shows that the first four interventions, all medical aids -i.e., reading 
glasses, rollator walker, watch for the visually impaired, lift chair-, are currently not 
reimbursed. While CVZ deemed reading glasses (#1) and the rollator walker (#2) to 
be customary care -i.e., they do not meet the requirements of both being specifi-
cally for people with an ailment/disability and delivery by trained specialists only-, 
watches for the visually impaired (#3) and smoking cessation programs (#4) were not 
deemed customary care. Furthermore, the (additional) costs of these four medical 
aids were deemed bearable for the individual patient. Whereas for reading glasses 
this was the main argument for exclusion, for the rollator walker, the watch for the 
visually impaired and the lift chair the substitution argument played an important 
role as well. The lift chair by far is the most expensive of these interventions. How-
ever, CVZ argued that furniture in general is expensive and because it is foreseeable 
that people at some point in time will have more difficulties standing up they can 
anticipate this when buying new furniture (College voor Zorgverzekeringen, 2008b). 
The fifth intervention, smoking cessation programs (#5), is presently reimbursed. 
These programs were removed from the package in 2012 (Stivoro, 2013) with 
relevant savings for patients -i.e., they would not have to spend their money on 
tobacco anymore- being the main political argument for doing so. In this case, CVZ’s 
advice to reimburse these programs (based on favorable cost-effectiveness (Parrott 
et al., 1998; Feenstra et al., 2005; Hoogendoorn et al., 2010) and smoking’s large 
burden of disease (College voor Zorgverzekeringen, 2009b)) was neglected. Since 
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2013 however, these interventions have entered the benefit package again because 
their usage had dropped significantly (Stivoro, 2013). Interventions six and seven 
-i.e. Codeine (#6) and Infliximab (#7)- should be reimbursed when judged solely on 
the basis of the NoI-element, which is in line with the current reimbursement policy. 
Applying the Necessity criterion, CVZ deemed incontinence materials (#8) for pure 
stress-incontinence not to meet the requirements for reimbursement, i.e., the dis-
ease burden was too low. As other types of incontinence would not be characterized 
by a low disease burden and distinguishing between these groups is not possible, 
CVZ recommended a co-payment for all incontinence materials of €75 per year. As 
this approximately equals the yearly amount that people with mild incontinence 
issues pay, CVZ stated that the financial accessibility of incontinence materials did 
not decrease (College voor Zorgverzekeringen, 2011a). Because orthopedic shoes 
(#9) substitute for regular shoes, CVZ recommended installing a fixed co-payment as 
the additional costs of this footwear are too high for people to bear (College voor 
Zorgverzekeringen, 2012). Finally, a floppy ear correction (#10) is seen as a cosmetic 
intervention the costs of which can be borne by the individual patient.
These examples show that it is possible to systematically address the identified 
considerations underlying the NoI-element and the checklist could inform appraisal 
discussions in a structured way.
5.6 disCussioN
The Dutch Healthcare Insurance Board has developed a framework of four criteria to 
guide decisions on reimbursement of healthcare interventions. Applying this frame-
work consistently in practice turned out to be challenging, however. Although much 
progress has been witnessed over the last years in operationalizing specific criteria, 
this has been less the case for the sub-criterion of necessity to insure. Both in terms 
of the criterion’s conceptual clarity as in terms of its measurability, much remained 
unclear. This paper aimed to address the latter issues by highlighting the elements 
included in the criterion necessity to insure, as well as its place in the decision making 
framework. Moreover, we presented a newly developed checklist for NoI that allows 
it to be applied both systematically and package-broad.
Grouped in the two themes of health insurance as an instrument and financial 
accessibility, the proposed checklist introduces eight questions which address the 
most relevant issues to see whether it is necessary to insure an intervention from the 
individual level. Its anticipated users are decision makers at CVZ who prepare assess-
ment reports which serve as input for the ACP. Through that process, the checklist 
facilitates systematic discussion of the NoI-element of the necessity criterion in the 
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ACP. This ensures the process of these discussions to be transparent and understand-
able while its outcomes are replicable, thereby limiting arbitrariness to a minimum. 
Currently, the checklist is being implemented in CVZ’s package management frame-
work where it will be used in assessing interventions.
Of course the framework has some limitations as well. Most notably, it does not 
answer the question how much people can and/or should pay themselves. Imple-
menting a financial threshold below which interventions should not be reimbursed 
is a political decision. Through ability to pay studies (Russell, 1996; Van Doorslaer et 
al., 2006) scholars could provide politicians and policy makers with information on 
the range within which such a threshold should fall. Secondly, although the checklist 
provides transparency, consistency and comprehensiveness in the process of address-
ing CVZ’s NoI-element, the operationalization of its questions is broad and does not 
provide concrete help in answering these questions. Therefore, incremental but con-
tinuous improvement of the checklist is required. A third limitation is the fact that, 
more often than not, filling out the checklist does not provide a clear cut answer 
regarding reimbursement decisions. It merely signals a possible problem that needs 
to be discussed in the appraisal phase. The weighing of the various considerations 
would be an important question for future research.
The implications of the checklist will mostly concern the process of decision making. 
Increasing transparency, consistency and comprehensiveness will give more legiti-
macy to the decisions made by policy makers (Daniels & Sabin, 1997; Daniels, 1999). 
When the retrospective analysis of actual decisions being taken is an indication, 
NoI’s impact on future reimbursement decisions will be limited, i.e., most decisions 
in Table 1 are in line with the expected outcome if NoI alone was decisive in decision 
making. Rather, the decisions can be explained better and are more predictable.
Governments face increasingly difficult decisions on entitlements because they are 
accountable for both ensuring that people’s mandatory financial contributions are 
employed justifiably as well as guaranteeing the financial accessibility of their health 
care systems. For the NoI-element of the necessity principle, the proposed checklist 
is a first step in providing transparency, consistency and comprehensiveness in these 
decisions.
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ABstrACt
This paper reports the most cost-effective policy options to support and improve 
breast cancer control in Costa Rica and Mexico.
Total costs and effects of breast cancer interventions were estimated using the 
health care perspective and WHO-CHOICE methodology. Effects were measured in 
disability-adjusted life years (DALYs) averted. Costs were assessed in 2009 United 
States Dollars (US$). To the extent available, analyses were based on locally obtained 
data from the Caja Costaricensse de Seguro Social (CCSS – national health insurance 
system) and the Ministry of Health (MoH) in Costa Rica and the Unidad de Analisis 
Económico (UAE) of the MoH in Mexico.
In Costa Rica, the current strategy of treating breast cancer in stages I to IV at 
a 80% coverage level seems to be the most cost-effective with an incremental 
cost-effectiveness ratio (ICER) of US$4,739 per DALY averted. At a coverage level 
of 95%, biennial clinical breast examination (CBE) screening could improve Costa 
Rica’s population health twofold, and can still be considered very cost-effective (ICER 
US$5,964/DALY). For Mexico, our results indicate that at 95% coverage a mass-media 
awareness raising program (MAR) could be the most cost-effective (ICER US$5,042/
DALY). If more resources are available in Mexico, biennial mammography screening 
for women 50-70yrs (ICER US$12,718/DALY), adding Trastuzumab (ICER US$13,994/
DALY) or screening women 40-70yrs biennially plus Trastuzumab (ICER US$17,115/
DALY) are less cost-effective options.
We recommend both Costa Rica and Mexico to engage in MAR, CBE or mam-
mography screening programs, depending on their budget. The results of this study 
should be interpreted with caution however, as the evidence on the intervention 
effectiveness is uncertain. Also, these programs require several organizational, 
budgetary and human resources, and the accessibility of breast cancer diagnostic, 
referral, treatment and palliative care facilities should be improved simultaneously. 
A gradual implementation of early detection programs should give the respective 
Ministries of Health the time to negotiate the required budget, train the required 
human resources and understand possible socioeconomic barriers.
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6.1 iNtroduCtioN
Due to population ageing and changing lifestyles in low-and-middle countries (LMICs), 
breast cancer incidence rates are increasing (Althuis et al., 2005; Parkin & Fernandez, 
2006). Given the organizational and financial constraints faced by the health systems 
in LMICs the majority of breast cancers are diagnosed at late stages (Agarwal et al., 
2009). Accordingly, the majority of breast cancer deaths occur in LMICs (Porter, 2008; 
Ferlay et al., 2010). The World Health Organization (WHO) therefore states that early 
detection and implementation of cost-effective interventions should be a priority 
in LMICs (World Health Organization, 2012a). In an attempt to support LMICs with 
breast cancer control, the Susan G. Komen for the Cure foundation provided a grant 
to investigate the cost-effectiveness of several breast cancer control interventions in 
seven LMICs1 to a consortium of the WHO, Erasmus University Rotterdam (EUR) and 
Radboud University Nijmegen Medical Center (RUNMC). Cost-effectiveness analyses 
may support governments in deciding how to spend scarce resources in health care 
most efficiently.
In each country, during four phases, the consortium works closely with local au-
thorities and experts in the fields of breast cancer, health economics, epidemiology 
and public policy. First, a three-day technical workshop is held, where the consortium 
explains a general cost-effectiveness model based on WHO-CHOICE methodology 
(described elsewhere (Tan-Torres Edejer et al., 2003; Groot et al., 2006)) which is to be 
tailored to the country specific situation. In the second phase, lasting approximately 
six months, local authorities identify and assemble the (local) data required for the 
cost-effectiveness model. Subsequent in phase three, the cost-effectiveness analyses 
are carried out. Thereafter, a second workshop is organized. Here the results of the 
analyses are discussed among representatives of all local institutions involved in 
breast cancer care and made available for actual policy making by the local health 
authorities, i.e., the fourth phase. This paper identifies the most cost-effective inter-
ventions for breast cancer control in both Costa Rica and Mexico from a health care 
perspective.
After presenting an overview of the situation regarding breast cancer in both 
Costa Rica and Mexico, we discuss the methods, data and interventions considered 
in this study and discuss the results.
1. Costa-Rica, Mexico, Brazil, Colombia, Ghana, India, Peru.
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6.2 BreAst CANCer iN CostA riCA ANd MexiCo
Cancer incidence and mortality rates are rising across Central America (Robles & 
Galanis, 2002; González-Robledo et al., 2010). In Costa Rica and Mexico breast cancer 
ranks among the top-five causes of death for women over 25 years old (Knaul et al., 
2008). Between 1995 and 2003, breast cancer incidence increased by 32.3% to a rate 
of 40.07 per 100,000 women in Costa Rica (Ministerio de Salud, 2007). In Mexico, 
breast cancer incidence increased as well and in both countries breast cancer mortal-
ity rates have increased since the 1980s (López-Ríos et al., 1997; Robles & Galanis, 
2002; Martínez-Montañez et al., 2009). In Costa Rica 13.14 breast cancer deaths 
per 100,000 women in 2006 were observed, the highest number among malignant 
neoplasms. Mortality rates per 100,000 women range from 28.19 in the province 
Dota to 1.23 in Guácimo, while in the provinces Los Chiles, La Cruz, and Garabito no 
breast cancer related deaths were registered (Ministerio de Salud, 2007). In Mexico 
mortality rates doubled over the last 20 years. The average mortality rate per 100,000 
women in Mexico stands at 9.9 with regional differences ranging from 13.2 and 
11.8 in the Federal District and the north, respectively, to 9.7 and 7.0 in the center 
and the south of the country, respectively (Palacio-Mejía et al., 2009). This increase 
caused breast cancer to overtake cervical cancer as the most deadly cancer among 
females in 2006 (Martínez-Montañez et al., 2009; Palacio-Mejía et al., 2009).Where 
in 1979 1,144 females died from the disease, in 2006 4,497 deaths were registered 
(Palacio-Mejía et al., 2009).
Although in Costa Rica and Mexico official recommendations for both breast 
self-examination (BSE) and mammography screening have existed for over a de-
cade, their coverage levels remain very low and the large majority of breast cancer 
patients present at the hospital with advanced disease (Ministerio de Salud, 2000; 
Franco-Marina et al., 2009; Knaul et al., 2009).
In light of the above, Non-Governmental Organizations (NGOs) and the general 
public put pressure on governments in Costa Rica and Mexico to improve treatment 
and early diagnosis through screening (Fundacion Nacional de Solidaridad Contra el 
Cancer de Mama, 2011; Fundación Cim*ab, 2011). Hence, both countries face choices 
on efficient allocation of scarce resources for breast cancer screening.
6.3 MetHods ANd dAtA
general approach
We used the WHO-CHOICE methodology, described in detail elsewhere (Tan-Torres 
Edejer et al., 2003; Groot et al., 2006), as a basis of our analysis. This approach com-
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pares all possible interventions in a specific disease area to a situation where no 
interventions are implemented. The latter, a counterfactual ‘null scenario’, acts as 
a reference to compare the costs and effects of existing and new interventions. An 
intervention in isolation, or a combination of different interventions, is then imple-
mented for 10 years in a modeled population. However, to include effects that occur 
after these 10 years, this modeled-population is tracked for 100 years. This approach 
enabled us to make comparisons of the costs and health effects across a wide range 
of competing interventions, identify differences in relative cost-effectiveness and 
identify the most efficient mix of interventions to improve population health.
Breast Cancer Model
Costs and health effects are calculated using a state transition population model 
developed and explained in detail by Groot et al. (2006). Its structure is presented 
in Figure 1 (Groot et al., 2006). The model simulates the development of a national 
population and accounts for births, background mortality and breast cancer epide-
miology of a country. It includes a healthy state, a deceased state, and stage I to IV 
breast cancer states following the classification of the American Joint Committee 
on Cancer (AJCC) (Greene et al., 2006). The effectiveness of each intervention is 
expressed in changes in disability weights (DWs, i.e., health state valuations (HSVs)), 
case fatality rates (CFs, i.e., improved survival for treatment scenarios), or in more 
positive stage distributions (in awareness raising and screening interventions). Since 
the interventions affect mortality (CFs) and morbidity (DWs), intervention effective-
ness is expressed in disability adjusted life years (DALYs) averted. The difference in 
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figure 1: Graphical representation of the model showing the relationships between the 
different health states through the incidence rates of breast cancer (Ix1–Ix4), the different 
stage specific case fatality rates (Fx1–4), and the background mortality (M) (Groot et al., 
2006). Stage specific relapse rates to stage IV were used to correct health state valuations only 
(Rx1–Rx3)
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the total number of healthy years lived by the population between each scenario 
and the null-scenario gives the population health gains in DALYs averted.
Zelle et al. (2012) improved the published model (Groot et al., 2006) by correcting 
HSVs for relapse, assuming that patients could only relapse to stage IV at a constant 
rate (Adjuvant Online, 2010). This rate was calculated as the average over the 10 year 
period in which the interventions were implemented. Although the probability of 
relapse normally decreases over time, Zelle et al. (2012) calculated the average rate 
because the model does not allow for different relapse rates over time. As a result, 
while the relapse rates are underestimated in early and overestimated in later years, 
the average amount of relapsed patients after 10 years is approximately the same.
interventions
An important element of the overall project is to select a set of appropriate interven-
tions for breast cancer control in LMICs. Therefore, a study group at WHO-CHOICE 
defined a mix of 11 common and preferable practices in 2009 (Zelle et al., 2012). Par-
ticipating countries can combine and adapt these practices to appropriately inform 
their specific policy questions. For Costa Rica and Mexico focus was placed on the 
cost-effectiveness of screening and treatment combinations. The most urgent policy 
questions in both countries concerned the age groups that should be targeted for 
screening and whether treating Her2/NEU+ patients with Trastuzumab (Herceptin™) 
was cost-effective. Therefore, the basic awareness raising intervention was excluded 
and different intervention scenarios, including treatment with Trastuzumab, were 
added. Combining the 11 common practices with or without Trastuzumab led to a 
total of 19 scenarios. The current situations of breast cancer control in Costa Rica and 
Mexico were modeled at 80% and 70% geographic coverage levels -i.e., reaching 
80% and 70% of those people who need services- respectively. All other interven-
tions were evaluated at a geographic coverage level of 95%. An overview of the 
interventions is listed in Table 1.
effectiveness
A key factor is the stage distribution of patients presenting at the hospital, given 
that the breast cancer stage determines the survival and disability of a patient and 
the effectiveness of each intervention (Greene et al., 2006).
In Costa Rica we obtained the current stage distribution from Ortiz (Ortiz, 2007), 
who studied breast cancer survival in Costa Rica between 2000 and 2003. Demo-
graphic data and incidence rates were obtained from the Statistical office of the 
Costa Rican MoH. For the prevalence we used the 2004 Global Burden of Disease 
estimates (World Health Organization, 2008b).
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For Mexico, we used the current stage distribution from Knaul et al. (2009), who 
studied 1904 patients that were all treated within the Mexican Social Security In-
stitute (IMSS, its abbreviation in Spanish). Demographic data were obtained from 
the Mexican National Population Council (Consejo Nacional de Población, 2011).
For Mexico we obtained incidence rates based on GLOBOCAN 2008 adjusted by 
age-group considering the distribution from the Mexican Histopathology Registry 
2006 (Secretaría de Salud de Mexico - Dirección General de Epidemiología, 2006; 
International Agency for Research on Cancer, 2012). For the prevalence in Mexico, 
as in Costa Rica, we used 2004 Global Burden of Disease estimates (World Health 
Organization, 2008b).
The case fatality rates for the treatment scenarios were based on Groot et al. 
(2006) (stage III & IV) and Zelle et al. (2012) (stage I & II), who corrected those from 
Groot et al. (2006) for the use of chemotherapy in stage I and II. We take these 
CF’s to represent technical efficiency, representing the maximum amount of DALYs 
that can be averted based on successful implementation of breast cancer diagnosis, 
treatment and follow-up strategies.
Since screening and awareness interventions as defined in international literature, 
alter the stage distribution, their effects on the stage distribution at presentation 
were estimated using the same methods applied by Zelle et al. (2012). Zelle et al. 
(2012) used international study results to estimate the health effects of various 
screening options and accounted for the sensitivity of the screening method, at-
tendance rates (80% in both countries), incidence rates and demography in target 
groups.
Costs
In line with the WHO-CHOICE approach we distinguished patient, program and 
training costs, which were calculated by multiplying quantities of applied proce-
dures by their corresponding unit costs. Patient costs were dependent on patient 
consumption (utilization) of explicit resources (procedures) for diagnosis, treatment, 
follow-up, early detection and screening.
Although Costa Rica has developed several guidelines for treating breast cancer 
over the years (Ministerio de Salud, 2000; Ministerio de Salud, 2009), local specialists 
informed us that treatments differ somewhat across hospitals. Therefore, together 
with these specialists, we revised the entire set of resource items to reflect the (aver-
age) current breast cancer treatment practices in Costa Rica. Specialists in Mexico 
had a similar opinion. As its health care system has three main public institutions 
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providing health care,2 treatment and reimbursement between these institutions 
may differ due to, for example, differences in salaries and drug prices. Hence we 
used resource utilization estimates of IMSS, which provides social insurance to ap-
proximately 40% of Mexico’s population (Knaul & Frenk, 2005).
Whenever possible we used locally obtained costing data. When not available 
we applied the original WHO-CHOICE estimates for either country. These estimates 
are based on econometric analysis of a detailed WHO-CHOICE database from South 
Africa including a set of standard salaries, drugs, outpatient visits, materials and 
supplies, capacity utilization and transportation multipliers (WHO Department of Es-
sential Health Technologies, 2005). In Costa Rica, the CCSS provided readily available 
unit costs of most breast cancer procedures. For Mexico, contrary to Salomon et al. 
(2012), who used the WHO-CHOICE original estimates on costs, in this study we used 
a detailed micro-costing exercise performed by IMSS (Instituto Mexicano del Seguro 
Social, Unidad Análisis Económico, 2012).
Costs of the procedures used for Costa Rica and Mexico are listed in Table 3.We also 
integrated evaluation costs of women presenting without breast cancer, included 
the costs of diagnosing all other stages (for stages I-IV separately) and, regarding 
screening interventions, included costs for evaluating false positives.
For the program-level costs, which capture management, administrative, media 
and law-enforcement costs, as well as costs for training of healthcare personnel, we 
used local salaries and WHO-CHOICE allocation rules for Costa Rica. For Mexico we 
used the standard WHO-CHOICE program cost estimates and allocation rules. Media 
and operating costs -i.e., prices for broadcasting, flyers, and posters- were provided 
by the CCSS in Costa Rica and the MoH in Mexico.
Training costs were primarily based on training the required health care work-
ers for each intervention. We maintained the allocation assumptions listed in the 
WHO-CHOICE model as set by Zelle et al. (2012) and used local salaries and WHO 
standard salaries for Costa Rica and Mexico respectively. In both countries all costs 
were estimated in 2009 local currency units —i.e., Costa Rican colones (CRC) and 
Mexican pesos (MXN)- and converted to U.S. dollars (US$) using the 2009 exchange 
rate (1.00US$ = 560.45CRC and 1.00US$ = 13.06MXN$) (Oanda, 2013; The World 
Bank Group, 2013c). Both health effects (DALYs) and costs (US$) were discounted at 
2. -  Instituto Mexicano del Seguro Social (IMSS) – covers salaried workers in the private 
sector.
 -  Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) – 
provides benefits for government workers. 
 -  Seguro Popular – voluntary public insurance for non-salaried workers or the unem-
ployed.
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a rate of 3% annually, which is recommended by WHO-CHOICE (Tan-Torres Edejer et 
al., 2003).
Cost-effectiveness analysis
The average cost-effectiveness ratio (ACER) of each intervention is calculated by 
dividing the average costs of the intervention by the average number of DALYs 
averted. These ACERs provide information on the set of interventions a region 
should finance to maximize health gains. The incremental cost-effectiveness ratios 
(ICERs) are calculated in relation to the last intervention purchased in each country, 
by dividing the incremental costs by the incremental health effects. These ICERs are 
used to establish an expansion path which shows the order in which the various 
interventions should be introduced if cost-effectiveness is the only consideration 
(Evans et al., 2005). Only interventions with the lowest cost for additional effects are 
considered on this expansion path. WHO-CHOICE defines interventions that have 
a cost-effectiveness ratio of less than one times the gross domestic product (GDP) 
per capita as very cost-effective, and those with a ratio that falls between one and 
three times the GDP per capita as cost-effective (World Health Organization, 2012b). 
In Costa Rica, this means that interventions that cost less than US$6,629 per DALY 
averted can be considered very cost-effective, and interventions that cost between 
US$6,629 and US$19,888 per DALY averted can be considered cost-effective. For 
Mexico these thresholds are US$8,416 and US$25,249 per DALY averted, respectively.
sensitivity analysis
In line with Zelle et al. (2012) we performed a deterministic sensitivity analysis for 
both Costa Rica and Mexico to assess the impact of key parameters on our cost-
effectiveness estimates. In both countries we increased the DW’s with 10%. Whereas 
costs of outpatient visits were increased by 25%, we raised the costs of mammog-
raphy with 200%. In estimating the impact of various screening interventions we 
decreased the sensitivity of CBE and mammography by 25% and assumed screening 
attendance rates of 60%. When available we also used alternative stage distributions 
for the current situation and different CFs. The unit costs for surgical procedures in 
Costa Rica were much lower than those of Mexico. To test the impact of this we 
substituted these costs with the Mexican values.
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Table 4 shows the results for Costa Rica (panel A) and Mexico (panel B). Both costs, 
effects and cost-effectiveness are presented. In Figure 2 these results are presented 
graphically, the expansion paths are shown as black lines.
Costa rica
Table 4 panel A shows the annual number of DALYs averted in treating the individual 
stages I-IV to vary between 193 (stage III) and 573 (stage II). Jointly these interven-
tions in each stage can avert almost 1,400 DALYs per year. Adding palliative care only 
averts a small number of DALYs. The costs of treating the individual stages range 
between approximately US$4 million and US$5 million per year. Adding basic and 
extensive palliative care programs to stage IV treatment adds approximately US$0.1 
and US$1 million to the yearly costs of stage IV treatment. At the 80% coverage level 
the current country situation in Costa Rica is highly cost-effective with an ICER below 
the country’s GDP per capita, i.e., US$4,739/DALY. In expanding Costa Rica’s breast 
cancer services, our analysis shows that treatment of all stages plus a CBE screening 
program targeting women between 40 and 70 years of age (I-IV + CBE (40-70)) is 
the next best option. At a total yearly cost of almost US$13 million, CBE averts 2,381 
DALYs per year. This can be considered a very cost-effective intervention as the ICER 
of this intervention is below Costa Rica’s GDP per DALY.
From figure 2 it follows that although the ACER of implementing mammogra-
phy screening for women between 50-70 years is still below Costa Rica’s GDP per 
capita per DALY, the ICER (as compared to CBE screening) is not lower than this 
threshold, i.e., the slope of the expansion path is steeper than US$6,629/DALY. While 
still considered a cost-effective intervention, mammography screening in age group 
50-69 averts 2,619 DALYs per year at a yearly cost of US$16 million. Increasing the 
age group for mammography screening to women between 40-70 years shows a 
similar trend, i.e., averting 3,015 DALYs at an annual cost of US$21 million can be 
considered cost-effective. Adding Trastuzumab to this intervention, while resulting 
in the highest number of DALYs averted per year -i.e., 3,274 DALYs at a total yearly 
cost of US$29 million-, is not considered cost-effective as its ICER is higher than three 
times the GDP per DALY.
The combinations of various interventions are all close to the expansion path 
meaning they avert DALYs at a slightly less favorable ICER but could nevertheless be 
meaningful to implement. For example, expanding the current program’s coverage 
to reach 95% or implementing a Mass-media Awareness Raising program (MAR), 
could be interesting options if the available budget is not sufficient to implement a 
screening strategy.
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figure 2: Cost-effectiveness of breast cancer interventions and expansion path according to 
Incremental Cost-Effectiveness Ratios (ICERs) for Costa Rica & Mexico
 
  
Panel A: Costa Rica
EPC
GDP
3 times GDP
Current 80%
Current (80%) + Trast.
I  & Relapse
II  & RelapseIII  &
 Relapse
IVBPC
current (95%)
I - IV + mammo (50-70)
I - IV + mammo (50-70) + Trast
I - IV + mammo
 (40-70)
I - IV + mammo 
(40-70) + Trast
I - IV & MAR
I - IV + CBE (40-70)
I - III + MAR
 + BPC
I - IV + CBE 
(40-70) + BPC
I - IV + mammo (40-70) + BPC
I - IV + mammo 
(50-70) + EPC
0
5
10
15
20
25
30
35
0 500 1000 1500 2000 2500 3000 3500
Effects per year in DALYs averted
C
os
ts
 p
er
 y
ea
r i
n 
m
ill
io
n 
U
S$
Dotted lines represent cost-effectiveness threshold of 1 and 3 times 2009 GDP/capita, i.e., 
6,629 US$/DALY and 19,888 US$/DALY (Oanda, 2013; The World Bank Group, 2013c).
 
Panel B: Mexico
EPC
GDP
3 times GDP
Current 70%
Current (70%)
 + Trast.
I  & Relapse
II  & Relapse
III  & Relapse
IV
BPC
Current (95%)
I - IV + mammo (50-70)
I - IV + mammo 
(50-70) + Trast
I - IV + mammo (40-70)
I - IV + mammo 
(40-70) + Trast
I - IV & MAR
I - IV + CBE (40-70)
I - III + MAR + BPC
I - IV + CBE
 (40-70) + BPC
I - IV + mammo (40-70) + BPC
I - IV + mammo 
(50-70) + EPC
-
100
200
300
400
500
600
0 10.000 20.000 30.000 40.000 50.000 60.000
Effects per year in DALYs averted
Co
st
s 
pe
r y
ea
r i
n 
m
ill
io
n 
US
$ 
  
Dotted lines represent cost-effectiveness threshold of 1 and 3 times 2009 GDP/capita, i.e., 
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Mexico
Table 4 panel B shows that the annual number of DALYs averted in the individual 
stages I-IV varies between 1,503 (stage IV) and 10,629 (stage II). Jointly these inter-
ventions in each stage avert approximately 26,000 DALYs per year. The addition of 
palliative care does not gain much health.
With an ACER of US$5,715 the current situation with 70% coverage is very cost-
effective. The analysis shows it is better to increase the coverage level of the current 
intervention to 95% rather than add Trastuzumab. In our analysis, implementing a 
program of Mass-media awareness raising (MAR) buys health most efficiently. Our 
results show that MAR averts 32,777 DALYs per year at a yearly cost of US$165 mil-
lion, which leads to an ACER of US$5,042 per DALY averted.3 If a higher budget were 
available, implementing mammography screening for women aged 50-70 would be 
the first next step. This intervention averts 44,192 DALYs per year at an estimated 
yearly cost of US$310 million. Even more resources would allow subsequently add-
ing Trastuzumab and increasing the age group to 40-70. These interventions fill out 
the expansion path and avert 47,616 and 50,714 DALYs per year at an estimated 
yearly cost of US$358 and US$471 million respectively. It should be noted that a CBE 
screening program, with an expected health gain of 39,769 DALYs averted at a cost 
of US$260 million, could be an interesting ‘in-between’ option.
sensitivity analysis
Sensitivity analysis showed our results to be particularly sensitive to different as-
sumptions on stage distribution at presentation and case fatality rates (Table 5). The 
Costa Rican CFs we obtained from Ortiz (Ortiz, 2007) differed strongly from those 
we deem to reflect technical efficiency (Groot et al., 2006; Zelle et al., 2012). Using 
these CFs causes the ACERs to vary between minus 82.7% for stage I and plus 65.5% 
for stage II. With regards to the current stage distribution, for Costa Rica we used the 
distribution from Groot et al. (2006). With this less favorable stage distribution, the 
current country situation was no longer part of the expansion path. Rather, the CBE 
screening program now became the most cost-effective.
For Mexico we ran the model with three different current stage distributions 
obtained from different studies (Groot et al., 2006; Flores-Luna et al., 2008; Comisión 
3. It should be noted that we estimate the MAR intervention to lead to a fixed stage 
distribution (see also: Zelle et al. (2012)). Although by implementing MAR in Mexico, 
the proportion of patients in stage IV actually goes up, we decided to include this 
intervention nonetheless because the total number of DALYs averted are substantially 
higher than the effects of the current country situation. This is due to the strong 
improvement in the proportions of patients in stage I and decrease in stage III (the 
proportion in stage II improves slightly).
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Nacional de Protección Social en Salud, 2011). These different stage distributions 
caused the ACERs to increase between 0 – 15%. When using the higher CFs from 
Salomon et al. (2012) for the intervention scenarios, the ACERs increased to a greater 
extent (34.7% for the current country situation).
For both countries, changes in the other parameters also led to different outcomes 
although the impact was smaller. For example, in Costa Rica the WHO default unit 
costs for a mastectomy or a lumpectomy were relatively low. Unable to obtain these 
unit costs from Costa Rica, using the higher Mexican unit costs showed their impact 
on the ACERs to be marginal.
6.5 disCussioN
Our results indicate that in both Costa Rica and Mexico treating stage IV disease 
only, or treating stage IV and providing basic or extended palliative care is not cost-
effective. In general, interventions ensuring more patients to present at the hospital 
in earlier stages seem the most cost-effective.
These results are in line with other studies which find mammography screening 
for women aged 50-70 to be cost-effective in sub-Saharan Africa and South East Asia 
(Groot et al., 2006; Ginsberg et al., 2012). Although Ginsberg et al. (2012) did not 
study the cost-effectiveness of clinical breast examination or other awareness rais-
ing programs, they acknowledge less expensive means of early detection in limited 
resource settings could be cost-effective in LMICs. When modeling the expected 
outcomes of such strategies - though based on limited evidence - Zelle et al. (2012) 
find that CBE screening and mass media awareness raising interventions indeed ap-
pear cost-effective in Ghana.
Although mammography interventions can be considered cost-effective, their total 
annual costs (budget impact) are high and may therefore not be appropriate for 
wide scale implementation.
If the necessary resources are not available both countries could choose to lower 
coverage levels or implement interventions with comparable ACERs (buying health 
just as efficiently) but with a lower budget impact. For Costa Rica, our analysis shows 
the most cost-effective option for expanding the current breast cancer services 
would be a CBE screening program combined with treatment of all stages. The 
yearly costs of this program are about US$12 million. In 2009, the per capita health 
expenditure in Costa Rica was US$660 (10.3% of GDP) (The World Bank Group, 
2013c). With a population of approximately 4.5 million, implementing a CBE screen-
ing program would add US$2.82 to this amount (0.43% increase). Although this 
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increase may seem feasible, the implementation and effectiveness of this program 
is highly dependent on the availability of human resources and the capacity of the 
healthcare system to refer and treat all new-found cases (Pisani et al., 2006; Miller 
et al., 2008; Anderson et al., 2011). Also, if the implementation of a CBE screening 
program would be unfeasible, MAR could be an interesting option as it is slightly less 
cost-effective but has a smaller yearly budget impact (US$10 million). Yet, the very 
limited evidence on MAR’s effectiveness requires our estimates to be interpreted 
with caution. Implementing a screening program for which the evidence base is 
stronger (e.g. mammography for women between 50-70 years of age) could be 
recommended if the yearly costs of US$16 million are affordable. Mammography 
screening in age group 40-70 costs much more (about US$21 million) and is therefore 
less economically attractive.
The Mexican MoH already decided to start increasing the use of the available infra-
structure and mammography equipment for the population most at risk (women 50 
to 70 years old and women with more than two risk factors). The gradual expansion 
will give enough time to train the required human resources. From our analysis the 
yearly costs of a mammography screening program for women 50-70 years of age 
at 95% coverage eventually would be US$310 million per year, a threefold increase 
over the current situation. Next, once a reasonable increase on coverage would be 
reached the Mexican MoH plans to increase the coverage rate to women between 
40-49 years of age (Fernández, June 8th, 2012). According to our estimates the yearly 
costs of implementing such a program would be US$422 million. With approximately 
110 million inhabitants and a per capita health expenditure of US$525 in 2009 (6.43% 
of GDP) (The World Bank Group, 2013c), implementing these programs would add 
US$2.82 (0.54% increase) and US$3.84 (0.72% increase) respectively to the per capita 
health expenditure.
However, our analysis shows that perhaps strengthening actual MAR or CBE screen-
ing programs to be a more attractive first step in improving breast cancer services 
from an economic perspective. With yearly costs of US$165 and US$260 million if 
started from zero, the strengthening of existing programs is more affordable and 
more politically feasible as it would represent modest increases to existing budgets.
One of the principal questions we received from policy makers in both Costa Rica 
and Mexico concerned the addition of Trastuzumab to the treatment regimens. 
In Costa Rica we were asked to estimate the impact of implementing HER2/neu+ 
tests and prescribing Trastuzumab to those patients who have overexpression of 
this gene. As data on the proportion of patients with overexpression of the HER2/
neu+ gene were not available, it was jointly decided to assume 30% of the breast 
cancer patients to have overexpression of the HER2/neu+ gene and to be eligible for 
Trastuzumab (Slamon et al., 2001). As a result of adding Trastuzumab, we estimate 
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Costa Rica can avert between 230 – 270 extra DALYs per year at an additional cost of 
approximately US$7 million per year. For Mexico we obtained the actual proportion 
of patients receiving Trastuzumab in IMSS. Here the health gains comprise between 
2,800 and 3,400 extra DALYs per year averted and the additional costs fall between 
US$45 – 51 million. It is worth noting that in Mexico Trastuzumab is already provided 
as part of the treatment for all eligible women in stages I to IV. Our analysis shows 
the addition of this bio-pharmaceutical to increase the cost of treatment of stages I 
to IV by more than 48%, generating the need of developing public policies focused 
on negotiating price reductions that can contribute to mid- and long-term financial 
sustainability. The use of tools as the ones presented in this paper can provide techni-
cal evidence on the benchmark price that the Mexican health system could use in 
negotiations considering the threshold of one times the GDP per capita.
The limitations regarding the model are essentially the same as those reported in 
previous studies (Groot et al., 2006; Zelle et al., 2012). First, as evidence on the ef-
fectiveness of awareness raising, CBE and mammography screening in Costa Rica 
and Mexico were absent, we relied on the same model approach as used by Zelle 
et al. (2012). Second, when calculating unit costs for Mexico we did not account for 
the mark up of transportation costs (as generally recommended by WHO-CHOICE) 
and did not include the costs of facilities. Including these costs would have probably 
resulted in slightly higher unit costs. Third, we did not adjust the disability weights 
in those scenarios in which Trastuzumab was added because we did not find robust 
evidence on the impact of Trastuzumab on disability weights/quality of life values for 
breast cancer in each of the four stages. Because we had seen in the palliative care 
scenarios that changing the DWs had a minimal impact on the results, we decided 
against adding something of low quality and limited impact. Fourth, there is little 
evidence that Trastuzumab has a positive effect on overall survival in early stages. 
As one of the few references Smith et al. (2007) provide evidence that women with 
early stage breast cancer experience a better overall survival with Trastuzumab than 
without. Given the local practice and policy interest of including Trastuzumab in 
early stages, we used this as the basis of our case fatality rates. Fifth, for this study 
we spoke to the oncologists, radiologists and surgeons that we had access to. With 
that our interviews focused on the areas of the capitals of both countries, i.e., San 
José and Mexico City. We acknowledge a representative sample covering a wider 
geographic area would have been desirable. Finally, in adopting a health care per-
spective we did not take into account travel and opportunity costs. Including these 
costs would probably have increased costs generally. Our general conclusions remain 
the same although the ranges of several ACERs are overlapping. The limitations fit 
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within the overall goal of WHO-CHOICE which is to provide general indications of 
cost-effectiveness, i.e., not precise estimates of specific interventions.
In summary, for improving their current breast cancer control programs, our 
analysis suggests that both Costa Rica and Mexico would benefit from implementing 
strategies that advance early detection. For these countries, a mass-media aware-
ness raising program and/or a CBE screening program coupled with treatment of 
all stages and careful monitoring and evaluation could be feasible options. If these 
strategies are implemented, the provision of breast cancer diagnostic, referral, treat-
ment and, when possible, basic palliative care services is essential and should be 
facilitated simultaneously.

Chapter 7
Equity in Ghanaian Breast Cancer 
Treatment Outcomes: A modeling Study 
in Komfo Anokye Teaching Hospital
Forthcoming as:
Niëns LM, Nyarko KM, Zelle SG, Jehu-Appiah C, Rutten FFH. “Equity in 
Ghanaian Breast Cancer Treatment Outcomes: A modeling study in Komfo 
Anokye Teaching Hospital” 
The Breast Journal - Letter to the editor.
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ABstrACt
With more and better health care services becoming available in Ghana, the equitable 
distribution of health outcomes becomes more important. In this study, we analyze 
which socio-economic groups benefit most from available breast cancer services in 
Komfo Anokye Teaching Hospital (KATH) in Kumasi, Ghana. Using a mathematical 
model we estimate differences in Disability Adjusted Life Years (DALYs) averted 
between SES-groups. Although KATH patients from higher quintiles generally had a 
more favorable stage distribution, and thus avert more DALYs than those from lower 
quintiles, this difference was very small. Yet, compared to patients not receiving 
treatment at all, the number of DALYs averted by our sample was significant. The 
fact that over 75% of the patients presented with late stage disease begs the ques-
tion if people actually have adequate information about breast cancer. It seems that 
equity in Ghanaian breast cancer care will benefit more from increasing awareness 
of breast cancer (symptoms) and treatment services to patients who currently do not 
seek nor receive care.
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7.1 iNtroduCtioN
Breast cancer is the most common cancer among women worldwide. Each year it 
is diagnosed in over 1 million women and accounts for 400.000 deaths (Groot et 
al., 2006). Although incidence rates are higher in high-income countries, low- and 
middle-income countries (LMICs) account for the majority of breast cancer deaths 
also because in LMICs the mortality-to-incidence ratio is much higher (Parkin et al., 
2005). This problem is likely to get worse as changing lifestyles and improvements 
in sanitation and management of infectious diseases will probably result in higher 
breast cancer incidence rates in LMICs. Incidence levels have been rising at 5% per 
year in some developing areas (International Agency for Research on Cancer Working 
Group on the Evaluation of Cancer-Preventive Strategies, 2002; Stewart & Kleihues, 
2003; Ferlay et al., 2004).
In high-income countries much progress has been made in reducing breast cancer 
mortality (Parkin et al., 2001; Parkin et al., 2005). However, the benefits of decreased 
mortality are not distributed equitably over the population. Studies have revealed 
differences in breast cancer burden by race (Ward et al., 2004), urbanization (Joseph 
Sheehan et al., 2004), insurance status (McDavid et al., 2003; Wilf-Miron et al., 2010) 
and socio-economic status (SES) (Lantz, 2006). Defined as “the absence of avoid-
able or remediable differences among groups of people, whether those groups are 
defined socially, economically, demographically, or geographically” the equitable 
provision of health care is an important goal of the World Health Organization 
(World Health Organization, 2010). Besides the efficient use of resources when 
implementing health care programs, the question of how to ensure that their ben-
efits are equitably distributed is thought to be equally important in LMICs (Magrath 
& Litvak, 1993; Pal & Mittal, 2004).
Equity in breast cancer care has been studied in high-income countries (McDavid et 
al., 2003; Joseph Sheehan et al., 2004; Ward et al., 2004; Lantz, 2006), but less so in 
middle-income countries (Charry et al., 2008; Velasquez-De Charry et al., 2009), and 
almost not at all in low-income countries. The relatively heavy data requirements 
for carrying out equity studies in combination with non-existing (national) cancer 
registries in many low-income countries may account for this (Parkin et al., 1999; 
Parkin et al., 2005).
This study tries to address this void in the literature and assesses equity of treat-
ment outcomes of breast cancer care in Komfo Anokye Teaching Hospital (KATH) in 
Kumasi, Ghana. We investigated whether lower SES patients in KATH present with 
more advanced disease and have worse health outcomes.
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The paper is structured as follows. First, the Ghanaian health care system and its 
equity profile are shortly discussed. Second, our data collection and methods are 
described. Next, we present and interpret our results.
7.2 eQuity ANd BreAst CANCer treAtMeNt iN gHANA: tHe roLe of 
HeALtH iNsurANCe
In Ghana, most breast cancer care is provided in the two academic hospitals -i.e., Korle 
Bu Teaching Hospital in Accra and Komfo Anokye Teaching Hospital in Kumasi- and 
the Peace and Love Hospital, a specialized breast clinic located at Oduom, Ashanti 
Region and Accra. The Ghanaian Health Service (GHS) does not have a national early 
detection program for breast cancer in place (Ohene-Yeboah & Adjei, 2012; Zelle 
et al., 2012) but several non-governmental organizations (NGOs)1 work on raising 
awareness and explain self-breast examination to women in remote villages. In the 
three aforementioned institutions mammography is available for diagnostic reasons. 
Treatment of patients in general involves a lumpectomy or mastectomy, endocrine 
therapy and (if required) chemo- and/or radiotherapy. Due to lack of resources 
diagnosing HER2/neu receptor status often is not possible (Ohene-Yeboah & Adjei, 
2012). For the same reason most patients are not treated with expensive monoclonal 
antibodies like Trastuzumab.
In March 2004 access to the GHS was improved when the Ghanaian Govern-
ment officially launched the Ghanaian National Health Insurance System (NHIS). It 
replaced a cash-and-carry system whereby patients had to pay for health services 
out-of-pocket (Sarpong et al., 2010). With the indigent and the poor exempt from 
paying premiums (Jehu-Appiah et al., 2010), within four years over 55% of Ghana’s 
population was registered (Jehu-Appiah et al., 2011). While a real accomplishment, 
evidence suggests that enrollment among the poor, both urban and rural, is rather 
low (Asante & Aikens, 2007; Health Sector Advisory Office, 2008; Jehu-Appiah et 
al., 2010; Jehu-Appiah et al., 2011). In a report written for the Ghanaian Ministry of 
Health Asante and Aikins note that:
“the association between NHIS card holders and socio-economic status is significant 
(p< 0.0001) with respondents being more likely to hold an NHIS membership card if 
they belong to richer quintiles.” (Asante & Aikens, 2007)
1. Two NGOs working on Breast cancer in Ghana are: “Mammocare” and the “Sister 
Support Network”.
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As Ghana does not have a national cancer registry (yet) and knowledge of cancer 
patterns is mostly “based on hospital series collected by clinicians and pathologists” 
(Parkin et al., 1999; Parkin et al., 2005) in this paper we study whether the outcomes 
of breast cancer treatments in KATH are equitably distributed across income quin-
tiles.
7.3 MAteriALs ANd MetHods
data
Between November 2009 and January 2010 we assembled 200 records of breast 
cancer patients that had received or were still receiving treatment at KATH in Ku-
masi. All patients diagnosed between January 1st 2008 and December 31st 2009 
were eligible for the study. In 2008 and 2009 respectively 149 and 140 breast cancer 
patients were seen. The non-response of 89 was due to the inability to trace patients, 
lack of consent and death at the time of study.
To determine differences in treatment outcomes, we collected data on breast 
cancer stage at diagnosis. The breast cancer’s stage helps medical practitioners to 
estimate the prognosis of the disease and decide on treatment options. It is often 
done according to the general principles of the American Joint Committee on Cancer 
(AJCC) staging system which takes into account the size of the tumor, the number 
of positive regional lymph nodes and possible metastasis (Fleming et al., 1997). 
The AJCC staging system includes both a clinical and a pathological classification. 
Whereas clinical classification “is based solely on evidence gathered before initial 
treatment of the primary tumor” (Singletary & Conolly, 2006), pathological clas-
sification “takes into account evidence obtained from surgery and from detailed 
pathologic examination of the primary tumor, lymph nodes, and distant metastases” 
(Singletary & Conolly, 2006). Although pathology services in Ghana are becoming 
more available, local investigators were only able to retrieve the clinical stage of 
90 patients (Stalsberg et al., 2008). The characteristics of the 110 patients for which 
they could not identify the clinical stage were very similar to those 90 for which they 
could.
ses
Our patients’ SES was estimated from their expenditures on: clothing, education, 
food, funerals, garbage collection, health, housing, lighting, remittances to other 
households, sanitation (toilet), transportation, wages and water. These were re-
trieved through face to face interviews of patients receiving treatment at the time 
of the study and telephone based interviews for those who had being diagnosed 
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with breast cancer but were at home during the time of the study. For the interviews, 
through which we also identified insurance status, we used a questionnaire as devel-
oped and validated by Jehu - Appiah et al. (2011). The SES-quintiles were constructed 
by ranking our sample by household expenditures. Since we had both SES and breast 
cancer stage for 90 patients, each quintile contained 18 patients. The cut-off points 
used to assemble our quintiles equal the maximum monthly household expenditure 
figures of every eighteenth patient.
Model
To see if treatment outcomes differed between patients, in line with other equity 
studies (Kongsri et al., 2011; Rahman et al., 2011; Ruhago et al., 2011), we calculated 
the averted Disability Adjusted Life Years (DALYs) per SES group. The DALY is a sum-
mary measure of population health which is “calculated as the sum of the years of 
life lost due to premature mortality in the population and the equivalent ‘healthy’ 
years lost due to non-fatal health conditions” (Tan-Torres Edejer et al., 2003). Hence, 
to calculate DALYs we need information on case fatality rates (CFs) and quality of 
life estimates or disability weights (DWs). It follows that averting DALYs equals gain-
ing health. The effects of breast cancer interventions for each of the four cancer 
stages in Ghana have been calculated by Zelle et al. (2012) who used an improved 
mathematical model as initially developed by Groot et al. (2006). Based on WHO-
CHOICE methodology (described elsewhere (Tan-Torres Edejer et al., 2003; Groot 
et al., 2006)) this model uses CFs from Bland et al. (1998) and estimates DWs from 
various other studies (de Koning et al., 1991; Murray & Lopez, 1996.; Launois et al., 
1996; Norum, 1999). In the model, patients in each of the four AJCC breast cancer 
stages receive the treatment currently given in Ghana and are exposed to stage 
specific CFs and DWs. For each of the five quintiles in our sample, we calculated 
the DALYs averted by entering a quintile-specific stage distribution in the model. In 
line with WHO-CHOICE methodology DALYs are discounted at an annual rate of 3% 
(Tan-Torres Edejer et al., 2003). DALYs averted are calculated without age weights 
as to not distort the total DALYs averted by elderly women receiving a lower weight 
than middle aged women (Tsuchiya, 1999).
Patients not receiving treatment do not avert DALYs associated with breast can-
cer control. They experience the natural progression of the disease and therefore 
have much higher case fatality rates. As such, in our analysis, the SES-quintiles and 
how their different stage distributions affect the number of DALYs averted, will be 
compared with the population not receiving treatment. Hence, we combine access 
to treatment and SES with our analysis of the breast cancer stage at presentation of 
90 patients in KATH.
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7.4 resuLts
Table 1 shows relevant characteristics of our patient sample. Over 95% of our 90 
patients had health insurance. Although the average age (54.67 years) and num-
ber of children (4.00) were higher in the 1st quintile than in the other quintiles 
(45.78 – 50.28 years and 2.80 – 3.93 children) these differences were not statistically 
significant. The stage distribution of our total sample we find to be slightly different 
from those reported by Ohene-yeboah and Adjei (2012) (also from KATH), Zelle et 
al. (2012) (from Korle Bu Teaching Hospital sample) and Groot et al. (2006), i.e., 
the total proportion of patients in low (I & II) and high (III & IV) stages is similar in 
all distributions.2 University educated patients were only found in the 4th and 5th 
quintile and the monthly average household expenditures of the latter (Ghana Cedi 
(GHC) 379) were more than three times those of the 1st quintile (GHC 124) and more 
than twice those of the 2nd quintile (GHC 177). Comparing these average household 
expenditures with those found in the latest round (5th, in 2005-06) from the Ghana 
Living Standards Survey (GLSS, a nationally representative household survey) showed 
those from the KATH sample to be higher. However, applying the consumer price in-
dex (CPI) from the World Bank’s Development Indicators to correct for price increases 
between 2006 and 2010 nullified these differences (Table 2) (The World Bank Group, 
2013c). Thus, the patients in our sample have similar expenditure patterns for each 
quintile as the population of Ghana as a whole.
The stage distributions and DALYs averted per patient for each of the SES-quintiles 
are presented in Table 3. Stage distributions between the 1st, 2nd, and 3rd SES-
quintiles are very similar with no or only 5.6% of patients presenting at the hospital 
with stage I disease. In the 4th quintile, 27.8% of the patients present in stage I. 
Hence, whereas overall over 75% of the patients presented with late stage disease 
(III or IV) in the 4th quintile this is just 50%. In the 5th quintile all patients presented 
in stage II or III. Although more favorable for the higher SES-groups, overall stage 
distributions are not significantly different (p-value Fischer’s exact test: 0.083). From 
our analysis it results that the 18 patients from our 1st quintile in KATH, would avert 
19.50 DALYs compared to no treatment (Table 3). This is an average of 1.084 DALYs 
averted per patient. Assuming the stage distribution of all patients equals that of 
the 5th quintile leads to 20.93 DALYs averted, or an average of 1.163 DALYs averted 
2. For stages I through IV the following distributions were reported:
- Ohene-Yeboah: 3.6% - 11.2% - 70.0% - 15.2%
- Zelle et al.: 2.3% - 20.5% - 50.0% - 27.3%
- Groot et al.: 9.4% - 14.2% - 58.0% - 18.4%
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table 1: Descriptive Statistics of SES-quintiles
variable ses
 i ii iii iv v
Age
Minimum 30 39 26 35 29
Maximum 85 70 86 74 78
Mean 54,67 48,72 45,78 50,28 48,94
Std. Deviation 17,71 8,50 15,18 9,49 14,04
Parity
Minimum 2 1 1 0 1
Maximum 6 6 7 10 10
Mean 4,00 3,67 2,80 3,50 3,93
Std. Deviation 1,77 1,75 1,81 3,44 2,52
Monthly household 
expenditure
Minimum 60,00 158,00 202,50 236,00 287,00
Maximum 158,00 202,00 231,00 284,00 556,00
Mean 123,84 176,97 215,46 259,81 379,42
Std. Deviation 28,25 13,28 9,20 14,13 90,08
Marital status
married 9 9 8 12 10
single 1 2 3 1 1
widowed 3 6 6 0 0
divorced 5 1 1 5 6
missing 0 0 0 0 1
total (N) 18 18 18 18 18
Health insurance
Yes 18 17 17 17 17
No 0 1 1 1 1
total (N) 18 18 18 18 18
education Level
none 11 4 2 4 1
elementary 7 11 9 5 8
secondary 0 3 7 7 8
university 0 0 0 1 1
missing 0 0 0 1 0
total (N) 18 18 18 18 18
Breast cancer stage
I 0 0 1 5 0 6 6,67%
II 2 3 2 4 4 15 16,67%
III 13 13 13 7 14 60 66,67%
IV 3 2 2 2 0 9 10,00%
total (N) 18 18 18 18 18 90 100,00%
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per patient. DALYs averted for the other three quintiles fall between these values. 
Patients in the 4th quintile had the most favorable stage distribution (27.8% and 
22.2% in stage I and II respectively) and averted on average 1.10 DALYs. The patients 
in the 4th quintile avert less DALYs than those from the 5th because the effects are 
discounted at a rate of 3%. Discounting corrects for the fact that in general society 
prefers to receive benefits sooner rather than later. Hence, future effects receive less 
weight and are scaled down to their present value. Because patients in earlier stages 
avert most of their DALYs in the future the present value of their DALYs averted is 
lower.
7.5 disCussioN
We combined expenditures and clinical breast cancer stage for 90 patients in Komfo 
Anokye Teaching Hospital in Kumasi, Ghana, with a cost-effectiveness model based 
on WHO-methodology, and studied the equity situation in KATH. Although we did 
find a trend of lower wealth quintiles having a slightly less favorable stage distribu-
table 2: Monthly average household expenditure
ses Quintiles
Patient sample KAtH 
- 2010
ghana Living standards 
survey (gLss) 2005-06
gLss 2005-06 brought 
to 2010 with CPi
I GHC 124 GHC 68 GHC 117
II GHC 177 GHC 104 GHC 176
III GHC 215 GHC 131 GHC 222
IV GHC 260 GHC 162 GHC 276
V GHC 379 GHC 239 GHC 407
total GHC 231 GHC 160 GHC 272
table 3: Average number of DALYs averted for five SES-quintiles in KATH treated for breast 
cancer.
ses 
quintiles
stage distribution a,b dALys per patient 
no age weight but 
discounted at 3% per 
year c
dALys per patient 
no age weight 
undiscounted c
stage i stage ii stage iii stage 
iv
I 0.0% 11.1% 72.2% 16.7% 1.08 1.56
II 0.0% 16.7% 72.2% 11.1% 1.11 1.61
III 5.6% 11.1% 72.2% 11.1% 1.10 1.61
IV 27.8% 22.2% 38.9% 11.1% 1.10 1.77
V 0.0% 22.2% 77.8% 0.0% 1.16 1.71
a stage distributions were not significantly different – Fisher’s Exact Test: 0.084 (2-sided)
b assumed to be equal to KATH population
c compared to no treatment at all.
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tion, indicating that richer patients present themselves at the hospital sooner, the 
differences in DALYs averted between SES-quintiles in KATH were very small. Our 
results show that patients who could access KATH did not experience inequities in 
treatment outcomes. However, there are probably many breast cancer patients that 
cannot access breast cancer diagnosis and treatment. This has most likely to do with 
the lack of adequate information on breast cancer signs and symptoms (low aware-
ness) and a poor treatment infrastructure (urban only) and referral system (van den 
Boom et al., 2004; Harford et al., 2011). Indeed, to improve breast cancer outcomes, 
ensuring that people present themselves at the hospital with early stage disease is 
paramount. The fact that in our sample over 75% of our patients still present at the 
hospital with late stage disease signals that there is an awareness problem. Shulman 
et al. (2010) show that in the US “mortality-to-incidence ratios decreased dramati-
cally, even before the generalized use of mammography or adjuvant chemotherapy 
and antiestrogen therapy that commenced in the mid- to late 1970s”. US data 
on breast cancer survival before 1974 suggest that these improvements in breast 
cancer survival are due to breast education and awareness programs (Flannery & 
Sullivan, 1978; Jatoi et al., 2005). More recent work also advocates the increase of 
awareness, education and capacity at primary and community health care facilities 
in low-income countries like Ghana to address the ever increasing burden of breast 
cancer (Anderson, 2006; Anderson & Carlson, 2007; Collingridge, 2009; Kerr & Midg-
ley, 2010; Harford et al., 2011). Furthermore, as treating early stage breast cancer is 
found to be less costly than late stage disease (Campbell & Ramsey, 2009), it comes as 
no surprise that Zelle et al. (2012) found a mass media campaign to increase aware-
ness to be one of the most cost-effective interventions.
This study has some limitations. First, as we had a non-response of 89 patients and 
were able to retrieve clinical stage for 90 patients only, possible selection bias could 
affect the breast cancer stage at diagnosis and SES of our sample. If these 89 patients 
were of low-SES and this was correlated with a worse stage at diagnosis this might 
explain why we did not find significant differences between stage distributions. 
On the other hand, our sample’s stage distribution differs only slightly from those 
found by other authors (Groot et al., 2006; Ohene-Yeboah & Adjei, 2012; Zelle et al., 
2012). Also, we showed that although the large majority of our patients reside in the 
Ashanti region (one of Ghana’s richest regions in the country’s middle belt (Business 
Guide, 2011)) their SES is similar to that of the Ghanaian population. Second, the 
high insurance uptake of our patients, also in the poorer quintiles, was surprising 
as average household expenditures did not differ from the general population and 
previous studies in Ghana reported a strong relationship between income and health 
insurance uptake (Asante & Aikens, 2007; Health Sector Advisory Office, 2008; Jehu-
Appiah et al., 2010; Jehu-Appiah et al., 2011). Upon further investigation our local 
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partners told us many people in Ghana only register with the NHIS once they get 
sick, which might explain the high insurance uptake in our sample (Nyarko, 2011). 
After registration it takes approximately 6 months before benefits can be claimed, 
however. Hence, although the received treatment at KATH is paid for out of pocket 
initially, for conditions which last longer (chronic), registering with the NHIS once 
confronted with sickness appears to be rational. Because we do not know which 
patients already had insurance upon reporting at the hospital we cannot answer 
the question if there is a positive relationship between insurance and treatment 
outcomes as was found in previous studies (McDavid et al., 2003). Furthermore, 
although all the patients in our sample received treatment, from interviews with 
doctors and local NGOs,3 we know that numerous breast cancer patients in Ghana 
in fact do not. This may be attributed to the fact that breast cancer is a taboo for 
many in the Ghanaian population (Errico & Rowden, 2006). Another reason may be 
the geographical coverage of breast cancer services of approximately 10% (Zelle et 
al., 2012). As detailed information about the group of patients not receiving care is 
lacking, we cannot exclude this group to also encompass (some) people who have 
insurance. Of course, if a large percentage of the untreated in fact also has insurance 
then other barriers to access than financial may exist as well. In addition, as medical 
tourism is flourishing in Africa (Connell, 2006; Herrick, 2007; Helble, 2011), Ghana’s 
richest people may go abroad for treatment, thereby not being part of our sample 
(Africa news, 2010). While our study shows the health outcomes in KATH are equita-
bly distributed over the SES quintiles, it is too small for extrapolation to Ghana’s total 
population (of breast cancer patients). Nonetheless, since KATH is one of the two 
breast cancer disease management centers in Ghana 4 (which see the vast majority 
of breast cancer patients, i.e., also those from Peace and Love hospital) we argue 
that the sample may provide a reasonable picture of current Ghanaian breast cancer 
patients. The fact that it contained a relatively low number of patients from other 
regions may signal access to services is hindered by low geographical availability of 
services as well. As Ghana is in the process of setting up a cancer registry, hopefully 
in the future some of these limitations may be addressed.
3. “Mammocare” and the “Sister Support Network”
4. The other is Korle Bu Teaching Hospital in Accra
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7.6 CoNCLusioN
The fact that treating similar patients with the same intervention causes the outcomes 
to be the same is not new (Dignam et al., 1999; Blackstock et al., 2006). Inequity 
across those treated in Komfo Anokye Teaching Hospital with different SES appears 
to be limited. The fact that the large majority of our patients presented with late 
stage disease signals low awareness. Low geographical availability of breast cancer 
treatment services may hinder access too. As treatment of breast cancer is effective 
in averting DALYs, the best option to improve equity in Ghanaian breast cancer care 
is probably to improve awareness and access to care.
Chapter 8
Gendered Epidemiology: Sexual 
Equality and the Prevalence of HIV/
AIDS in Sub-Saharan Africa
Based on:
Niëns LM, Lowery D. “Gendered Epidemiology: Sexual Equality and the 
Prevalence of HIV/AIDS in Sub-Saharan Africa.”
Social Science Quarterly 2009 90(5): 1134-44.
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ABstrACt
Given that HIV/AIDS in sub-Saharan Africa is largely spread through heterosexual 
contact, there is marked variation in levels of gender equity across sub- Saharan 
African countries, and levels of gender equity are likely to influence both exposure 
to sexual practices that increase the likelihood of exposure to HIV and the efficacy 
of prevention programs, we hypothesize that levels of gender equity account for 
the levels of and changes in the prevalence of HIV/AIDS across sub-Saharan African 
countries.
We explore this hypothesis by first discussing the role of gender and several other 
contextual variables in the spread of HIV/AIDS. The resulting model is tested with 
regression analyses of both the level and change of HIV/AIDS in sub-Saharan African.
We find strong support for our hypothesis. This suggests that further policy atten-
tion be given to gender equity in combating HIV/AIDS.
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8.1 iNtroduCtioN
In explaining variations in levels of HIV/AIDS across countries, scholars have identi-
fied determinants that range from those that can be readily manipulated, such as 
adoption of programs to distribute condoms, to those that cannot be changed, such 
as a country’s legacy of colonialism. Among the most interesting of these, we think, 
are those determinants that fall between these extremes of ease of manipulation. 
Of these, we think that perhaps one of the most interesting is the level of gender 
equity, an expectation that is driven by three hard facts about sub-Saharan Africa. 
First, HIV/AIDS in sub-Saharan Africa is largely spread through heterosexual contact 
(Akeroyd, 2004; UNAIDS, 2006). Second, there is marked variation in levels of gender 
equity across African countries (United Nations Development Program, 2012a). And 
third, levels of gender equity are likely to influence both exposure to sexual practices 
that increase the likelihood of exposure to HIV (Schoepf, 1988; Orubuloye et al., 
1996) and the efficacy of prevention programs, such as the use of condoms (Kesby, 
2004). We test the hypothesis that HIV prevalence is related to gender equity and 
then note policy implications of our findings.
8.2 tHe geNdered CoNtext of Hiv/Aids
HIV/AIDS in sub-Saharan Africa (henceforth simply Africa) is largely spread through 
heterosexual contact, with men largely responsible for the spread of the disease 
(Akeroyd, 2004; Halperin et al., 2008). And while, at the outset of the epidemic, the 
sex ratio of HIV/AIDS cases was almost equal, over time, data showed that infections 
among women increasingly outnumbered those in men (Akeroyd, 2004; UNAIDS, 
2006). It seems plausible, then, that relationships between men and women influence 
each sex’s exposure to the disease and opportunity to practice prevention. Therefore, 
it is likely that gender issues bearing on those relationships are an important factor 
in explaining variations in the course of the epidemic.
Gender matters in several ways. At the broadest level, Connell (1987) has argued 
that such gender differences can be explored by looking at the structures of labor, 
power, and cathexis that determine the relationships between men and women in 
a society. The labor factor concerns such variables as the organization of housework 
and childcare, unequal wages, the division between unpaid/paid work, and so on. 
The second factor has to do with the nature of authority, control, and coercion in a 
society. Cathexis refers to those relationships subject to desire and desirability, jeal-
ousy, distrust, and emotional relationships with children. Wingood and DiClemente 
(2000) applied Connell’s framework to the AIDS epidemic to assess how variation 
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in these factors influenced women’s vulnerability to HIV. Until the late 1990s, poli-
cies dealing with HIV/AIDS were based on the assumption that the individual had 
total control over his or her behavior. Still, such policies were more often than not 
aimed at women (Akeroyd, 2004). But in promoting these programs, Wingood and 
DiClemente (2000) noted that the kinds of differences in power noted by Connell 
that heighten women’s vulnerability to AIDS were simply not taken into account. 
This failure had significant consequences for the effectiveness of prevention and 
treatment programs. Indeed, according to Baylies and Burja (1995), it is primarily 
gendered inequality that puts both men and women at risk. As a result, policies 
that focus on gender issues may be a fundamental tool in fighting HIV/AIDS and a 
precondition for more effective treatment and prevention programs.
More specifically, culturally, legally, and economically, females are often not equal 
to men, and these differences may foster higher HIV prevalence among women. 
Because of their subordinate position, women all too often do not have the final say 
when it comes to cultural violence and sexual practices associated with the spread 
of HIV/AIDS. Practices in which a woman’s vagina is damaged, for example, circumci-
sion, and intra-vaginal substances that dry and tighten the vagina before sexual 
intercourse, increase the risk of becoming infected (Schoepf, 1988; Orubuloye et al., 
1996; Mgalla et al., 1997). Further, the belief that sex with a virgin will cure AIDS 
is common in Africa (Schoepf, 2004). This puts young women at risk of rape. The 
latter is a manifestation of power over the powerless and also regularly occurs in 
settings of conflict (see footnote 1). But it should be clear that these specific forms 
in which exposure to HIV is heightened are consistent with Connell’s broader notion 
of gendered power structures.
Micro-level research (Kesby, 2004), as well as conventional survey evidence (Mc-
Fadden, 1992; Meursing, 1997; Akeroyd, 2004), also supports the idea that gender 
matters in fighting HIV. Mgalla, Wambura, and de Bruyn, for example, argue that 
different norms apply to men and women when it comes to sexual activity, norms 
that decrease women’s negotiation power regarding condom use and faithfulness 
(Mgalla et al., 1997). Still, it is not clear that differences in sexual practices associated 
with exposure to HIV/AIDS and the efficacy of prevention practices are sufficient to 
account for the very substantial variation across countries and over time in levels 
of HIV/AIDS. However, based on the foregoing, we hypothesize that the LEVEL OF 
GENDER EQUALITY in a country is negatively related to HIV prevalence. HIV levels 
should decrease across countries as women become empowered and more equal to 
men. Further, the growth rate of HIV/AIDS should be associated with changes in the 
level of gender equity across countries.
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Obviously, gender is not the only thing that might plausibly influence cross-national 
variation in HIV/AIDS levels.1 Based on prior work, and recognizing the complexity 
of the causal processes at work, our model includes controls for ECONOMIC DE-
VELOPMENT (Shelton, 2005; McIntosh, 2006), ECONOMIC GROWTH (Brown, 2004), 
EDUCATION (Schoepf, 1988; UNAIDS, 2006), and how well the HEALTH-CARE system 
functions (Schoepf, 1988; Hunt, 1989; UNAIDS, 2006). The final factor is RELIGION, 
which is thought to influence vulnerability to HIV in several ways (Noell et al., 1993; 
Mgalla et al., 1997; Lagarde et al., 2000; Mbulaiteye et al., 2000; Bailey, 2001). Still, 
prior research (Gray, 2004; Oppong & Agyei-Mensah, 2004) has found that the per-
centage of Muslims in a country negatively predicted HIV prevalence.
8.3 testiNg tHe HyPotHesis
data and operationalization
We test two sets of models using separate dependent variables. The dependent 
variable in the first set of models is HIV PREVALENCE RATES as published by UNAIDS 
(UNAIDS, 2006).2 In 2003, HIV prevalence rates varied from a low of 0.20 percent 
in Mauritius to a high of 32.40 percent in Swaziland, with a mean of 7.29 percent. 
Separate estimates were generated for each year from 2000 to 2005, with the 
1. We also examined a number of other variables that might be expected to influence 
HIV/AIDS prevalence. However, none generated significant estimates in any of the 
models we examined, nor did their exclusion discernibly influence the estimates of 
the variables retained in the models. These included level of VIOLENCE (UNAIDS, 
2006; Akeroyd, 2004; Oppong and Agyei-Mensah, 2004) as measured by the number 
of refugees residing in a country as a percentage of its total population (UNHCR, for 
number of refugees; World Bank, for total population—both for 2000–2005 period), 
form of government (Przeworski, Alvarez et al., 2000), as measured by the Freedom 
House Index (Freedom House, data for 2000–2005), level of NGO ACTIVITY (Marmot, 
2004), as measured by the number of NGOs engaged in HIV/AIDS related activities in a 
country, and the legacy of COLONIAL EXPERIENCES on AIDS prevalence, as measured 
with dummies for the four largest colonizers in sub-Saharan Africa. We also examined 
participation in THE SOUTHERN AFRICAN DEVELOPMENT COMMUNITY (SADC) with 
a dummy for its 14 member counties. SADC issued in July 2003 a declaration on HIV/
AIDS indicating a joint anti-AIDS effort. None of these variables generated discernible 
results. We also examined Lieberman’s finding that the ethnic fractionalization of 
a country influences HIV/AIDS (Lieberman, 2007), but we assume that this effect is 
captured by the more proximate variable of health spending.
2. We use all sub-Saharan Africa countries as defined by UNAIDS. UNAIDS recently 
changed its methodology in its surveys of HIV prevalence rates, effective in the 2007 
report. Thus, we use the 2006 report for consistency across the 2000–2005 period.
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dependent and independent variables measured in the same year or, in very few 
cases (noted in the text), the most temporally proximate value of the independent 
variable or as noted for intentionally lagged variables. All produced strikingly similar 
results.3 We present, therefore, only the models for 2000 and 2005.4 The second set 
of models employ as a dependent variable CHANGE IN HIV PREVALENCE as measured 
by change in a country’s HIV prevalence between 2000 and 2005. Change in HIV 
prevalence rates from 2000 to 2005 varied from a low of -11.70 percent in Botswana 
to a high of 8.15 percent in Swaziland, with a mean change of -1.56 percent. Several 
specifications of the change score model were tested, including several with virtually 
all combinations of baseline 2000 and change from 2000 to 2005 values of the inde-
pendent variables. Again, all the models produced similar results with few estimates 
discernibly different from zero. We present, therefore, only a simple change score 
model including the baseline value of AIDS prevalence in 2000 as a control to assess 
whether there is a ceiling/floor effect or inertia in infection levels that make change 
more or less likely, the baseline and change score values of our measure of gender 
equity, and the 2000 baseline value of the other independent variables.
To measure the critical GENDER variable, we used the Gender-Related Development 
Index (GDI) from The U.N. Development Program (UNDP) development reports. This 
index is based on measures of average achievement across three basic dimensions 
captured in the human development index. These are a long and healthy life (based 
on life expectancy at birth), knowledge (based on the adult literacy rate and the 
combined primary, secondary, and tertiary gross enrollment ratio in schools), and a 
decent standard of living (estimated earned income is used). The GDI is calculated 
in three steps. First, for each dimension, indices for both males and females are 
calculated. Second, the results are combined in one index that penalizes differences 
in achievement between men and women. Finally, through combining the three 
indices, the GDI is calculated.5 We used the index values from the 2000–2005 UNDP 
development reports (data from 1998/2003). The 2003 report values of the Gender-
3. We also examined a number of other potential lags in the analysis. All produced quite 
similar results. In perhaps the most telling of these, Models 4, 5, and 6 in Table 1, 
which use 2005 values for the dependent variable, were re-estimated using not the 
most proximate lags of the independent variables, but the much longer lags used in 
Models 1, 2, and 3 of Table 1. Essentially identical results to those presented in Table 
1 were obtained. The results are also robust to potential violations of the normality 
assumption and outliers.
4. Number of observations for the means vary slightly because of missing data.
5. See HDR (2005:343), available at: http://hdr.undp.org/en/media/HDR05_complete.pdf.
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Related Development Index varied from 0.27 in Niger to 0.78 in Mauritius, with a 
mean of 0.45. From the 2000 to 2005 reports, the values of the index varied from 
-0.17 in Swaziland to 0.10 in Equatorial Guinea, with a mean change of under 0.01.
Obviously, the GDI on its own terms is best viewed as a general development 
measure, albeit one heavily weighted for differences in gender equity. To use the 
GDI as a valid measure of gender equity, then, we must control for its underlying 
components reflecting development more generally.
This is especially true since the two most key elements of the GDI reflect two of our 
most plausible rival explanations, those associated with economic development and 
level of education. To both distill a more valid measure of gender equity and generate 
interpretable estimates to test these rival hypotheses, we include separate measures 
of economic development and level of education in the model as controls. Once we 
statistically control for level of economic development and level of education, the 
GDI estimate should indicate the unique impact on HIV/AIDS of gender inequality in 
development. The UNDP reports provided the indicators for the variable ECONOMIC 
DEVELOPMENT: the gross domestic product per capita per year based on purchas-
ing power parities (GDP per-capita/PPP). Values of this measure in 2003 varied from 
548 in Sierra Leone to 19,780 in Equatorial Guinea, with a mean of 2,711.6 LEVEL 
OF EDUCATION is operationalized by the education index from UNDP development 
reports, which is based on the adult literacy rate and the combined gross enrolment 
ratio for primary, secondary, and tertiary schools. We used the education indices 
from the 2000 through 2005 reports (data from 1999/2004). The values in the 2003 
report varied from 0.16 in Burkina Faso to 0.81 in South Africa (mean = 0.55).
The importance a government attaches to its HEALTH-CARE SYSTEM is measured 
by general government spending on health as a percentage of total government 
expenditure in 1998–2003 (World Health Organization, 2012c).7 Health-care expen-
ditures as a proportion of total government expenditures varied from a low of 2.00 
percent in Burundi in 2003 to a high of 17.60 percent in Liberia, with a mean of 8.97 
percent. Data on RELIGION are taken from the 2006 Freedom House survey. Percent 
6. Change in the values of the economic development measure varied from -999 to 
15,834, with a mean of 811. The comparable values for education were -0.12, 0.17, 
and 0.02. For health-care expenditures, the values were -7.20, 6.70, and 0.42.
7. There is, however, the possibility of collinearity between health-care spending and 
level of economic development. But the fact that we were able to generate statisti-
cally discernible estimates for both in several of the models suggests that collinearity 
is not so severe as to preclude valid inferences about independent influences.
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Muslim varied from 1.00 percent in Zimbabwe in 2000 to 98.00 percent in Comoros, 
with a mean of 38.16.8
There are four final things to note about the estimating models. First, our hy-
potheses about economic development are complex given that they point to the 
effects on AIDS prevalence of both the level and rate of change in GNP. We found no 
evidence of the latter in our models (not reported) of change in AIDS prevalence. But 
in the first, static set of models, we include the economic development variables as a 
second-order polynomial to assess whether the effects of wealth on AIDS prevalence 
vary across values of wealth or whether they have a curvilinear relationship with 
AIDS prevalence. Second, given potential collinearity between the gender develop-
ment index and percent Muslim,9 we examine models both including and excluding 
percent Muslim. Third, we employ one-tailed tests for our gender variables given 
our strong expectations about their relationship with AIDS prevalence. And fourth, 
given few observations and potential collinearity, we employ somewhat more re-
laxed criterion levels.
8.4 resuLts
Table 1 presents the results for the models employing the 2000 (Columns 1 through 
3) and 2005 (Columns 4 through 6) values for AIDS prevalence. Starting with the con-
trol variables, the education coefficient is positive and significant across all models. 
In contrast, while the estimates for per-capita spending on health generated positive 
estimates in all cases, only those in the 2005 models were discernibly different from 
zero, albeit only modestly so. The percentage of the population that was Muslim 
generated a negative estimate in all four of the models in which it was included, 
although none was significant. More importantly for our purpose, the inclusion of 
percent Muslim does not seem to diminish the estimates for our key independent 
variable – the GDI. Indeed, the estimates for GDI are greater in magnitude in the 
models including percent Muslim: Models 2 and 3 for 2000 and 5 and 6 for 2005. 
The inclusion or exclusion of percent Muslim had, however, a strong impact on the 
8. We also looked at Africa’s three most widespread religions—Islam, Christianity 
(Catholic and Protestant), and indigenous beliefs—using separate dummies, but with 
null results. There was no substantively meaningful variation in percent Muslim over 
the period we examined. We examine only static measures, therefore, of the religion 
variable.
9. 10The correlations between GDI and percent Muslim over recent years were not as 
strong as some might expect, ranging from -0.45 in 1998 to -0.34 in 2001.
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coefficients for economic development. That is, the estimates for per-capita GDP 
were not significant in Models 1 and 4, which exclude percent Muslim, but they were 
positive and highly significant in the remaining models, suggesting that AIDS preva-
lence increases as nations become wealthier. But the inclusion in Models 3 and 6 of 
the squared value of per-capita GDP in the second-order polynomial specification of 
the impact of economic development modifies this conclusion to some degree. That 
is, the negative and significant estimates for the squared values of per capita GDP 
indicate that the generally positive impact of wealth on AIDS declines as nations 
become wealthier. What of our key explanatory variable –the GDI? As seen in the 
shaded portion of Table 1, GDI produces highly significant, negative estimates across 
all the models. As expected, countries with greater levels of gender equality had 
significantly lower levels of AIDS in both 2000 and 2005.
Table 2 employs change in HIV/AIDS prevalence from 2000 to 2005 as our dependent 
variable. The model includes the baseline value of AIDS in 2000 to control for pos-
sible ceiling or floor effects or simple inertia in the spread of HIV/AIDS. The baseline 
values of economic development, education, health spending, and percent Muslim 
table 1: OLS Test of Determinants of HIV/AIDS Prevalence, 2000 and 2005
2000 HIV/AIDS Prevalence 2005 HIV/AIDS Prevalence
Independent 
Variable
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Gender Index -59.220###
(25.007)
-121.754###
(28.482)
-137.868###
(21.713)
-60.863###
(19.906)
-77.532###
(23.159)
-83.332###
(15.127)
Economic 
Development
0.000
(0.001)
0.002***
(0.001)
0.010***
(0.002)
0.000
(0.000)
0.002**
(0.001)
0.009***
(0.001)
Economic 
Development Sq.
– – -0.007***
(0.002)
– – -0.006***
(0.001)
Education Index 55.764***
(12.810)
66.525***
(14.572)
65.174***
(10.950)
53.548***
(10.189)
42.529***
(13.469)
42.226***
(9.776)
Per Capita Health 
Spending
0.468
(0.379)
0.381
(0.284)
0.161
(0.219)
0.903**
(0.343)
0.796*
(0.397)
0.520*
(0.264)
Percent Muslim – -0.017
(0.043)
-0.022
(0.032)
– -0.052
(0.059)
-0.043
(0.039)
Constant 0.499 19.744 21.649 -4.576 8.688 4.943
R-Sq. 0.434 0.659 0.816 0.529 0.575 0.828
N 36 28 28 35 26 26
### = p<0.01, one-tailed test. * = p<0.10; ** = p<0.05; *** = p<0.01, two-tailed; values 
between brackets are standard errors.
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were also included in the models.10 To control for ceiling or floor effects for gender 
equity, we include in two of the models (3 and 4) both the baseline 2000 and change 
from 2000 to 2005 values of the GDI while excluding the latter in Models 1 and 2. 
Finally, Models 1 and 3 again exclude percent Muslim in order to assess the sensitivity 
of the estimates for the gender equity to collinearity.
As might be expected, the positive and significant estimate of the 2000 value of 
HIV/AIDS prevalence indicates that there is considerable inertia in its spread. Coun-
tries with the highest levels of AIDS in 2000 experienced the fastest growth rates 
from 2000 to 2005. This inertia is so powerful that the effects of the control variables 
are greatly diminished in the change score models in Table 2; only per-capita health 
spending in Model 1 and economic development in Models 3 and 4 generate signifi-
cant estimates at even modest criterion levels. Turning to the critical gender equity 
variables, it seems that the baseline level of gender equity in 2000 also has little 
independent impact on change in AIDS prevalence; while negative as expected, the 
10. Again, change scores for these variables were also examined with few discernible 
effects. The estimates in Table 2 seem quite robust in the face of decisions to include 
or exclude these additional variables in the estimating models or to exclude outlying 
cases.
table 2: OLS Test of Determinants of Change in HIV/AIDS Prevalence, 2000–2005
Changes in AIDS Prevalence 2000–2005
Independent Variable Model 1 Model 2 Model 3 Model 4
HIV Prevalence 2000 0.791***
(0.084)
0.863***
(0.146)
0.683***
(0.095)
0.728***
(0.181)
Gender Index 2000 -4.818
(13.327)
-21.420
(28.295)
-17.955
(13.187)
-46.961
(30.121)
Change in Gender Index 
2000–2005
– – -36.810##
(13.313)
-27.589#
(15.684)
Economic Development 2000 0.000
(0.000)
0.001
(0.001)
0.000 *
(0.000)
0.001*
(0.001)
Education Index 2000 5.703
(7.797)
10.798
(14.231)
8.825
(7.547)
16.780
(15.043)
Per Capita Health Spending 
2000
0.366*
(0.183)
0.381
(0.284)
0.311
(0.192)
0.160
(0.223)
Percent Muslim – 0.015
(0.032)
– -0.003
(0.032)
Constant -4.123 -0.666 0.974 9.126
R-Sq. 0.868 0.868 0.901 0.905
N 34 26 31 23
# = p<0.10; ## = p<0.05, one-tailed test. * =p<0.10; *** =p<0.01, two-tailed test; values 
between brackets are standard errors.
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estimated values for GDI in Models 1 and 2 are smaller than their standard errors. 
Again, the effect of this variable seems to be largely captured through the inclusion 
in the models of the baseline 2000 values of the dependent variable. But as seen in 
Models 3 and 4, inclusion of both the 2000 level of GDI and its changes in value from 
2000 to 2005 suggests that gender equity does indeed matter. That is, the estimates 
for GDI in both Models 3 and 4 are of considerably greater magnitude than those 
observed for Models 1 and 2. While again not surprising given the considerable iner-
tia in AIDS infection found for all the control variables, neither 2000 GDI estimate in 
Models 3 and 4 is significant. Still, both are now considerably greater in magnitude 
than their standard errors. More importantly, and unlike the control variables, 
change in gender equity seems to matter. Both estimates of change in GDI from 2000 
to 2005 in Models 3 and 4 are negative and discernibly different from zero.
8.5 CoNCLusioNs
We have found strong support for the expectation that gender equity influences 
HIV/AIDS-prevalence. Critically important in terms of public policy, it matters both in 
terms of level (Table 1) and change in AIDS prevalence (Table 2). That is, the results in 
Table 2 suggest that public policy efforts to improve levels of gender equity can have 
a marked impact on the spread of HIV/AIDS. Indeed, these effects suggest that this 
impact is rather large and impressive when compared to very weak effects found for 
comparable changes in levels of economic development, education, and health-care 
spending. And levels of gender equity are not constants even over the five-year 
timeframe we have examined. As noted earlier, while the static values of GDI across 
all sub-Saharan African countries ranged across 0.51 points in 2003, changes in these 
values within countries ranged across a full 0.27 points between 2000 and 2005. Thus, 
considerable change in gender equity is possible. As a consequence of public policy, 
then, efforts to improve gender equity might well influence the rate of change in 
HIV/AIDS prevalence.
Our finding that public policy efforts to improve gender equity can impact HIV-
prevalence does, in itself, not justify the reallocation of resources. First, we fully 
admit that the composite GDI is a crude index that does not adequately reflect the 
specific ways in which gender equity might matter in specific places at specific times. 
We do not yet know how specific cultural practices and/or the precise nature of 
women’s access to the levers of public policy influence exposure to and treatment 
of AIDS. In research design terms, these are issues of construct validity – precisely 
determining the specific elements of a general cause that influence an observed 
outcome. Second, once these issues of construct validity are addressed and policies 
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to improve gender equity are identified, it is not said they provide value for money, 
i.e., are cost-effective. Further attention to both these issues are the necessary next 
steps in our analysis as we seek to develop sound policy advice for African nations as 
they struggle with the manifest threats posed by the HIV/AIDS pandemic.
Chapter 9
Discussion
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9.1 iNtroduCtioN
The main purpose of this thesis is to contribute to the understanding of the role 
and importance of affordability in relation to choices in health care and to its mea-
surement. This will be done according to the research questions presented in the 
introduction:
1. How can the affordability of health care services be measured in LMiCs?
2.  How can the concept of affordability inform choices regarding the benefit 
package of a mandatory health insurance system?
3. How can choices regarding the allocation of scarce resources be informed?
After that, we will highlight some limitations and policy implications of our re-
search and identify future research questions.
9.2 MAiN fiNdiNgs
PArt i – Affordability at the micro level in low- and middle-income 
countries: the example of medicine affordability.
The first part of this dissertation concerned the question how affordability of health 
care services can be measured in low- and middle-income countries (LMICs). We ad-
dressed this question focusing on medicines, as in LMICs medicines are mostly paid 
for out-of-pocket and constitute a major part of total health care expenditures. The 
World Health Organization and Health Action International express medicine afford-
ability in the number of day’s wages the Lowest Paid Government Worker (LPGW) 
needs to procure a course of treatment (Cameron et al., 2009b). The simplicity of this 
concept ensures its ease of calculation and intelligibility; people within a country can 
easily position themselves relative to the LPGW of that country. However, the metric 
may misrepresent affordability when many people earn more or less than the LPGW. 
Furthermore, it hampers cross-country comparison of medicine affordability as the 
LPGW-wage differs both in absolute and in relative terms between countries.
In chapters 2 and 3 we set out to explore and apply alternative applications of 
methods that address some of the limitations of the LPGW-concept. In chapter 2 we 
explored two alternative applications of methods that can be and have been used to 
estimate medicine affordability: the catastrophic payment method and the impov-
erishment method. Within the catastrophic payment method a medicine is deemed 
unaffordable when its cost exceeds a certain proportion of the available income. The 
impoverishment method looks at the absolute level of available resources before 
and after procurement of a medicine. When due to the procurement of a medicine 
someone is pushed below a poverty line, the medicine is deemed unaffordable. The 
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use of these methods is commonly dependent on the availability of detailed house-
hold survey data which in LMICs often is not readily available. We showed that these 
methods can also be applied using aggregated data, which yielded quite favorable 
results. Of course, the usefulness of the proposed application of these methods with 
aggregated data depends largely on their validity. In that context, we highlighted 
that in Indonesia and India the World Development Indicators’ household final 
consumption expenditure estimates are substantially higher than the income data 
collected in household surveys (Ravallion, 2003). As a result, the use of macro meth-
ods leads to underestimation of impoverishment assuming that micro approaches 
are more valid. In chapter 2, the main critique on the LPGW approach -i.e. that it 
may overestimate affordability- was confirmed, as in many countries a substantial 
proportion of the population earns less than the LPGW. In chapter 3, we compared 
the affordability of four medicines across sixteen countries with the impoverishment 
method based on macro-data. The results in this study illustrated that a substantial 
proportion of the population would be pushed into poverty as a result of medicine 
procurement, implying that in many LMICs the affordability of treatments is low and 
indeed lower than often reported (Cameron et al., 2009b; Niëns et al., 2010). We also 
found that the lowest priced generic medicines in general were substantially more 
affordable than originator brand products. Hence, increasing the use of quality-
assured generics could reduce the impoverishing effect of medicines.
Chapter 4 went deeper into the issue of an appropriate threshold to be used in 
defining and operationalizing the impoverishment and catastrophic payment meth-
ods. Such a choice obviously influences the affordability outcomes and cannot be 
unambiguously made. We showed the impact of the methods chosen to measure 
affordability, as well as the thresholds chosen within those methods, to be significant 
on final outcomes and argued that it may be worthwhile to create a (preliminary) 
standard for calculating affordability to increase comparability between studies. 
We suggested using both the impoverishment and catastrophic payment methods. 
Moreover, applying a (standard) range of thresholds would be a logical choice, given 
the current variation.
PArt ii – Affordability at the macro level in a developed country: 
delineating entitlements in systems of (social) health insurance.
In the second part of this dissertation the central question focused on how the con-
cept of affordability can inform choices regarding the benefit package of a manda-
tory health insurance system. We took the Netherlands as an example because, as 
in many high-income countries, the scope of its (social) health care insurance system 
is critically examined. The Dutch Health Care Insurance Board (CVZ) is responsible 
for advising the Ministry of Health on what should be included in the basic benefit 
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package of its mandatory health care insurance scheme. CVZ applies a ‘package 
management’ framework that consists of four criteria, i.e., necessity, effectiveness, 
efficiency and feasibility. The level of operationalization of these criteria differs in 
practice, however. Whereas effectiveness and efficiency are operationalized through 
the concepts of evidence-based medicine and cost-effectiveness, the operationaliza-
tion of the necessity and feasibility criteria remains less clear. This is worrisome, since 
in Dutch public policy, the argument that interventions for which patients should be 
able to bear the costs themselves should not be part of the benefit package, appears 
to become more prominent. Therefore, chapter 5 took forward the operationaliza-
tion of the necessity criterion. Encompassing the elements of disease burden and 
‘necessity of insurance’ (NoI), the necessity criterion serves to inquire if the disease or 
required health care warrants a claim on solidarity given the cultural context. More 
specifically, we focused on the NoI-element which concerns the question whether it 
is socially necessary or appropriate to insure an intervention. We showed the lack of 
an instrument to operationalize the NoI-element frustrated its application in CVZ’s 
decision making process and developed a checklist that should facilitate and stan-
dardize the inclusion of the NoI-element in the decision making process. Consisting 
of eight questions grouped under the themes of health insurance as an instrument 
and financial accessibility, the checklist improves the process of decision-making by 
making the arguments related to the NoI-element more transparent, consistent and 
comprehensive, thereby limiting arbitrariness. As a result, the decisions can be better 
explained and, ideally, will become more predictable.
PArt iii – Health economics at the macro level in low- and middle-income 
countries: choices in breast cancer and Hiv/Aids.
In the first two parts of this dissertation we saw that in countries with both high 
and low levels of resources, issues of affordability are indeed important. The third 
and final part continued with studies that showed how health economics can help 
policymakers in making choices given scarcity of resources. As the first two parts 
of this dissertation made clear, policy makers in both high-income and LMICs face 
questions about how to keep health care affordable on the individual and societal 
levels. When policy makers make decisions at a societal level, good governance 
requires the process of reaching these decisions to be transparent, consistent and 
comprehensive (Daniels & Sabin, 1997; Daniels, 1999). The final three chapters in this 
dissertation used health economic techniques to inform those decisions. In chapter 
6 we studied the cost-effectiveness of various policy options in breast cancer care 
in Costa Rica and Mexico. In this chapter our results showed that both countries 
could benefit from scaling up their national breast cancer programs. Ideally the 
proportion of patients presenting themselves at earlier stages for treatment should 
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increase. As the yearly costs of mammography screening programs are very high, for 
both countries a mass-media campaign or a program of clinical breast examination 
screening might be interesting options for early detection and improvement of their 
respective breast cancer care programs. In chapter 7, we studied whether higher 
socio-economic status (SES) groups in Ghana had better health outcomes in breast 
cancer care. We found that even though in higher SES-groups more patients were 
diagnosed in earlier stages than in lower SES-groups, this difference was not statisti-
cally significant, which may be attributable to a small sample size. In chapter 8, we 
analyzed the relationship between different variables of the United Nations’ Human 
Development Indicators and the change in HIV-prevalence in sub-Saharan Africa. In 
all our results, the Gender Development Index variable was found to have a highly 
significant, negative relationship with HIV-prevalence. Although causality has not 
been proven, this information may be useful for policymakers in that it suggests that 
developing policies to address gender inequality may have a significant impact on 
HIV-prevalence.
9.3 LiMitAtioNs ANd PoLiCy iMPLiCAtioNs
From the onset of this thesis, it was clear that affordability is a highly relevant yet 
inherently vague concept (Bradley, 2008). Only in a world with limitless resources 
affordability would not be an issue. This dissertation has shown that issues of af-
fordability in health care are present in both low- and middle-income as well as 
in high-income countries, both at the patient and at the societal level. The main 
purpose of this dissertation was to increase the understanding of the affordability 
concept in health care. In considering the implications of our findings, it is important 
to address the limitations of our studies and to formulate future research questions.
A first limitation of this thesis relates to the research questions posed. For example, 
in chapters 2 and 3 we looked at the affordability of medicines. However, in estimat-
ing the affordability of health care, arguably, it is better to not consider a single 
category only. Indeed, studying the affordability of single medicines ignores the fact 
that health care treatments often encompass multiple medicines and physician or 
hospital services. The latter are often also paid for out-of-pocket in LMICs. Future 
research thus could focus on devising a standard regarding which costs to include 
and how to include them. Also, the question about how to calculate the affordability 
of medicines for acute conditions is not answered yet. Because these medicines are 
often used during short periods of time, patients can more easily resort to coping 
mechanisms like using their savings, borrowing or selling of assets.
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Second, although the concepts of impoverishment and catastrophic payment 
are well accepted in the context of LMICs (Cameron et al., 2009a), in high-income 
countries their use can be more problematic. As we acknowledged in chapter 2, the 
application of the impoverishment and catastrophic expenditure methods depends 
to a large extent on a country’s economic situation. In The Netherlands the trend is 
to exclude low-cost, affordable care from the basic benefits package (e.g. medical 
devices). One might use the aforementioned methods in setting limits to the costs 
of individual treatments, below which they can be left out of the package.1 How-
ever, numerous problems arise in setting such a limit. First, it is unclear how this 
limit interferes with the general deductible in the Dutch health care system. Second, 
it is unclear how to deal with accumulating costs when more than one low-cost 
item is used, separately perhaps affordable, but jointly unaffordable. Third, in the 
Netherlands excluding interventions solely on the basis of affordability is uncom-
mon, and more aspects are considered in the decision. In the Netherlands, the CVZ’s 
package management process incorporates both efficiency and feasibility (which, 
among others, looks at the budget impact) criteria. Therefore, implementing ad-
ditional co-payments, next to a mandatory deductible, for treatments that already 
passed CVZ’s package management criteria (and thus efficiency requirements) leads 
to an interesting situation. The mandatory yearly deductible is much discussed in the 
Netherlands. First set at €150 when implemented in 2008 (van de Ven & Schut, 2008) 
it has increased to €220 in 2012 (Schut et al., 2013) and €350 in 2013 (van Ginneken 
et al., 2013). In chapter 5 we highlighted CVZ’s Necessity of Insurance element, which 
encompasses the deliberations of the 1991 Dunning committee grouped under its 
‘own account and responsibility’ criterion. It includes the argument that the costs of 
an intervention should play a role in decisions regarding their in-/exclusion into the 
basic benefit package. Given the broad range of considerations, of which affordabil-
ity is just one, a fixed monetary threshold for affordability was not set. One may even 
question whether it is possible to set a clear and single threshold for affordability, 
since in a final decision to reimburse a specific health care technology many other 
factors may play a (more important) role.
Third, in different economic circumstances different thresholds play a role. Be-
cause in LMICs out-of-pocket payments make up a large portion of total health care 
expenditure, the required poverty line and proportion of income thresholds used 
when applying the impoverishment and catastrophic payment methods significantly 
influence what we deem affordable for an individual. Chapters 2, 3 and 4 all con-
1. Using the catastrophic payment principle, taking 2.5% as the maximum proportion of 
income to be spent and the lowest level of Dutch social security payments (‘Bijstand’), 
which is about €12,000 per year, one could derive a threshold of €300.
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cerned the threshold from an individual perspective. When doing cost-effectiveness 
analysis in countries with national (social) health insurance systems like Costa Rica 
and Mexico, the cost-per-DALY averted threshold captures what is deemed good 
value for money for a country, which is related to what these countries can afford to 
pay for health care. Hence, in chapter 6 the threshold was used to identify the most 
efficient health care programs, which in a (social) health insurance system are then 
paid for publicly. However, the discussion about what the value or willingness to pay 
for a QALY gained or DALY averted is still ongoing (Culyer et al., 2007; McCabe et al., 
2008; Bobinac et al., 2010; Shiroiwa et al., 2010). Furthermore, policymakers in Costa 
Rica and Mexico expressed the opinion that, although the efficiency of a treatment 
as measured in a cost-per-QALY/DALY is important, for them the budget impact 
was just as important. So whereas the cost-per-QALY/DALY threshold expresses, 
theoretically, what a country is willing to pay (given what they can afford), other 
considerations, including budget impact, may play an important role as well.
Fourth, in the cost-effectiveness analysis of breast cancer care in Costa Rica and 
Mexico in chapter 6 we had to rely on assumptions regarding the effectiveness of sev-
eral interventions that involved either screening or raising awareness. This requires 
the results of several modeled scenarios to be interpreted with caution. However, 
sensitivity analyses showed our conclusions to be robust. Ideally, simultaneously to 
implementing a clinical breast examination screening program or a mass awareness 
raising program studies measuring the effect of these programs are implemented.
Fifth, in studying the equity of treatment outcomes in Ghanaian breast cancer 
care, the fact that in chapter 7 we did not find a statistical significant relationship 
between socio-economic status and the number of DALYs averted might be due to 
the small sample size. It was unfortunate that the available budget did not allow us 
to include the patient population from Ghana’s second academic hospital (Korle Bu, 
Accra). Possibly this would have led to more robust results.
The main limitation of chapter 8 concerns the fact that the Gender Development 
Index is composite in nature. Although it expresses the differences between sexes 
on three dimensions (1 - life expectancy at birth; 2 - the adult literacy rate and the 
combined primary, secondary, and tertiary gross enrollment ratio in schools and 
3 - the estimated income earned) the index does not provide information on how 
gender differences influence women’s exposure to and treatment of HIV/AIDS. Policy 
makers would benefit from studies that help explain these issues of construct validity 
to improve policy advice for African nations struggling with the HIV/AIDS-epidemic. 
Of course, scarcity of resources requires to also study the efficiency of these policy 
options to further inform policymakers.
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9.4 future reseArCH
This thesis provides more insight in the issue of affordability in health care. Nonethe-
less, the above introduced limitations are real and warrant further research.
First, comparing affordability of health care across borders is difficult due to 
differences in prices, income and health care financing. In those countries where 
OOP-payments account for the majority of health care expenditures, to improve the 
comparability of affordability, the costs of a ‘basic basket of health care interven-
tions’ should be studied using purchasing power parities.
Second, although the developed checklist structures the debate concerning the 
necessity of insurance element of the necessity criterion in the Netherlands, guide-
lines for how to answer these questions are not developed yet. Developing these 
would be a next logical step in the process of increasing transparency, consistency 
and comprehensiveness in these decisions.
Third, while cost-effectiveness studies provide useful information for policy mak-
ers, priority setting decisions are complex as many other considerations play a role 
(Baltussen & Niessen, 2006). Future research could focus on using multi-criteria-
decision-analysis to help policy makers in both Costa Rica and Mexico, to inform 
their decisions in breast cancer.
Although affordability remains a vague concept, the problems surrounding it are 
real. This holds for people not being able to pay for essential health care (e.g. medi-
cines), governments struggling with keeping their national (social) health insurance 
systems affordable and researchers attempting to meaningfully operationalize and 
measure affordability. Because the impact of policy decisions on the affordability of 
health care can be large as can be the health impact of such decisions, increasing 
the understanding of affordability and providing policy makers and politicians with 
better information to inform their policy decisions is important. Inefficient health 
care and increasing levels of inequity are things we certainly cannot afford.
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Summary
Scarcity of resources is an important element in in many health care discussions. 
With health care costs increasing and resources being limited, scholars and policy 
makers in low- and middle-income countries (LMICs) as well as in high-income 
countries are confronted with difficult decisions on how to organize their health 
care systems and which treatments to reimburse (and for whom). In many LMICs, 
economic development leads to higher expectations of the health care systems, 
and increasing expenditures. In high-income countries, new medical technologies 
and aging populations are partly responsible for increasing and difficult to contain 
health care costs. In this dissertation, we focus on the issue of affordability. More 
specifically, we address three main questions: i) How can the affordability of health 
care services be measured in LMICs? ii) How can the concept of affordability inform 
choices regarding the benefit package of a mandatory health insurance system? iii) 
How can health economics help policymakers in making choices when resources are 
scarce? The aim of this thesis is to advance the understanding of the affordability 
concept in health care in LMICs and high-income countries and hence contribute to 
both the methodological development of methods to calculate affordability as well 
as their usefulness for policy makers in daily practice.
PArt i – Affordability at the micro level in low- and middle-income 
countries: the example of medicine affordability.
The first part of this thesis focuses on the affordability of health care in LMICs. 
Affordability in these countries is addressed from the individual perspective as in 
the majority of LMICs a health insurance system is not in place and the majority of 
patients have to pay for their treatments out-of-pocket. Therefore, the question we 
ask in this part is whether an individual patient can afford to pay for a treatment, i.e. 
micro affordability. In Chapter 2 of this dissertation we consider two methods that 
can be used to calculate the affordability of medicines for individual patients. The 
catastrophic method quantifies the proportion of the population whose resources 
would be catastrophically reduced by spending on a given medicine. Expenditures 
are labeled as ‘catastrophic’ when they exceed a certain percentage of the available 
income. The impoverishment method estimates the proportion of the population 
that would be pushed below a relevantly defined poverty line due to procuring a 
given medicine. The abovementioned percentage and poverty line therefore con-
stitute the thresholds against which affordability is measured. The gold standard 
of calculating catastrophic payment and impoverishment rates is using household 
level data. However, in many LMICs these data are not gathered regularly. This not 
only limits the opportunity to calculate the proportion of the population at risk of 
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or experiencing catastrophic payments or impoverishment, but also the evaluation 
of policies aimed to improve the affordability of medicines. Furthermore, because 
these household level data are not regularly available, comparing the affordability 
of medicines both over time and across countries is limited. The use of aggregated 
data can address some of these issues. We illustrate this with an application of these 
two methods using aggregated data. This provides more insight to policymakers 
regarding affordability of health care.
In chapter 3 of this thesis, we apply the impoverishment method with aggregated 
data across a sample of 16 countries to calculate the affordability of 4 essential medi-
cines. Comparing medicine prices to people’s available income and using poverty 
lines of US$1.25 and US$2.00 we show that a large proportion of the population in 
these countries is at risk of becoming impoverished if they have to procure one of 
these medicines. To improve this situation we recommend policy makers to promote 
the use of quality-assured low-priced generic versions of these medicines and, where 
possible, implement health insurance systems.
The concept of affordability is normative in nature, i.e. what one deems afford-
able varies across people. Calculating the affordability of medicines, or any other 
commodity, requires information from three sources: i) the price of this commod-
ity, ii) income(s) and iii) a threshold of unacceptable burden. Whereas the first two 
are taken from data sources, the latter essentially involves an arbitrary, normative 
choice. In chapter 4, using the example of medicine purchases in Indonesia, we 
study the impact of using different thresholds both for the catastrophic payment 
and impoverishment methods. As expected, we show the impact of the thresholds 
chosen to considerably influence the catastrophic payment and impoverishment 
rates. Consequently, we argue that it is important to further standardize methods 
and thresholds in applied research. This increases the comparability of results and 
facilitates sound assessments of affordability, which policy makers need to improve 
the affordability and access to health care.
PArt ii – Affordability at the macro level in a developed country: 
delineating entitlements in system of (social) health insurance.
In high-income countries where systems of (social) health insurance are functioning, 
many governments have taken steps to control increasing costs. Besides implement-
ing deductibles and co-payment arrangements, the entitlements of the basic benefit 
packages are also critically examined. Governments are responsible for ensuring that 
people’s mandatory financial contributions are employed in a responsible manner 
and, at the same time, that the financial accessibility of their health care system is 
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guaranteed. In the Netherlands, the Dutch Healthcare Insurance Board (CVZ) is re-
sponsible for advising the Minister of Health about the content of the basic benefit 
package. CVZ uses the criteria of Necessity, Effectiveness, Efficiency and Feasibility 
to determine if an intervention should be reimbursed. The operationalization of 
these criteria is not finished, however. In chapter 5 we aim to take forward the 
operationalization of the necessity of insurance (NoI-) element which, together with 
the concept of disease burden, forms the Necessity criterion. The NoI-element asks 
whether it is socially necessary or appropriate to insure an intervention. The opera-
tionalization of the NoI-element is not finished yet, both in terms of content as well 
as process. We introduce a framework which aims to help the assessors of interven-
tions at CVZ to systematically evaluate all important considerations encompassed in 
the NoI-element. The framework poses 8 questions that are grouped in the themes 
of health insurance as an instrument and financial accessibility. The framework thus 
provides guidance, structure and transparency regarding the NoI element.
PArt iii – Health economics at the macro level in low- and middle-income 
countries: choices in breast cancer and Hiv/Aids.
Besides measuring affordability, health economic techniques can be used to help 
inform the difficult decisions that policy makers are confronted with when deciding 
on how to allocate scarce resources. The final three chapters of this dissertation 
report on the application of some of these techniques in the fields of breast cancer 
and HIV/AIDS.
Breast cancer incidence and prevalence are increasing in LMICs. Although they are 
still much lower than in high-income countries, the majority of breast cancer mortal-
ity occurs in LMICs. In chapter 6 we calculate the most cost-effective policy options 
for treating breast cancer in both Costa Rica and Mexico. Local experts indicated the 
most urgent policy questions in both countries to be the age-groups that should be 
targeted for screening and whether treating Her2/NEU+ patients with Trastuzumab 
(Herceptin™) was cost-effective. Using WHO-choice methodology, for both Mexico 
and Costa Rica, we calculated the cost-effectiveness of the current breast cancer 
programs and 18 other treatment scenarios by comparing them with a null scenario 
in which no care is delivered. According to WHO-choice methodology effects were 
measured in disability-adjusted life years (DALYs) averted. Costs were assessed in 
2009 United States Dollars (US$). To the extent available, analyses were based on 
locally obtained data.
We show that the current strategy of treating breast cancer in stages I to IV at 
a 80% coverage level seems to be the most cost-effective in Costa Rica with an in-
cremental cost-effectiveness ratio (ICER) of US$4,739 per DALY averted. Our results 
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show that in Costa Rica a biennial clinical breast examination (CBE) screening pro-
gram (95% coverage) could double the number of DALYs averted. With an ICER of 
US$5,964/DALY, this can still be considered (very) cost-effective. Our analyses indicate 
furthermore that a mass-media awareness raising program (MAR) maybe the most 
cost-effective for Mexico (ICER US$5,042/DALY). Biennial mammography screening 
for women 50-70yrs (ICER US$12,718/DALY), adding trastuzumab (ICER US$13,994/
DALY) or screening women 40-70yrs biennially plus trastuzumab (ICER US$17,115/
DALY) also improve population health but are less cost-effective options.
For improving their current breast cancer control programs, our analysis suggests 
that both Costa Rica and Mexico would benefit from implementing strategies 
that advance early dtection. For these countries, a mass-media awareness raising 
program and/or a CBE screening program coupled with treatment of all stages and 
careful monitoring and evaluation could be feasible options. If these strategies are 
implemented, the provision of breast cancer diagnostic, referral, treatment and, 
when possible, basic palliative care services is essential and should be facilitated 
simultaneously. Agradual implementation of early detection programs should give 
the respective Ministries of Health the time to negotiate the required budget, train 
the required human resources and understand possible socioeconomic barriers to 
uptake. Also, these programs require several organizational, budgetary and human 
resources, and the accessibility of breast cancer diagnostic, referral, treatment and 
palliative care facilities should be improved simultaneously.
In chapter 7 we report on the equity situation of breast cancer care provided in Komfo 
Anokye Teaching Hospital (KATH) in Kumasi, Ghana. Using the same mathematical 
model as used in chapter 6 we analyze in which socio-economic groups most DALYs 
are averted when being treated at KATH. We calculate the DALYs averted from dif-
ferences in stage distributions. Our results show that while patients from higher 
SES-quintiles sooner present themselves at the hospital, their stage distribution is 
not significantly different from patients of lower SES-quintiles. Hence, we find no 
significant association between SES and health outcomes at KATH, although this 
might be due to a small sample size. As over 75% of the patients present at KATH 
with late stage disease and in Ghana the geographical coverage of breast cancer 
services is low, improving awareness regarding and access to breast cancer services 
for patients seems the best option to improve breast cancer outcomes.
Scholars have shown levels of HIV-prevalence to be influenced by, among others, 
levels of education, prosperity, health care spending, gender equity, religious affili-
ation etc. In chapter 8 we try to explain variations in levels of HIV-prevalence over 
a 5-year span by looking at these variables jointly. We find strong support for our 
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expectation that gender equity influences HIV-prevalence. Gender equity matters 
both in terms of the level as well as in the change of HIV-prevalence. Of course, 
this finding in itself does not justify the reallocation of resources to interventions 
focusing on improving gender equity as these might not provide value for money, 
i.e. may not be cost-effective.
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Samenvatting
Beperkte financiële middelen zijn een belangrijk onderwerp binnen veel discussies 
over de gezondheidszorg. Beleidsmakers in zowel lage- en midden-inkomenslanden 
alsook hoge-inkomenslanden zien de kosten in de gezondheidszorg stijgen. Omdat 
de beschikbare financiële middelen beperkt zijn worden zij geconfronteerd met 
moeilijke keuzes over hoe hun gezondheidszorgsysteem te organiseren en welke 
behandelingen wel en niet te vergoeden. In veel lage- en midden-inkomenslanden 
leidt economische ontwikkeling tot hogere verwachtingen van het gezondheids-
zorgsysteem, wat gepaard gaat met een toenemende vraag en hogere kosten. In 
hoge-inkomenslanden zijn nieuwe medische technologiën en vergrijzende popula-
ties gedeeltelijk verantwoordelijk voor de immer stijgende kosten van de gezond-
heidszorg.
Het onderwerp van dit proefschrift is het thema betaalbaarheid in de gezond-
heidszorg. Meer specifiek probeert het een antwoord te formuleren op drie vragen: 
i) Hoe kan de betaalbaarheid van gezondheidszorg voorzieningen in lage- en mid-
den-inkomenslanden gemeten worden? ii) Hoe kan het concept van betaalbaarheid 
keuzes informeren met betrekking tot het verzekerde basispakket in een gezond-
heidszorg stelsel met een verzekeringsplicht? iii) Hoe kan gezondheidseconomie 
beleidsmakers helpen met het maken van keuzes in situaties waar de beschikbare 
financiële middelen beperkt zijn?
deeL i – Betaalbaarheid op het micro niveau in lage- en midden-
inkomenslanden: de betaalbaarheid van medicijnen.
Het eerste deel van dit proefschrift focust op betaalbaarheid van gezondheidszorg 
in lage- en midden-inkomenslanden. Betaalbaarheid in deze landen wordt benaderd 
vanuit een individueel perspectief omdat in het merendeel van deze landen mensen, 
bij gebrek aan een verzekeringssysteem, zelf hun medicijnen moeten betalen. De 
vraag die in dit deel gesteld wordt is dan ook of een individuele patiënt zich een be-
handeling met medicijnen kan veroorloven; betaalbaarheid op micro niveau. Hoofd-
stuk 2 van dit proefschrift beschrijft twee methodes die gebruikt kunnen worden 
om de betaalbaarheid van medicijnen voor individuele patiënten te berekenen. De 
methode van catastrofale betalingen kwantificeert de proportie van de bevolking 
wiens inkomen met meer dan een vooraf bepaald percentage zal afnemen wan-
neer men medicijnen dient te kopen. In deze benadering worden uitgaven die meer 
dan dit percentage van het totale beschikbare inkomen omvatten als catastrofaal 
beschouwd. De armoede methode schat de proportie van de bevolking die beneden 
een armoedegrens wordt gedrukt door uitgaven aan medicijnen. Het percentage en 
de armoedegrens in de methodes zijn de drempelwaardes waartegen betaalbaar-
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heid afgemeten wordt. De gouden standaard voor het berekenen van percentages 
van respectievelijk catastrofale betalingen en de proportie van de bevolking die 
onder een armoedegrens wordt gedrukt, is het gebruik van huishoudenquêtes. 
In lage- en midden-inkomenslanden komen deze enquêtes echter niet regelmatig 
beschikbaar, wat de mogelijkheden om beide methodes toe te passen aanzien-
lijk verkleint. Een ander gevolg is dat het vergelijken van de betaalbaarheid van 
medicijnen, zowel over de tijd alsook tussen landen, beperkt is. In dit proefschrift 
ontwikkelen we alternatieve operationalisaties van de twee methodes die enkele 
van deze beperkingen wegnemen. Gebruik makend van geaggregeerde data laten 
we zien dat het gebruik van de twee alternatieve operationalisaties met kwalitatief 
goede geaggregeerde data betrouwbare resultaten geven voor beleidsmakers om 
hun beleid op te baseren.
In hoofdstuk 3 van dit proefschrift gebruiken we de armoede methode met geag-
gregeerde data om in een selectie van 16 landen de betaalbaarheid van 4 essentiële 
medicijnen te berekenen. Door medicijnprijzen te vergelijken met het beschikbaar 
inkomen van mensen en armoedegrenzen van US$1.25 US$2.00 laten we zien dat 
grote groepen van de bevolking in deze landen het risico lopen in armoede gedrukt 
te worden wanneer ze deze medicijnen moeten aanschaffen. Om deze situatie te 
verbeteren adviseren we beleidsmakers om het gebruik van generieke medicatie 
van een goede kwaliteit te promoten en waar mogelijk een nationaal systeem met 
gezondheidszorgverzekeringen op te zetten.
Het concept ‘betaalbaarheid’ is van nature normatief: wat iemand betaalbaar acht 
verschilt. Voor het berekenen van de betaalbaarheid van medicijnen, of een ander 
goed, is informatie van drie parameters nodig: i) de prijs van het goed, ii) inkomens-
gegevens en iii) een drempelwaarde van onacceptabele last. Waar de eerste twee 
parameters uit gegevensbronnen worden genomen, behelst de drempelwaarde in 
feite een arbitraire keuze. Als zodanig ligt het ten grondslag aan het normatieve 
karakter van het betaalbaarheid concept. In hoofdstuk 4 maken we gebruik van 
medicijnaankopen in Indonesië om de impact van de drempelwaarde op zo de 
catastrofale betalingen alsook de armoede methode te bestuderen. We laten zien 
dat de keuze van verschillende drempelwaardes de uitkomsten van beide methodes 
sterk beïnvloeden. Derhalve beargumenteren we dat het van belang is om deze 
methodes, en het gebruik van drempelwaardes in toegepast onderzoek, verder 
te standaardiseren om zo de vergelijkbaarheid van de resultaten te vergroten en 
beleidsmakers te helpen bij het ontwikkelen van beleid gericht op het verbeteren 
van de betaalbaarheid van de gezondheidszorg.
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deeL ii – Betaalbaarheid op macro niveau in een hoog inkomensland: het 
afbakenen van aanspraken in sociale gezondheidszorgsystemen.
In hoog inkomenslanden waar op nationaal niveau (sociale) gezondheidszorgsys-
temen geïmplementeerd zijn, nemen veel overheden maatregelen om de immer 
stijgende kosten van deze systemen te beperken. Naast het invoeren van eigen 
risico’s en eigen betalingen, wordt ook de omvang van het verzekerde basispakket 
kritisch bestudeerd. Overheden zijn immers verantwoordelijk er voor te zorgen dat 
de verplichte bijdragen van verzekerden op een verantwoordelijke manier ingezet 
worden. Daarnaast dient ook de financiële toegang tot het gezondheidszorgsysteem 
gewaarborgd te blijven. In Nederland adviseert het College voor Zorgverzekeringen 
(CVZ) de Minster van Volksgezondheid ,Welzijn en Sport over de inhoud van het 
basispakket. Het CVZ gebruikt de criteria van Noodzakelijkheid, Effectiviteit, Doel-
matigheid, en Uitvoerbaarheid om te peilen of een interventie verzekerde zorg is. 
Echter, de operationalisatie van deze criteria is nog niet afgerond. In hoofdstuk 5 
proberen we de operationalisatie van het ‘noodzakelijk te verzekeren’ (NtV) element 
verder te brengen. Samen met het concept ziektelast maakt NtV deel uit van het 
Noodzakelijkheid criterium. Onder het NtV-element wordt onderzocht of het maat-
schappelijk bezien nodig of aangewezen is om een zorginterventie te verzekeren. In 
het licht van kritisch bestuderen van de omvang van het basispakket staat het NtV-
element in de belangstelling van beleidsmakers. De operationalisatie van het NtV-
element is nog niet voltooid, zowel op het gebied van de inhoud alsook wat betreft 
het proces. We introduceren een kader dat tot doel heeft de beoordelaars van het 
CVZ te helpen bij het systematisch evalueren van alle belangrijke overwegingen die 
binnen het NtV-elemement vallen. Het kader bestaat uit 8 vragen die gegroepeerd 
zijn in twee thema’s: zorgverzekering als instrument en financiële toegankelijkheid. 
De vragen functioneren als richtsnoer en het beantwoorden ervan biedt structuur en 
transparantie in de discussies die het CVZ over dit onderwerp voert.
deeL iii – gezondheidseconomie op macro niveau in lage- en midden 
inkomenslanden: keuzes in borstkanker en Hiv/Aids.
Technieken uit de gezondheidseconomie kunnen beleidsmakers informeren wan-
neer zij zich voor moeilijke keuzes gesteld zien staan. De laatste drie hoofdstukken 
van dit proefschrift rapporteren over onderzoeken op het gebeid van HIV/AIDS en 
borstkanker waar enkele van deze technieken zijn toegepast.
De incidentie en prevalentie van borstkanker stijgen in lage- en midden inkomens-
landen. Hoewel deze nog steeds veel lager zijn dan in hoge-inkomenslanden, vinden 
de meeste sterfgevallen als gevolg van borstkanker plaats in lage- en midden-inko-
menslanden. In hoofdstuk 6 berekenen we de meest kosten-effectieve beleidsopties 
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voor het detecteren en behandelen van borstkanker in Costa Rica en Mexico. De 
belangrijkste beleidsvragen van lokale experts betroffen de leeftijdsgroepen die 
gescreend zouden moeten worden en of het gebruik van Trastuzunab (HerceptinTM) 
bij Her2/NEU+ patiënten kosten-effectief was. Gebruikmakend van WHO-CHOICE 
methodologie berekenen we de kosten-effectiviteit van 19 behandelings-scenarios 
door deze te vergelijken met een ‘nul’-scenario waarin geen borstkanker zorg wordt 
geleverd. In lijn met de WHO-CHOICE methodologie zijn effecten gemeten in voor 
beperkingen gecorrigeerde levensjaren, zogenaamde DALYs (Disability Adjusted 
Life Years). Kosten zijn uitgedrukt in 2009 Amerikaanse dollars. Voor zover mogelijk 
zijn de analyses uitgevoerd op basis van lokaal verkregen data.
We laten zien dat de huidige strategie om borstkanker in stadia I tot en met IV 
te behandelen met een landelijke dekking van 80% in Costa Rica het meest kosten-
effectief lijkt te zijn met een incrementele kosten-effectiviteits ratio (ICER) van 
US$4,739/DALY. Onze resultaten laten zien dat een tweejaarlijks klinisch borstonder-
zoek (dekking 95%) het totale aantal vermeden DALYs kan verdubbelen.
Met een ICER van US$5,964/DALY, is dit nog steeds kosten-effectief. Onze analyse 
toont aan dat een programma gericht op het verbeteren van het bewustzijn bij men-
sen over borstkanker via de media het meest kosten effectief kan zijn voor Mexico 
(ICER US$ 5,042/DALY). Tweejaarlijkse mammografie screening voor vrouwen tussen 
50 -70 jaar (ICER US$12,718/DALY), het hieraan toevoegen van Trastuzumab (ICER 
US$13,994/DALY) en vervolgens het uitbreiden van het programma naar vrouwen 
tussen 40 -70 jaar (ICER US$17,115/DALY) leidt ook tot meer vermeden DALYs. Deze 
opties zijn minder kosten-effectief en alleen mogelijk wanneer er meer (financiële) 
middelen beschikbaar zijn.
Afhankelijk van het beschikbare budget bevelen we Costa Rica en Mexico aan 
om programma’s gericht op het vergroten van het bewustzijn van borstkanker via 
de media, klinisch borstonderzoek of mammografie in te voeren. Een geleidelijke 
implementatie van programma’s gericht op vroege detectie zou de Ministeries van 
Volksgezondheid in beide landen de tijd moeten geven om het benodigde budget 
bij elkaar te krijgen, het benodigde personeel op te leiden en mogelijke sociaal 
economische barrières in kaart te brengen en te slechten. Omdat het bewijs van 
de effectiviteit van de interventie gericht op het verbeteren van het bewustzijn bij 
mensen over borstkanker via de media onzeker is, is voorzichtigheid geboden bij 
het interpreteren van deze resultaten. Om de onderzochte programma’s te imple-
menteren dienen voldoende organisatorische, budgetaire and personele middelen 
beschikbaar gesteld te worden. Het verbeteren van de toegang tot diagnostiek, 
verwijzing, behandel en palliatieve voorzieningen is noodzakelijk zodat vrouwen 
met positieve screeningsresultaten ook daadwerkelijk behandeld kunnen worden.
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In hoofdstuk 7 rapporteren we over de billijkheid van de verdeling van uitkomsten 
in borstkanker behandelingen in Komfo Anokye Teaching Hospital (KATH) in Ghana. 
We maken gebruik van hetzelfde wiskundige model als in hoofdstuk 6, en analyse-
ren welke inkomensgroepen in de Ghanese bevolking de meeste ‘Disability Adjusted 
Life Years’ (DALYs) vermijden wanneer ze in KATH behandeld worden. Het aantal 
DALYs is het aantal gezonde levensjaren dat een bevolking vermijdt als gevolg van 
ziekte of vroegtijdig overlijden. We berekenen de vermeden DALYs vanuit hoe de 
tumoren in verschillende inkomensgroepen verdeeld zijn over de ziektestadia van 
borstkanker, de stadiumdistributie. Onze resultaten laten zien dat hoewel patiënten 
uit een hogere inkomensgroep sneller naar het ziekenhuis komen, hun stadiumdistri-
butie niet significant afwijkt van patiënten uit lagere inkomensgroepen. We vinden 
dus geen significante associatie tussen inkomensgroepen en behandeluitkomsten 
in KATH, hoewel dit een gevolg kan zijn van een kleine steekproef. Omdat meer 
dan 75% van de patiënten KATH binnenkomen met vergevorderde borstkanker en 
in Ghana de geografische beschikbaarheid van borstkanker voorzieningen laag is, 
lijkt het mensen bewust maken van borstkanker via de media en het de toegang 
tot borstkanker voorzieningen verbeteren de beste optie om de uitkomsten van 
borstkankerbehandelingen te verbeteren.
Wetenschappers hebben aangetoond dat HIV-prevalentie beïnvloed wordt door 
onder andere, het opleidingsniveau, (economische) welvaart, uitgaven aan de 
(publieke) gezondheidszorg, de mate van gelijkheid tussen mannen en vrouwen, 
religieuze affiliatie etc. In hoofdstuk 8 proberen we over een periode van 5 jaar ver-
schillen in HIV-prevalentie in sub-Sahara Africa te verklaren door naar alle eerderge-
noemde variabelen tegelijk te kijken. De uitkomsten steunen onze hypothese dat de 
gelijkheid tussen mannen en vrouwen van invloed is op HIV-prevalentie. Gelijkheid 
tussen mannen en vrouwen doet er toe zowel in termen van het absolute niveau van 
HIV-prevalentie alsook bij de verandering van HIV-prevalentie over 5 jaar. Natuurlijk 
rechtvaardigt deze bevinding niet direct een herallocatie van middelen naar het 
verbeteren van de gelijkheid tussen mannen en vrouwen zolang niet bekend is of ze 
kosten-effectief zijn.
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Het schrijven van het dankwoord bij een proefschrift is een bijzonder moment. Het 
resultaat van vier jaar werken wordt afgesloten met wellicht het enige stukje dat je 
naasten helemaal zullen lezen. Het is een mooie tijd geweest, waarin ik bijzondere 
mensen heb ontmoet en waarin het opdoen van kennis en persoonlijke groei hand 
in hand zijn gegaan. Dat dit werk er nu ligt is mede te danken aan de inzet en steun 
van velen. Enkele mensen in het bijzonder wil ik hier bedanken.
Allereerst mijn promotoren Werner Brouwer en Frans Rutten. Beste Werner, tijdens 
mijn tijd aan de Erasmus Universiteit is jouw begeleiding onmisbaar geweest. Zowel 
bij het schrijven van mijn masterscriptie maar vooral bij het proces dat tot dit proef-
schrift heeft geleid. Voor de manier waarop jij tussen verschillende onderwerpen 
schakelt en het overzicht bewaart heb ik grote bewondering. En dat alles met humor 
en relativeringsvermogen. Het maakte onze gesprekken, die de inhoud van dit 
proefschrift soms ver te buiten gingen, erg plezierig. Hartelijk dank daarvoor.
Mijn 2e promotor Frans Rutten. Beste Frans, van 2e lezer bij mijn masterscriptie tot 
2e promotor; de hele rit was je erbij. Dankjewel dat je me de vrijheid hebt gegeven 
het door Susan G. Komen for the Cure gefinancierde borst kanker project naar eigen 
goeddunken in te vullen. Je vertrouwen dat het goed zou komen wanneer ik alleen 
naar het buitenland vertrok, en je steun wanneer het tegen zat, waardeer ik zeer.
De leden van de promotiecommissie wil ik bedanken voor het bestuderen van mijn 
proefschrift en het opponeren bij de verdediging daarvan. Mijn co-auteurs ben ik 
dank verschuldigd voor hun bereidheid hun kennis en kunde met mij te delen. Ellen 
en Elly, het lijdt geen twijfel dat zonder jullie hulp hoofdstukken 2 t/m 5 er nooit wa-
ren gekomen. Sten, dankjewel voor de manier waarop je me wegwijs hebt gemaakt 
in het borstkanker model en mijn vragen daarover steeds beantwoord hebt. De vijf 
weken die we samen in Ghana gewerkt en gereisd hebben zal ik niet snel vergeten!
De mensen bij het CVZ wil ik bedanken voor de prettige samenwerking binnen het 
Academia project. I am grateful to Richard Laing, Alexandra Cameron and Margaret 
Ewen for providing me with the opportunity to work on the Health Action Interna-
tional & World Health Organization medicine prices and availability project. I could 
not have imagined that what started as my mastersthesis eventually would become 
an important part of my PhD. A word of thanks also for David Lowery; his enthusiasm 
and patience in supervising my first master’s thesis in Public Administration fostered 
my interest in research. I am happy our paper on HIV/AIDS is part of this dissertation. 
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Para mis colegas en Costa Rica y México; muchas gracias por su hospitalidad durante 
mis visitas. ¡No los voy a olvidar! De collega’s bij het iBMG wil ik hartelijk bedanken 
voor de prettige werksfeer. Van de gezamenlijke lunches, het invullen van de voet-
balpoule en de ROPA-run tot het bezoeken van verschillende congressen; ik heb 
ervan genoten.
Mijn paranimfen. Ernest, als broers hebben we veel meegemaakt maar behalve dat 
ik regelmatig op reis ging, heb je niet heel veel over mijn werk meegekregen. Ik ben 
erg blij dat je deze dag als paranimf met me kan beleven. Koen, dankjewel voor je 
steun en vriendschap in al die jaren. Dat je vandaag mijn paranimf bent vind ik heel 
bijzonder.
Mijn ouders. Lieve pap en mam, dat ik hier na al die jaren mag staan is iets wat 
weinigen voor mogelijk hadden gehouden. Bedankt voor de manier waarop jullie 
mij, ieder op je eigen manier, onvoorwaardelijk gesteund hebben.
De laatste loodjes wegen het zwaarst, daar is dit proefschrift geen uitzondering 
op. Dass es mit dir ein bisschen einfacher war und sehr viel mehr Spaß gemacht hat, 
ist klar für mich. Liebe Katja, es ist unglaublich dass bei dir meine Macken wirklich 
Special Effects sind. Vielen Dank für alles.
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PhD portfolio
Courses
- Training Tutor Vaardigheden in Probleem gestuurd onderwijs (Erasmus University 
Rotterdam - 2011)
- Medical Demography Fundamentals & Applications (NIHES - 2011).
- Advanced Economic Evaluation (Erasmus University Rotterdam - 2011)
- Panel / Longitudinal Data Analysis (University College London - 2010)
- Klaar in vier jaar (Erasmus University Rotterdam - 2010)
- Applied Health Econometrics (Erasmus University Rotterdam - 2010)
teACHiNg
- Lecturing and supervising working groups in Bachelors course “Verdelings-
vraagstukken”. (2010 - 2013)
- BSc Thesis supervisor. (2011 - 2013)
- MSc Thesis co-reader - Master Health Economics Policy and Law. (2010 - 2012)
- Diploma Course International Health and Policy Evaluation. (2010 - 2011)
CoNfereNCes
- 8th World Congress on Health Economics. 2011. Toronto, Canada. (Poster + short 
oral)
- 3rd Low Lands Health Economists’ Study Group. 2011. Soesterberg, The Nether-
lands. (Attendent)
- Global Summit on International Breast Health: Optimizing Healthcare Delivery. 
2010. Chicago, U.S.A. (Oral presentation)
- European Conference on Health Economics. 2010. Helsinki, Finland. (Oral Presen-
tation)
- 2nd Low Lands Health Economists’ Study Group. 2010. Egmond aan Zee, The 
Netherlands. (Attendent)
- 12th annual European congress of the International Society for Pharmacoeconom-
ics and Outcomes Research. 2009. Paris, France. (Poster)
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- 1st Low Lands Health Economists’ Study Group. 2009. Berg en Terblijt, The Neth-
erlands. (Attendent).
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control in Ghana” Tropical Medicine & International Health, 2012 17(8): 1031-
1043.
- Harford JB, Otero IV, Anderson BO, Cazap E, Gradishar WJ, Gralow JR, Kane GM, 
Niëns LM, Porter PL, Reeler AV, Rieger PT, Shockney LD, Shulman LN, Soldak T, 
Thomas DB, Thompson B, Winchester DP, Zelle SG, Badwe RA. Problem solving 
for breast health care delivery in low and middle resource countries (LMCs): 
consensus statement from the Breast Health Global Initiative. The Breast Journal 
2011 17(2): 1-10.
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Laurens M. Niëns was born in Weert on February 15th, 1983. After finishing high 
school in 2001 he started his studies at Leiden University, where he obtained his 
MA in Public Administration. He continued his education by enrolling in the Health 
Economics Policy and Law masters at the institute for Health Policy and Management 
(iBMG) at Erasmus University Rotterdam. For his graduation project he organized 
internships at Health Action International (HAI) and the World Health Organization 
(WHO). In a joint WHO/HAI project on Medicine Prices and Availability Laurens devel-
oped alternative applications of methods to estimate the affordability of medicines.
After graduating in 2009 he started working for iBMG as a junior researcher. 
Besides continuing to work on measuring the affordability of medicines in low- and 
middle-income countries, he studied the cost-effectiveness of various breast cancer 
interventions in central- and south-America together with Radboud University Ni-
jmegen and the World Health Organization. Sponsored by the Susan G. Komen for 
the Cure foundation, this project led him to organize and hold workshops in Costa 
Rica, Mexico and Brazil. In Ghana Laurens set up an equity study in breast cancer 
outcomes that was sponsored by the same foundation. 
During his time at iBMG Laurens taught in a bachelors’ course on rationing in 
health care, both as an instructor and lecturer. He also supervised several students 
with writing their bachelors’ thesis and taught on the Principles of Economic Evalua-
tion in the Diploma Course program on “International Health and Policy Evaluation”, 
as jointly organized by iBMG, the International Institute of Social Studies (ISS) and 
the Department of Public Health (MGZ) at the Erasmus Medical Center.
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